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ABSTRACT
Multiple Sclerosis (MS) is a demyelinating disorder of the central nervous
system affecting 0.1% of the population in the Northern hemisphere. MS is a complex
disease that depends on genetic and environmental factors and is controlled by multiple
genes that exert a modest effect in the overall disease outcome. The complex nature of
the disease complicates the study of individual genes and their contribution in the
disease process.
To investigate mechanisms underlying the development of diseases like MS and
how disease course can be manipulated, animal models have been extensively used,
with Experimental Allergic Encephalomyelitis (EAE) being the principle autoimmune
model for MS. Even though EAE, like MS, is a complex disease and polygenic in
nature, it can be reduced to monogenic intermediate or subphenotypes, which allows
for identification of the causative gene and its mechanism.
One such subphenotype of EAE in mice, Bordetella pertussis toxin-induced
histamine sensitization (Bphs) is controlled by Hrh1, gene encoding mouse histamine
receptor H1 (H1R), wherein sensitized animals of susceptible strains die upon histamine
challenge and resistant strains do not. Moreover, mice deficient in H1R (H1RKO) show
delayed onset and reduced severity in the clinical course of EAE. However, the
mechanism by which H1R and its polymorphisms regulate EAE is unknown.
As a disease susceptibility gene, Hrh1 could act in different cell types and at
several checkpoints in the disease process. This includes endothelial cells that regulate
blood-brain barrier, antigen presenting cells or T cells, which regulate the cytokine
production. Using transgenic mice expressing H1R exclusively in T cells, this study
shows that H1R expression in T cells is sufficient to restore the EAE severity and the
disease associated cytokine production of H1RKO mice to wild type levels.
H1R from susceptible and resistant strains of mice differ by three amino acids.
The P-V-P haplotype (H1RS) is associated with disease susceptibility whereas the L-MS (H1RR) haplotype is associated with less severe disease. In this study, using
transgenic mice, we show that reexpression of H1RS fully complements the clinical
EAE and the disease-associated cytokine production of H1RKO mice to wild type
levels, however, reexpression of H1RR fails to do so. These data suggest that H1RR is
not functional relative to H1RS. Mechanistically, using 293T cells, we show that the two
H1R alleles exhibit differential cell surface expression and altered intracellular
trafficking, with the H1RR allele being retained within the endoplasmic reticulum (ER).
Moreover, we show that all three residues (L-M-S) comprising the H1RR haplotype are
required for altered expression. Thus, polymorphisms influencing cell surface
expression of H1R regulate immune functions and autoimmune disease susceptibility.

CITATIONS

Material from this dissertation has been published in the following form:
Rajkumar Noubade, Roxana del Rio, Graeme Milligan, James F. Zachary, Elizabeth P.
Blankenhorn, Mercedes Rincon and Cory Teuscher. (2007). Histamine receptor H1 is
required for TCR-mediated p38 MAP kinase activation and IFN-gamma production.
Journal of Clinical Investigation, 117 (11), 1-13.
Material from this dissertation has been submitted for the publication of PNAS on
August 14, 2007 in the following form:

Rajkumar Noubade, Roxana del Rio, Benjamin McElvany, James F. Zachary,
Jason M. Millward, Denisa D. Wagner, Elizabeth P. Blankenhorn, Cory Teuscher.
(2007). Weibel Palade bodies negatively regulate blood brain barrier permeability
and brain inflammation in experimental allergic encephalomyelitis. PNAS.

ii

TABLE OF CONTENTS
CITATIONS..................................................................................................ii
ACKNOWLEDGEMENTS........................................................................iii
LIST OF FIGURES....................................................................................vii
LIST OF TABLES......................................................................................IX
CHAPTER 1: Comprehensive literature review........................................1
Multiple Sclerosis (MS) ......................................................................................................1
Etiology of MS.....................................................................................................................2
Myelin structure and functions............................................................................................3
Immunology of MS..............................................................................................................7
Genetics of MS..................................................................................................................11
Animal models of MS.......................................................................................................12
Experimental allergic encephalomyelitis (EAE)...............................................................13
CD4 T cell subsets and their cytokines in EAE.................................................................19
CD8 T cells in EAE...........................................................................................................21
B cells and autoantibodies in EAE.....................................................................................21
Genetic susceptibility of EAE............................................................................................23
Identification of histamine receptor H1 as a susceptibility gene in EAE...........................25
Histamine and histamine receptor H1................................................................................26
Histamine and histamine receptor H1 in MS and EAE......................................................30

CHAPTER 2: Histamine receptor H1 is required for TCR-mediated p38
MAP kinase activation and IFN-gamma production...............................34
Abstract..............................................................................................................................35
Introduction........................................................................................................................36
Results................................................................................................................................39
Discussion..........................................................................................................................50
Materials and methods.......................................................................................................55

v

References..........................................................................................................................63

CHAPTER 3: Polymorphisms in murine histamine receptor H1 lead to
differential cell surface expression and influence autoimmune disease
progression...................................................................................................79
Abstract..............................................................................................................................80
Introduction........................................................................................................................81
Results................................................................................................................................84
Discussion..........................................................................................................................92
Materials and methods.......................................................................................................96
References........................................................................................................................102

CHAPTER 4: Conclusions and future directions..................................113

APPENDIX A: Weibel-Palade bodies negatively regulate blood brain
barrier permeability and brain inflammation in experimental allergic
encephalomyelitis......................................................................................119
Abstract............................................................................................................................120
Introduction......................................................................................................................121
Results..............................................................................................................................124
Discussion........................................................................................................................129
Materials and methods.....................................................................................................134
References........................................................................................................................138

Comprehensive bibliography...................................................................151

vi

LIST OF FIGURES
CHAPTER 2 : Histamine receptor H1 is required for TCR-mediated
p38 MAP kinase activation and IFN-gamma production
Figure 1. H1R is required for IFNγ production by CD4 T cells.....................................69
Figure 2. Expression and function of HA-H1R in HEK293T cells................................70
Figure 3. H1R expression is downregulated upon activation in CD4 T cells................71
Figure 4. Transgenic expression of H1R in H1RKO CD4 T cells complements IFN-γ
production......................................................................................................................72
Figure 5. Activation of p38 MAP kinase by TCR ligation requires H1R signals..........73
Figure 6. Activation of p38 MAP kinase by TCR ligation is mediated by
histamine/H1R binding..................................................................................................74
Figure 7. H1R signaling directly in CD4 T cells regulates encephalitogenic Th1
effector responses..........................................................................................................75
Figure 8. Absence of histamine does not affect TCR-mediated ERK activation.........76

CHAPTER 3 : Polymorphisms in murine histamine receptor H1 lead to
differential cell surface expression and influence autoimmune disease
progression
Figure 1. Transgenic expression of H1RR in H1RKO T cells fails to complement EAE
in H1RKO mice...........................................................................................................105
Figure 2. Transgenic expression of H1RR in H1RKO T cells fails to complement
cytokine production by H1RKO mice.........................................................................106
Figure 3. H1RS and H1RR activate Gαq/11 G proteins equally well..............................107
Figure 4. H1RS and H1RR are differentially expressed on the cell surface..................108
Figure 5. H1RR is retained in endoplasmic reticulum..................................................109
Figure 6. ER retention of H1RR requires all of its three polymorphic residues...........110

vii

APPENDIX A: Weibel-Palade bodies negatively regulate blood brain
barrier permeability and brain inflammation in experimental allergic
encephalomyelitis
Figure 1. Assessment of Bphs in B6 and VWFKO.....................................................143
Figure 2. Early onset and severe clinical course of EAE in VWFKO mice................144
Figure 3. Severe histopathological EAE in VWFKO brain.........................................145
Figure 4. Normal T cell responses in EAE induced B6 and VWFKO mice...............146
Figure 5. VWFKO mice exhibit increased BBB permeability compared to B6 mice
following injection with MOG35-55+CFA+PTX..........................................................147
Figure 6. Increased BBB permeability in VWFKO mice is independent of
encephalitogenic T cells..............................................................................................148
Figure 7. BBB compromise and repair by endothelial cells differs depending on the
peripheral inflammatory stimulus...............................................................................149
Figure 8. Comparison of BBB permeability in animals immunized with components of
adjuvants either alone or in combination....................................................................150

viii

LIST OF TABLES
CHAPTER 2 : Histamine receptor H1 is required for TCR-mediated
p38 MAP kinase activation and IFN-gamma production
Table 1: Clinical disease parameters in MOG35-55+CFA+PTX immunized mice.........77
Table 2. Clinical disease parameters in 2x (MOG35-55+CFA) immunized mice...........78

CHAPTER 3 : Polymorphisms in murine histamine receptor H1 lead to
differential cell surface expression and influence autoimmune disease
progression
Table 1. Clinical disease traits following immunization of mice with MOG35-55+CFA+
PTX and 2x (MOG35-55+CFA).... ...............................................................................111
Table 2. The P-V-P and L-M-S haplotypes of H1R are evolutionarily conserved in
mice.............................................................................................................................112

ix

CHAPTER 1: COMPREHENSIVE LITERATURE REVIEW
Multiple Sclerosis
Multiple Sclerosis (MS), a prototypic demyelinating inflammatory disease of
the central nervous system (CNS) (Hafler, 2004), has been the most common
neurological disorder in young adults since it was first noted by Jean Martin Charcoat
in 1868 (Greenstein, 2007). More than 2.5 million people have been affected
worldwide, with 350,000 individuals in the United States (US). The estimated
prevalence rate in the year 2000, for the US Caucasian population was 1.91 per 1000
with an incidence rate of 7.3 per 100,000 (Berger et al., 2003). MS creates an
economical burden to the individual, the health care system and the society. In 1994,
the annual cost of MS in terms of direct care and loss of productivity in the US was
estimated to be $34,000/ patient with a mean life-time cost of $2.2 million. This
translates to a national cost of $6.8 billion/year. MS is more common in females than in
males (~ 2:1); however, affected men generally have a delayed onset with worse
prognosis (Kantarci and Wingerchuk, 2006).
A remarkable heterogeneity is seen in clinical MS with multiple forms
identified: (i) relapsing-remitting MS, observed in 85-90% of patients, with full or
partial recovery between relapses, with most developing into (ii) secondary progressive
MS with progressive clinical deterioration and, (iii) primary progressive MS with
neurological dysfunction from the onset without any clinical relapses (Hafler, 2004;
Holmoy and Vartdal, 2007). The symptoms vary depending on the component of the
CNS involved, brain or spinal cord, and include motor, sensory, autonomic and
cognitive disabilities. About 50% of MS patients become dependent on a walking
1

aid by year 15 of the disease (Kantarci and Wingerchuk, 2006; Weinshenker et al.,
1989).

Etiology of MS
One hundred and fifty years after its discovery, the etiology of MS is still
unknown; however, genetic (Mackay and Myrianthopoulos, 1966; Sadovnick et al.,
1988) as well as environmental factors (Dean et al., 1976; Kurtzke and Hyllested, 1987)
have been implicated in its susceptibility. Considered to be a complex disease with
multiple disease-susceptibility genes, MS lacks a clear pattern of inheritance. Hence it
is believed that the disease is triggered by some kind of environmental factor in
genetically susceptible individuals (Comabella and Martin, 2007; Hafler et al., 2005).
The support for the influence of genetic factors include: a 20-40 times greater
risk in siblings and fraternal twins of patients, a 150-300 times greater risk in identical
twins of patients and a lack of increased risk in adopted-relatives of patients (Allen et
al., 1994; Ebers, 2005; Ebers et al., 1995; Hafler et al., 2005; Jersild et al., 1973;
Kurtzke et al., 1982; Mackay and Myrianthopoulos, 1966; Risch and Merikangas,
1996). Familial studies have suggested that even phenotypic heterogeneity of MS has a
genetic basis with greater similarity of clinical course in patients who are relatives
(Kantarci et al., 2002).
The support for the involvement of environmental factors in MS include: noninfectious factors such as geography and migration, with lower MS risk among
individuals migrating from high-risk to low-risk areas (Alter et al., 1978; Alter et al.,
1966; Dean, 1967; Hammond et al., 2000; Kurtzke et al., 1985; Kurtzke et al., 1970);
latitude gradient, with 3% higher risk in individuals born in the north (420 N and
2

above) than individuals born in the south latitude (370 N and below) (Hernan et al.,
1999); exposure to sunlight; circulating levels of vitamin D, with low levels being
associated to higher risk (Ascherio and Munger, 2007; Munger et al., 2004; SoiluHanninen et al., 2005; Soilu-Hanninen et al., 2007); and an incomplete concordance in
monozygotic twins (Ebers, 2005; Weinshenker, 1996).
An infectious etiology with a variety of viral and bacterial agents associated
with increased risk has been proposed, with Epstein-Barr virus (EBV) infection the
most consistent and strongest risk factor (Ascherio and Munger, 2007; Coo and
Aronson, 2004; Kurtzke, 1968, 1993; Marrie, 2004; Thacker et al., 2006). This multifactorial etiology triggers a disease in MS patients characterized, neuropathologically,
by discrete lesions (or plaques) mostly in the white matter of the CNS tissue, causing
inflammatory infiltrates, demyelination, astrocytic proliferation (astrogliosis) and
axonal damage. It is widely believed that the inflammatory infiltrates are
pathogenically the primary factors and that MS is an autoimmune disease with an
immune attack against myelin proteins (McFarland and Martin, 2007).

Myelin structure and functions
The myelin sheath is a multilamellar membrane, uniquely found and essential to
the functioning of the vertebrate nervous system (Tzakos et al., 2005). In the CNS, the
myelin sheath is formed by the wrapping of plasma membrane extensions of
oligodendrocytes, specialized glial cells, in highly regular concentric layers around the
axons. These concentric layers are practically fused together with very little or no
cytoplasm (Kursula, 2006). High-resolution electron microscopic studies of myelin
sheath

have

demonstrated

periodic electron-dense and -light layers. Dense
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layers, spaced between 150-170 A0 apart, are formed by the apposition of the
cytoplasmic surfaces of the plasma membrane extensions of the oligodendrocytes. The
light layers, also known as intraperiodic lines, are formed by the apposition of the
extracellular surfaces of the plasma membrane (Baumann and Pham-Dinh, 2001). The
thickness of the myelin sheath varies with the length of the axon, with longer axons
having thicker myelin (Waxman and Sims, 1984). The longitudinal organization of the
myelin sheath is also unique, with three distinct anatomical and functional domains
(Porter and Tennekoon, 2000).
The myelin sheath is segmented, forming internodes of about 150-200 μm
length (Butt and Ransom, 1989). The internodes are separated by spaces where myelin
is lacking and the axolemma is exposed to the extracellular milieu. These are called
nodes of Ranvier and are enriched in voltage gated sodium channels (120,000/μm2, the
highest density in the nervous system) (Baumann and Pham-Dinh, 2001). Each
successive myelin wrap, at its lateral margins, creates a loop containing some
cytoplasm, called paranodal loops or paranodes (Porter and Tennekoon, 2000). The
junction of paranodal loops with axons, known as juxtaparanodal region, is rich in
potassium channels and thus segregates them from the voltage gated sodium channels
in the nodes of Ranvier (Porter and Tennekoon, 2000; Rios et al., 2003). This
organization is important for the normal conduction of electrical impulses along the
axons (Kursula, 2006). Myelination alters the electrical properties of the axons because
the myelin sheath has high resistance and low capacitance (Tolhurst and Lewis, 1992).
Therefore, once an action potential is generated at one node of Ranvier, it flows down
the axon quickly to the next node rather than leak back across the membrane. Thus, an
4

electrical impulse jumps from one node to the next node, a method of propagation
known as saltatory conduction (Baumann and Pham-Dinh, 2001; Salzer, 2002). Myelin
is very effective in increasing conduction velocity. An axon of about 1-5 μm in
diameter can propagate an electrical impulse at about 20 meters per second if it is
myelinated, while a non-myelinated axon needs to be 500-1000 μm thick in order to
propagate an electrical impulse at the same rate (Hall, 1992).
Myelin constitutes about 40-50% of the CNS white matter on dry weight basis
(Tzakos et al., 2005). It is a poorly hydrated structure containing about 40% water in
contrast to the highly hydrated (80%) grey matter. Like all other cell membranes, it is
composed of a lipid bilayer with intercalated proteins. However, in contrast to the other
cell membranes, it is uniquely made of lipids (70% of the dry weight). The lipids are
composed of cholesterol, phospholipids and glycolipids, with an enrichment of
glycosphingolipids (Baumann and Pham-Dinh, 2001; Porter and Tennekoon, 2000).
The low water content and lipid-rich composition of myelin contributes to its insulating
properties and favor rapid nerve conduction velocity. When the myelin is damaged by
diseases or when it is not formed due to genetic defects, it results in serious
neurological conditions, including motor and sensory deficits (Porter and Tennekoon,
2000).
The myelin proteins, comprising the remainder 30% of the myelin dry weight,
consist of a restricted set of proteins (Kursula, 2006). Most of these proteins are
exclusively found in myelin and oligodendrocytes and are important in myelination
and/or maintenance of myelin architecture (Tzakos et al., 2005). Myelin basic protein
(MBP) is one of the most abundant proteins, constituting 30% of the total myelin
5

proteins, and is present at the cytoplasmic surfaces of the myelin membranes (Baumann
and Pham-Dinh, 2001). MBP is essential for myelin compaction (Campagnoni and
Macklin, 1988). Mutant mice, with a large deletion of the MBP gene (shiverer mice),
lack the major dense line of myelin (Privat et al., 1979; Roach et al., 1985).
Proteolipid protein (PLP) and its splice variant, DM20, are the most abundant
myelin proteins, constituting 50% of the total myelin proteins (Kursula, 2006). The
absence of PLP/DM20 leads to a loosely wrapped myelin sheath and loss of
intraperiodic lines, correlating with reduced physical stability (Boison et al., 1995).
Therefore, PLP, along with MBP, is believed to cement the myelin sheath, like a
zipper, by forming membrane junctions after myelin compaction (Boison et al., 1995;
Klugmann et al., 1997) Further, the absence of PLP/DM20 leads to axonal damage and
axonal degeneration, indicating that myelin plays a pivotal role in maintaining axonal
integrity and function (Baumann and Pham-Dinh, 2001; Boison et al., 1995).
Myelin oligodendrocyte glycoprotein (MOG) is a minor myelin protein and is
present on the outermost lamellae of the myelin sheath and is present in
oligodendrocyetes, particularly on the processes (Tzakos et al., 2005). MOG is a
surface marker for oligodendrocyte maturation and its presence correlates with late
stages of maturation (Baumann and Pham-Dinh, 2001; Solly et al., 1996). The amino
acid sequence of MOG is highly conserved among animal species, suggesting an
important biological function (Tzakos et al., 2005) in the completion, compaction
and/or maintenance of myelin (Johns and Bernard, 1999).
Myelin associated glycoprotein (MAG) is another minor glycoprotein important
in myelin compaction (Tzakos et al., 2005). Absence of MAG leads to increased
6

cytoplasm content between lamellae and lower number of myelin wraps (Li et al., 1994;
Montag et al., 1994). Other myelin proteins include connexin32, a gap junction protein,
and 2’3’-cyclic nucleotide-3’-phosphodiesterase (CNPase) found in the cytoplasm of
paranodes (Tzakos et al., 2005).

Immunology of MS
MS is considered to be a coordinated immunological attack against myelin
proteins in the CNS (Ferber et al., 1996). A large body of literature provides evidence
that the immune system is involved in the disease process (McFarland and Martin, 2007).
Even though specific self-antigen(s) has not been definitively demonstrated, it is
generally accepted that CD4 T cells reactive to major constituents of the myelin sheath,
MBP (Berger et al., 2003; Bielekova et al., 2000; Bielekova et al., 2004), PLP (Bielekova
et al., 2004) and MOG (Genain et al., 1999; Olsson et al., 1992; Soderstrom et al., 1993)
mediate the autoimmune pathology of the disease. Myelin-specific T cells are easily
detected in normal individuals (Sospedra and Martin, 2005). The triggers that cause these
cells to attack myelin are largely unknown.
A role of infectious agents has long been proposed to break the tolerance to
myelin components in genetically susceptible individuals through molecular mimicry and
bystander activation (Fujinami and Oldstone, 1985) (Lang et al., 2002; Tejada-Simon et
al., 2003; Wucherpfennig and Strominger, 1995) (Anthony et al., 1997; Waldner et al.,
2004). Environmental factors, described earlier, are also considered to trigger the
activation of autoreactive CD4 T cells in genetically susceptible individuals. In this
regard, histamine elicited by environmental factors or generated during an ongoing
infection could act as a mediator of such a disease-inducing
7

trigger.

The

myelin-

reactive CD4 T cells penetrate CNS through the blood-brain barrier (BBB), formed by
specialized endothelial cells that are connected through tight junctions (Minagar and
Alexander, 2003).These endothelial cells are typically ensheathed by basal lamina and
astrocytic end-feet processes (Kim et al., 2006)
Astrocytes are the most abundant glial cells in CNS (Minagar et al., 2002). They
are critical for the development, structural support and the maintenance of BBB. In coculture systems, astrocytes upregulate the several proteins of tight junction structure that
connects the endothelial cells (Dehouck et al., 1990; Rubin et al., 1991). The BBB
endothelial cells exhibit an apical or luminal polarization of transporters like pglycoprotein, glucose transporter 1 (GLUT1), thus forming a transport barrier (Abbott et
al., 2006). Astrocytes up-regulate the expression and the polarized localization of these
transporters (Kim et al., 2006). BBB also acts as a metabolic barrier and astrocytes
upregulate several of the BBB-specific enzymes such as monoamine oxidase, superoxide
dismutase, that support the protective and detoxifying roles of BBB (Haseloff et al.,
2005). The perivascular end-feet of the astrocytes are highly specialized with high
density of orthogonal array of particles containing the water channel aquaporin 4 and the
potassium channel Kir4.1. The polarity of these proteins, which are anchored to the basal
lamina through a proteoglycan protein called agarin, contributes to the integrity of BBB
(Minagar et al., 2002). Moreover, astrocytes secrete several factors such as basic
fibroblast growth factor, glial-derived neurotrophic factor, angiopoetin 1 and TGFβ, that
induce several aspects of BBB (Kim et al., 2006).
The entry of T cells into the CNS is a multistep process involving the induction
of adhesion molecules such as vascular cell adhesion molecule (VCAM) on the
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endothelial cells, mostly by cytokines including IFN-γ, TNF-α and IL-23 released
during the inflammatory process. The interaction of these adhesion molecules with their
binding partners, such as VLA-4, on the surface of activated CD4 T cells allows the
CD4 T cells to adhere to the endothelial cells and diapedese into the CNS (Brocke et
al., 1993; Butcher et al., 1999). Matrix metalloproteases (MMP), particularly MMP-2
and -9, surround the inflamed BBB endothelial cells and degrade the basal membrane
as well as the extracellular matrix of parenchyma, thus enabling the T cells to spread in
the CNS (Anthony et al., 1997; Clements et al., 1997; Lindberg et al., 2001; Pedotti et
al., 2003).
After gaining access to the white matter, the CD4 T cells re-encounter the
myelin antigens presented to them by the resident antigen presenting cells (APCs),
particularly microglial cells (Minagar et al., 2002). Activated T cells produce several
cytokines, which in turn activate more APCs and thus set up a pro-inflammatory loop
that provides an infiltrate rich in activated T cells, macrophages and other cells of
hematopoietic origin such as B cells and mast cells. The activated macrophages attack
myelin and phagocytose large chunks of the myelin sheath (Ferber et al., 1996;
Sospedra and Martin, 2005) and produce toxic materials such as nitric oxide (Brenner
et al., 1997; Conlon et al., 1999). There is a myelin-directed cytotoxic T cell response,
an auto-antibody response and an activation of the complement cascade (Compston et
al., 1986; Keegan et al., 2005; Lalive et al., 2006; Laurell and Link, 1972; Lucchinetti
et al., 1996; Morgan et al., 1984).
This concerted attack of T and B cells, complement cascade, inflammatory
mediators including cytokines and nitric oxide on the myelin sheath results in areas
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of severe demyelination. In addition, there is loss of myelin-producing oligodendroglial
cells, an increase in the number of fibrous scar tissue-forming astrocytes, and
permanent axonal damage (Conlon et al., 1999; Sospedra and Martin, 2005; Trapp et
al., 1998), thus resulting in the pathophysiological defects observed in the affected
individual.
The cytokine-producing phenotype of myelin-specific T cells determines the
ability of these cells to cause inflammation in the CNS. Organ-specific autoimmune
diseases such as MS are thought to be primarily mediated by Th1 type of CD4 T cells.
These cells are differentiated in the presence of interleukin (IL)-12 and are
characterized by the production of large amounts of IFN-γ, TNF-α and IL-2 (Ferber et
al., 1996; McFarland and Martin, 2007; Sospedra and Martin, 2005). Increased levels of
IFN-γ, TNF-α in the serum (Hohnoki et al., 1998) and of IL-12 in cerebrospinal fluid
(CSF) (Dormond et al., 2002) of MS patients have been observed. However, these
cytokines worsened the disease upon systemic administration (Panitch et al., 1987;
Sharief and Hentges, 1991). The disease-enhancing effect of these cytokines has been
associated with their ability to enhance the expression of adhesion molecules on the
vascular endothelium (Ferber et al., 1996). Recently, IL-17 and IL-23 are being
considered to be the important proinflammatory cytokines in autoimmune diseases
(McFarland and Martin, 2007). Accordingly, an augmentation of IL-17 mRNA in
mononuclear cells of CSF and in brain tissues of MS patients is observed (Dormond et
al., 2002; Matusevicius et al., 1999). IL-23 is present in both active and chronic lesions
(Lundmark et al., 2007). Myeloid dendritic cells from MS patients express higher IL-23
than

those

from

normal

individuals (Vaknin-Dembinsky et al., 2006). All
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these proinflammatory cytokines, in addition to orchestrating the inflammation, play an
important role in the demyelination process by activating phagocytic cells and by
inducing apoptosis of myelin producing cells, which lead to impaired saltatory
conduction along the axon and pathological effects (Pouly et al., 2000; Selmaj et al.,
1991).

Genetics of MS
The evidence for genetic factors in MS susceptibility is compelling. Several
approaches including genetic linkage, candidate gene association and gene expression
studies have been used (Becanovic et al., 2004; Fernald et al., 2005). However, all have
failed to demonstrate a clear mode of inheritance in the disease. Consequently, it has been
concluded that MS is polygenic and affected by multiple genes, each exerting a modest
effect in the overall disease outcome (Sawcer, 2006). The most consistent association has
been with the major histocompatibility complex (MHC) class II or human leukocyte
antigen (HLA), specifically HLA-DRB1*1501-DQB1*0602 haplotypes located on
chromosome 6 (Hafler et al., 2007; Haines et al., 1996; Haines et al., 1998). In spite of its
strong linkage, HLA association explains only about 50% of the genetic etiology of MS
(Ebers and Sadovnick, 1994). Evidence for additional linkages to several chromosomes
outside HLA has been observed, supporting the complexity. Candidate gene studies have
suggested more than 100 such non-MHC genes, a conservative estimate suggesting about
30 genes, but no consensus has been accepted (Becanovic et al., 2006; GAMES, 2001,
2003).
Recently, using a large-scale genomewide association scan, The International
Multiple Sclerosis Genetic Consortium has

identified IL-2 receptor alpha (IL-2RA)
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and IL-7 receptor alpha (IL-7RA) alleles, along with those in the HLA locus, as risk
factors for MS (Hafler et al., 2007). The risk conferred by polymorphisms in IL-7RA is
confirmed by two additional, independent studies (Gregory et al., 2007; Lundmark et al.,
2007). However, risk contributed by IL-2RA and IL-7RA is minimal and explains only
0.2% of the variance (Peltonen, 2007). Moreover, the approaches used in these studies
have little statistical power to detect rare variants that could confer a relatively large
genetic risk (Hafler et al., 2007; Sawcer, 2006). Overall, it has been difficult to identify
genes associated with MS because of the genetic complexity of the disease, the genetic
diversity of the human population, the relatively small sample sizes, and the
environmental influence and possible variations in the disease diagnosis (Andersson and
Karlsson, 2004).

Animal models of MS
Due to the complex genetic architecture of MS, to investigate mechanisms of
disease development and disease manipulation, animal models have been extensively
used,. The most important advantage of animal models, compared to humans, is the better
control of genetic background and environment. In addition, large numbers of animals
can be studied. The disease can be deliberately induced and animals can be genetically
manipulated. Animal models have the potential to significantly reduce the genetic
complexity inherent in autoimmune diseases into intermediate or subphenotypes, such as
histamine sensitivity. In addition, animal models permit the refinement of candidate
regions to an interval small enough to allow identification of the causative gene using
classical positional cloning and candidate gene screening. Thus, even though animal
models do not completely display all the

disease parameters found in the human
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disease they model, specific traits of animal models reflect a particular pathway and give
better mechanistic understanding of a particular stage of the human disease (Andersson
and Karlsson, 2004).
There are two major strategies of discovering genetic contribution to the
development of disease using animal models. The first one, “gene-to-disease” pursues a
hypothesis-based role of a particular gene in the disease development and is performed
using gene-knock out and transgenic mice. The other, “disease-to-gene” strategy, is an
unbiased, hypothesis-free approach aimed at identifying the disease-relevant part of the
genome. This strategy involves the use of hybrids of one susceptible strain of mice
crossed with a resistant strain. Development of the disease is studied in these mice
followed by a marker assisted genome screen. Statistical linkage analysis is used to relate
disease development to a genetic variant at a defined genetic location. Subsequent
refinement will yield identification of the candidate gene, which can further be
investigated for genetic polymorphisms between the parental strains and the influence of
these polymorphisms on the disease development process. Both the strategies of genetic
analysis of susceptibility genes have their advantages and are complementary to each
other (Andersson and Karlsson, 2004).

Animal models of MS-experimental allergic encephalomyelitis (EAE)
Animal models that simulate features of MS provide a powerful tool for
investigating the pathogenesis of the disease. Several mouse models, virus-induced
and/or autoimmune, have been developed that reflect clinical and pathological attributes.
The viral models for MS include the Theiler’s murine encephalomyelitis virus (TMEV)
(Lipton and Dal Canto, 1976), recombinant-

TMEV (Olson et al., 2001), murine
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hepatitis virus (MHV) (Matthews et al., 2002), Semliki forest virus (Mokhtarian and
Swoveland, 1987) and Sindbis virus (Mokhtarian et al., 1989). All these neurotropic
viruses induce demyelination either by directly infecting the neurons or by activating
autoreactive T cells though molecular mimicry (Ercolini and Miller, 2006; Grigoriadis
and Hadjigeorgiou, 2006).
EAE is the principle autoimmune animal model for MS. With 70 years of
history, it is one of the most endured animal models of a human disease (Pedotti et al.,
2003). EAE was originally developed by Rivers and colleagues as a model for
neuroparalytic accidents in patients who received anti-rabies vaccine, by inducing
disseminated encephalomyelitis in monkeys by repeated injections of rabbit brain extracts
(Rivers et al., 1933). The introduction of adjuvants, such as Fruend’s complete adjuvant
(CFA), greatly facilitated the induction of the disease with a single or fewer injections of
antigen (Fruend et al., 1947). Subsequently, the disease has been induced in several
animals including non-human primates (Genain et al., 1995), guinea pigs (Fruend et al.,
1947), rats (Lipton and Freund, 1952), rabbits (Morrison, 1947), hamsters (Tal et al.,
1958), goats (Lumsden, 1949), sheep (Innes, 1951), dogs (Thomas et al., 1950), and mice
(Olitsky et al., 1950). It is now well established that the experimental disease is mediated
by T cells reactive to components of the myelin sheath. This prototypical model for cellmediated autoimmune disease in general is the best available animal model for human
CNS inflammatory demyelinating disease. EAE simulates several features of MS
including its pathology, histopathology and pathogenesis making it a powerful tool in the
investigation of the pathophysiology (Baxter, 2007; Blankenhorn et al., 2000; Gold et al.,
2006; Martin and McFarland, 1995; Palakal et al., 2007).
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EAE can be induced in genetically susceptible animals by inoculation with
either crude CNS tissue-homogenate or their components, such as PLP, MBP, MOG,
MAG, myelin oligodendrocyte basic protein, or the encephalitogenic peptides in an
appropriate adjuvant (Encinas et al., 1996; Kuchroo et al., 2002; Trotter et al., 1987;
Zamvil et al., 1985). CFA containing Mycobacterium tuberculosis H37RA, and
Bordetella pertussis toxin (PTX) are the most commonly used adjuvants in disease
induction. EAE can also be induced by adoptive transfer of CD4 T cells from immunized
animals into naïve mice, which underscores the importance of these cells in the immunoetiology of the disease (Baron et al., 1993; Bernard et al., 1976; Bernard and Mackay,
1983; Krueger et al., 2005; Langrish et al., 2005).
The development of EAE in the immunized mice occurs in two distinct stages,
the induction phase and the effector phase. During the induction or the initial priming
phase, up to day 10 post immunization, APCs present the immunized-component of the
myelin sheath to CD4 T cells as “foreign” antigen in lymph node and/or spleen and
activate them (Powell et al., 1990; Sayed and Brown, 2007).
Optimal activation of T cells requires two signals (Bretscher, 1999). The first
signal is delivered by the interaction of T cell receptor (TCR) with antigen presented by
MHC molecule on the surface of APCs. The second signal consists of engagement of
costimulatory molecules such as CD28, inducible costimulatory molecule (ICOS),
programmed death pathway 1 (PD-1), and CD154 expressed on T cells with CD80/CD86,
ICOS ligand, PD-1 ligand 1 (PD1-L1)/PD-1 ligand 2 (PD-L2) and CD40 respectively,
expressed on APCs (Agata et al., 1996; Hutloff et al., 1999; McAdam et al., 1998; Sharpe
and Freeman, 2002). The critical regulatory role in EAE of ICOS and optimal T cell
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activation is supported by complete absence of EAE in CD28-deficient mice (Chitnis et
al., 2001; Oliveira-dos-Santos et al., 1999), blockade of disease by administration of antiCD28 antibodies (Perrin et al., 1999), resistance of CD80/CD86-deficient mice to the
induction of EAE (Chang et al., 1999; Girvin et al., 2000), exacerbation of disease in
ICOS-deficient (Chitnis et al., 2001) and anti-PD1 antibody treated mice (Salama et al.,
2003). Another costimulatory molecule, CTLA-4, is expressed on activated CD4 T cells
and its interaction with CD80/CD86 is a negative regulator of T cell activation
(Karandikar et al., 1996). Administration of anti-CTLA4 blocking antibody during the
priming phase of EAE exacerbates the disease (Karandikar et al., 1996). In addition,
factors such as histamine play a critical role during priming of autoreactive T cells
(Chapter 2). In the presence of proper secondary signals, autoreactive CD4 T cells get
activated and differentiated into distinct lineages such as Th1 or Th17 cells, defined by
the unique set of cytokines they produce upon re-activation (Furuzawa-Carballeda et al.,
2007).
During the effector phase of the disease, the activated autoreactive T cells leave
the secondary lymphoid organs, traffic to the CNS and persist there to orchestrate the
inflammatory events. In healthy individuals, the traffic of lymphocytes into the CNS is
very low and tightly regulated by a highly specialized structure called the blood-brainbarrier (BBB) formed by endothelial cells connected though tight junctions (Engelhardt,
2006). Therefore, loss of BBB integrity is a critical checkpoint in the pathogenesis of
CNS inflammatory diseases (Noubade et al., 2007)(Appendix A of this thesis). Only
activated T cells, not naïve T cells, can penetrate the BBB, a process mediated by
adhesion molecules, chemokines and their respective chemokine receptors (Engelhardt
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and Ransohoff, 2005; Hickey et al., 1991; Matejuk et al., 2002; Wekerle et al., 1987).
Activated T cells express adhesion molecules such as lymphocyte function associated
antigen 1 (LFA-1) and very late antigen 4 (VLA-4). Endothelial cells are induced to
express adhesion molecules such as intracellular adhesion molecule 1 (ICAM-1),
vascular cell adhesion molecule 1 (VCAM-1), platelet/endothelial cell adhesion molecule
1 (PECAM-1) on their surface, mostly by cytokines such as IFN-γ and TNF-α (Baron et
al., 1993; Butter et al., 1991; Graesser et al., 2002; Wilcox et al., 1990). ICAM-1 and
VCAM-1 are ligands for LFA-1 and VLA-4, respectively. Interaction of the adhesion
molecules on T cells with their binding partners on endothelial cells (Baron et al., 1993;
Yednock et al., 1992) and the degradation of the type IV collagen of the basement
membrane underlying the endothelial cells by MMPs, results in extravasation of T cells
through BBB endothelial cells into the CNS tissue. Type IV collagen is present only in
the endothelial cell basement membrane and has distinct binding sites important for T
cell binding to the basement lamina of endothelial cells (Sacca et al., 2003).
MMPs are a family of proteolytic enzymes present at low levels in a normal
CNS but most of them, particularly MMP-2 and -9, are elevated during EAE. MMPs also
assist T cells to spread in the white matter by degrading the brain parenchyma (Agrawal
et al., 2006; Anthony et al., 1998; Clements et al., 1997; Dwyer et al., 1998; Harrington et
al., 2005; Kieseier et al., 1998; Pagenstecher et al., 1998; Toft-Hansen et al., 2004). Once
within the CNS, the T cells are re-activated when the normally-expressed myelin antigens
are presented by the resident microglial cells and/or astrocytes (Matsumoto et al., 1992;
Constantinescu et al., 2005; Stuve et al., 2002). The re-activation of CD4 T cells is
necessary for them to be retained within the CNS and exert their effector functions.
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Otherwise, the T cells exit rapidly or undergo apoptosis (Hickey, 2001).
The re-activation of CD4 T cells results in the increase of a number of proinflammatory molecules including MMPs, adhesion molecules, chemokines such as
RANTES, MCP1, MIP1α, MIP1β, osteopontin (Butterfield et al., 1999; Chabas et al.,
2001; Dogan and Karpus, 2004; Glabinski et al., 1995; Godiska et al., 1995), and
cytokines such as IFN-γ, TNF-α, IL-1, IL-6, IL-12, IL-17, IL-22 and IL-23. These
cytokines, particularly INF-γ and IL-23, activate macrophages and microglial cells, which
in turn upregulate their MHC class II molecules, re-present myelin antigen to CD4 T
cells, and thus set up an inflammatory loop (Becher et al., 2003; Constantinescu et al.,
2005; Ferber et al., 1996; Gutcher and Becher, 2007; Kuchroo et al., 1993).
Consequently, there is a sustained breach of BBB integrity and rapid, massive infiltration
of cells including CD4 T cells, CD8 T cells, macrophages, B cells, monocytes, mast cells
and neutrophils, into the CNS white matter.
The activated macrophages phagocytose myelin and myelin-producing cells
leading severe demyelination (Ferber et al., 1996; Pender, 1987). Myelin-reactive CD8
T cells (Chabas et al., 2001; Huseby et al., 2001), B cells, myelin-specific antibodies
(Iglesias et al., 2001; Lebar et al., 1986; Svensson et al., 2002), complement proteins
that form membrane attack complexes at the surface of oligodendrocytes (Jegou et al.,
2007; Piddlesden et al., 1993), oposonization of myelin by autoantibodies and
complement proteins (Jegou et al., 2007), all contribute to the demyelination.
Proteolytic enzymes (Guyton et al., 2005) and toxic products, such as reactive oxygen
and nitrogen intermediates (MacMicking et al., 1992), are released by infiltrated cells.
Increasing

evidence

suggests

that inflammatory mediators released from the
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infiltrated cells cause a considerable axonal loss (Park et al., 2005). All these events
result in an ascending paralytic disease, that begins with weakness and loss of tone in
the tail and progresses to complete paralysis of forelimbs, hind limbs, fecal and urinary
incontinence, moribund state in some animals, and occasional mortality.

CD4 T cell subsets and their cytokines in EAE
Historically, CD4 T cells of Th1 type, characterized by their ability to secrete
IFN-γ, are believed to be sufficient to orchestrate the inflammatory events and initiate
myelin destruction in CNS. IL-12 drives the differentiation of CD4 T cells into Th1
type cells (Harrington et al., 2006). Mice deficient in IL-12p40 are resistant MBPinduced EAE (Segal et al., 1998). CD4 T cells differentiated in vitro in the presence of
IL-12 induce disease in naïve recipients upon adoptive transfer (Baron et al., 1993;
Bernard et al., 1976; Bernard and Mackay, 1983). Administration of anti-IL-12p40
antibodies suppresses EAE in adoptive transfer recipients (Leonard et al., 1995). IL-18
also promotes Th1 differentiation (Okamura et al., 1995). Mice deficient in IL-18 are
resistant to EAE (Shi et al., 2000) and anti-IL-18 antibodies significantly reduce the
IFNg production and disease development during MBP-induced EAE in rats
(Wildbaum et al., 1998). The number of Th1 CD4 T cells in inflammatory lesions
correlate with disease severity (Merrill et al., 1992). Encephalitogenic MBP- and PLPspecific CD4 T cells clones are Th1 type (Ando et al., 1989; Baron et al., 1993;
Kuchroo et al., 1993). Mice deficient in T-bet, the key transcription factor for the
development of Th1 CD4 T cells (Szabo et al., 2000) do not develop EAE (Bettelli et
al., 2004). Silencing T-bet by RNA interference ameliorated EAE (Gocke et al., 2007).
TNF-α is upregulated in CNS during EAE (Juedes
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et

al.,

2000).

The

encephalitogenicity of MBP-specific T cell clones is strongly correlated with the TNFα production (Powell et al., 1990). However mice deficient in TNF-α, IFN-γ or IFN-γR
are susceptible to EAE (Ferber et al., 1996; Frei et al., 1997; Willenborg et al., 1996).
Similar observations were made in mice deficient in IL-12, particularly IL-12p35
(Becher et al., 2002; Ghosh et al., 2002).
In contrast, mice deficient in IL-23, a member of IL-12 family, were completely
resistant to EAE (Cua et al., 2003; Langrish et al., 2005). Further, these EAE-induced IL23-deficient mice completely lacked IL-17- positive cells in the CNS while IFN-γpositive cells were present. These discrepancies led to the identification of a distinct
subset of CD4 T cells called IL-17 producing-Th17 cells (Harrington et al., 2005;
Krueger et al., 2005). IL-17-deficient mice are resistant to EAE (Komiyama et al., 2006).
Subsequently, in addition to IL-17, the Th17 CD4 T cells have been shown to produce
IL-1β, IL-6, TNF-α, IL-22, GM-CSF (Furuzawa-Carballeda et al., 2007). The presence
of IL-6, TGF-β and IL-1β is essential for the generation of these cells and mice deficient
in IL-6 as well as IL-1R are resistant to EAE (Okuda et al., 1998; Schiffenbauer et al.,
2000). Additionally, IL-23-derived Th17 CD4 T cells induced EAE in naïve recipients
upon adoptive transfer (Krueger et al., 2005; Langrish et al., 2005). However, adding
complexity to the Th17 pathway is the observation that mice deficient in IL-17E, also
known as IL-25, have increased IL-23 expression and are hypersusceptible to EAE
(Kleinschek et al., 2007). Thus the relative contribution of Th1 versus Th17 CD4 T cells
to the development of EAE remains to be elucidated.
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CD8 T cells in EAE
Initial studies suggested that CD8 T cells may play a protective role in EAE
when a significant reduction in disease relapses was observed in CD8 knock-out or CD8
T cell-depleted mice (Jiang et al., 1992; Koh et al., 1992). However, several lines of
evidence such as predominance of CD8 over CD4 T cells in the brain of MS patients and
the close association of CD8 T cells with MS lesions (Booss et al., 1983; Cabarrocas et
al., 2003; Hauser et al., 1986; Neumann et al., 2002; Skulina et al., 2004) led to a more
careful analysis of these cells in EAE pathogenesis. One criticism for CD4 T cell
predominance in EAE has been that when EAE is induced by immunizing the mice with
myelin antigens in appropriate adjuvant, the antigens are presented by MHC class II
molecules and thus activate CD4 T cells rather than by MHC class I molecules (Ji and
Goverman, 2007). Therefore, when MHC class I restricted MBP-specific CD8 T cells
were adoptively transferred to naïve recipients, it resulted in severe EAE with extensive
demyelination (Huseby et al., 2001). More recently, CD8 T cells generated from mice
immunized in the traditional way with myelin antigens in CFA also induced a severe
EAE when adoptively transferred to naïve recipients, demonstrating the pathogenic role
of CD8 T cells in EAE (Abdul-Majid et al., 2003; Ford and Evavold, 2005; Ji and
Goverman, 2007; Sun et al., 2001).

B cells and autoantibodies in EAE
Generally EAE is thought to be a T cell-mediated disease. It does not require B
cells and antibodies, as B cell-deficient mice develop severe disease (Lyons et al., 1999;
Wolf et al., 1996). Antibody titer and disease severity do not directly correlate (Cross et
al., 2001). However, the most important diagnostic
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marker

for

early

MS,

particularly in patients with normal brain scans, is the presence of oligoclonal antibodies
and plasma cells in CSF (Paolino et al., 1996). But the heterogeneity of antigen
specificity of these antibodies questioned whether there are consequences of MS-related
antigen or represent MS-unrelated B cell responses. A very small proportion of these
antibodies were found to be against myelin antigens but their contribution to the actual
disease process is unknown (Cross et al., 2001; Ziemssen and Ziemssen, 2005).
B cells, plasma cells and myelin-specific antibodies are present in MS plaques
and areas of demyelination (Genain et al., 1999). However, evidence that autoantibodies
cause demyelination came from observations that administration of antimyelin antibodies
enhanced demyelination in rats and non-human primates (Genain et al., 1999;
Schluesener et al., 1987). In mice, it was found that B cells are critical in EAE induction
with MOG protein but not peptide (Lyons et al., 1999). Even though autoantibodies that
recognize many myelin proteins such as MBP and PLP have been identified to promote
demyelination and potentiate EAE (Cross et al., 2001; Endoh et al., 1986), antibodies to
MOG are considered to be more critical because MOG is expressed on the outer surface
of the myelin sheath (Gardinier et al., 1992).
Transgenic mice producing high titers of anti-MOG antibodies did not develop
spontaneous EAE but developed an early and exacerbated disease upon induction,
indicating that the autoantibodies can modify the disease course and pathogenesis
(Litzenburger et al., 1998). Anti-MOG antibodies capable of inducing EAE require
glycosylated epitopes on the surface of oligodendrocytes (Marta et al., 2005) and their
demyelinating ability depends on the activation of complement cascade rather than direct
cell mediated cytotoxicity (Urich et al., 2006). Additionally, B cells function as antigen
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presenting cells. The autoantibodies increase myelin opsonization and subsequent
phagocytosis by macrophages and microglial cells and thus contribute to demyelination
(Jegou et al., 2007; Ziemssen and Ziemssen, 2005).

Genetic susceptibility of EAE
The observation that different strains of mice differ significantly in their
susceptibility to EAE was made in the first study of EAE in mice when it was noted that
Swiss mice were susceptible to EAE induced by brain-tissue homogenate in Fruend’s
adjuvant, while the Rockefeller Institute strain of mice did not develop the disease
(Olitsky and Yager, 1949). Subsequently, a large number of studies analyzing the genetic
control of susceptibility and resistance to EAE have been carried out using inbred strains
of mice and, to date, a total of 40 quantitative trait loci (QTL) have been identified (Baker
et al., 1995; Blankenhorn et al., 2000; Butterfield et al., 1999; Butterfield et al., 1998;
Encinas et al., 1996; Encinas et al., 2001; Fillmore et al., 2003; Karlsson et al., 2003;
Mazon Pelaez et al., 2005; Sundvall et al., 1995; Teuscher et al., 2006a). A genomic
region on chromosome 17 containing MHC genes, like in MS, has been the strongest and
consistently linked region in EAE. Also, this was the first QTL to be identified (Fritz et
al., 1985).
A large number of non-MHC loci have also been identified to control EAE
susceptibility in mice. Among these, in addition to loci that control clinical disease
parameters, such as incidence (Baker et al., 1995; Bakker et al., 2002; Butterfield et al.,
1998; Encinas et al., 1996; Sundvall et al., 1995), disease onset (Butterfield et al., 1998;
Mazon Pelaez et al., 2005) and disease severity (Baker et al., 1995; Butterfield et al.,
1998; Mazon Pelaez et al., 2005), genes that control sub-phenotypes of the disease,
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such as histopathological lesion-severity either in the brain (Blankenhorn et al., 2000;
Butterfield et al., 1999; Karlsson et al., 2003) or spinal cord (Baker et al., 1995;
Blankenhorn et al., 2000; Butterfield et al., 1998; Karlsson et al., 2003), weight loss
(Encinas et al., 1996; Encinas et al., 2001), demyelination (Blankenhorn et al., 2000),
inflammation (Encinas et al., 2001; Mazon Pelaez et al., 2005) and paralysis (Encinas et
al., 2001), have been identified. QTLs controlling disease-subtypes, such as acute
progressive,

remitting-relapsing,

chronic

non-remitting

and

monophasic

non-

remitting/non-relapsing EAE (Butterfield et al., 1999; Karlsson et al., 2003), and those
controlling electro-pathophysiological changes of neurons that reflect the extent of
demyelination (Mazon Pelaez et al., 2005) have been reported.
EAE and MS are sexually dimorphic diseases with more females affected than
males. Accordingly, most of the loci identified are gender specific (Butterfield et al.,
1999; Fillmore et al., 2004; Fillmore et al., 2003). The effect of the Y-chromosome,
reflecting parent-of-origin, has also been documented (Teuscher et al., 2006a). In
addition, extrinsic factors such as the physical structure of the antigen-CFA containing
particles (on the surface against buried within) of the emulsion (Fillmore et al., 2003),
age and season (Fillmore et al., 2004; Teuscher et al., 2006a), use of pertussis toxin
(Blankenhorn et al., 2000) have been shown to override genetic checkpoints,
demonstrating the role of gene-environmental interactions in the disease susceptibility.
Thus different loci are linked to different aspects of the disease development process and
may reflect the heterogeneity observed in MS patients. The study of these loci in isolation
and their contribution to disease development may help in understanding the inherent
heterogeneity of the disease. One such locus is Bordetella pertussis induced histamine
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sensitization (Bphs), controlling susceptibility to histamine-induced death in PTX
sensitized mice (Sudweeks et al., 1993), has been identified to be Hrh1, the gene
encoding histamine receptor H1 protein (Ma et al., 2002).

Identification of histamine receptor H1 as a susceptibility gene in EAE
Anaphylactic-like hypovolemic shock syndromes can be induced in mice by
injecting vasoactive amines such as histamine or serotonin or a mixture of both (Bergman
and Munoz, 1965, 1968; Harris and Fulton, 1958; Iff and Vaz, 1966). Inbred strains of
mice varied in their sensitivity to these agents and the variation was genetically
determined (Bergman and Munoz, 1968; Iff and Vaz, 1966; Parfentjev, 1955; Tokuda et
al., 1963). Subsequently, it was found that products from Bordetella pertussis
significantly enhanced this sensitivity to vasoactive amine treatment and that inbred
strains of mice differ in their susceptibility to the enhancing effect. The B. pertussis
product was later identified as PTX (Bergman and Munoz, 1968; Black et al., 1988;
Munoz, 1957; Munoz, 1963; Vaz et al., 1977). SJL/J is the prototypic susceptible mouse
strain and C3H/HeJ and CBA/J are the prototypic resistant strains of mice to the PTXinduced histamine sensitivity. The susceptibility of inbred strains to the histaminesensitizing effects of PTX was found to be under the control of a single autosomal
dominant gene (Wardlaw, 1970). The strains of mice susceptible for Bphs developed
EAE, while the strains resistant to Bphs did not (Linthicum, 1982). However, it is
noteworthy that there are some exceptional strains of mice, suggesting that additional
genes control the disease susceptibility. Bphs is also associated with susceptibility to
experimental allergic orchitis (Teuscher, 1985).
Using microsatellite and random amplified polymorphic DNA (RAPD)
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markers and backcross populations of susceptible SJL/J and resistant C3H/HeJ and
CBA/J strains, the Bphs locus was mapped to a 33 centimorgan (cM) region of mouse
chromosome 6 (Sudweeks et al., 1993). The candidate interval was further refined to an
interval to include fewer genes (Meeker et al., 1999). For positionally cloning Bphs, a
panel of interval specific congenic lines was generated by introgressing the susceptible
SJL/J allele onto the resistant C3H/HeJ background. Studies of histamine sensitivity in
the congenic lines established that Bphs resided in a region containing Hrh1 (Ma et al.,
2002). The identity of Hrh1 as Bphs was further confirmed by the complete resistance of
histamine receptor H1 knock out (H1RKO) mice to Bphs. Further, H1RKO mice
exhibited a reduced severity and delayed onset of EAE compared to the wild type (WT)
mice (Ma et al., 2002), indicating that histamine, acting through histamine receptor H1,
regulates EAE.

Histamine and histamine receptor H1
Histamine [2-(4-imidazole) ethylamine] is a ubiquitously distributed biogenic
amine that mediates diverse physiological processes including neurotransmission and
brain functions, secretion of pituitary hormones, and regulation of gastrointestinal and
circulatory functions (Parsons and Ganellin, 2006). Additionally, histamine is a potent
mediator of inflammation and a regulator of innate and adaptive immune responses
(Akdis and Simons, 2006).
Mast cells and basophils are the major sources of stored histamine (Code and
Mitchell, 1957; Riley and West, 1953). The granule-stored histamine from these cells is
rapidly released upon various immunological and non-immunological stimuli. Mast celldeficient mice were induced to synthesize
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histamine upon phorbol ester stimulation

(Taguchi et al., 1982). This “nascent” or “inducible” histamine is proposed to be
synthesized by the induction of L-histidine decarboxylase (HDC), the rate-limiting
enzyme for histamine synthesis in cells such as activated monocytes/macrophages and
neutrophils (Ghosh et al., 2002; Kahlson and Rosengren, 1968; Shiraishi et al., 2000;
Takamatsu et al., 1996; Tanaka et al., 2004). T cells, B cells and dendritic cells also
synthesize “inducible” histamine (Aoi et al., 1989; Kubo and Nakano, 1999; Szeberenyi
et al., 2001). As these cells lack storage vesicles, histamine synthesized is immediately
released. The HDC activity is modulated by a variety of stimuli during infections and
inflammation (Schneider et al., 2002).
Histamine exerts its pleiotropic effect through four receptors that are designated
as histamine receptor H1, H2, H3, and H4, according to the chronological order of their
discovery (Hill et al., 1997; Parsons and Ganellin, 2006). H1R is widely distributed on a
variety of tissues and cell types including: mammalian brain; gastrointestinal tract;
genitourinary system; cardiovascular system; adrenal medulla; hepatocytes; nerve cells;
airway and vascular smooth muscle cells; endothelial cells; eosinophils; monocytes
neutrophils; dendritic cells; and lymphocytes (both T and B cells) (Hill et al., 1997;
Parsons and Ganellin, 2006; Smit et al., 1999). Biochemical characterization of the H1R
protein using photoaffinity binding studies and gel electrophoresis under reducing
conditions has revealed a molecular weight of 56kDa in mice, rats and guinea pig brain
(Ruat et al., 1988; Ruat and Schwartz, 1989; Ruat et al., 1990; Smit et al., 1999).
Purification of H1R protein has not been successful thus far. H1R was first cloned
from bovine adrenal medulla, which yielded an intron-less gene (Yamashita et al., 1991).
This enabled subsequent cloning of H1R from several species including mouse, which
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mapped to chromosome 6 (Inoue et al., 1996). The deduced amino acid sequence
represented a 488 amino acid protein with calculated molecular weight of 56kDa.
Modeling of the protein revealed the presence of seven transmembrane domains,
characteristic of G protein coupled receptors (GPCRs). A striking feature of the proposed
structure was a very large third intracytoplasmic loop (212 amino acids) and relatively
short intracellular C-terminal tail (17 amino acids). The histamine binding pocket is
formed between the third (TM3) and fifth (TM5) transmembrane domains (Hill et al.,
1997; Jongejan et al., 2005; Smit et al., 1992). Similar to H1R, H2R is also expressed on a
variety of cell types, while H3R expression is restricted mostly to neuronal cells in the
brain and some peripheral tissues. H4R is expressed exclusively on cells of hematopoietic
origin (Parsons and Ganellin, 2006).
GPCRs transduce the external signal of ligand binding by activating
heterotrimeric G proteins, which in turn couple to a variety of second messenger
signaling pathways (Fredholm et al., 2007). H1R couples to second messenger signaling
pathways via the activation of G proteins belonging to Gαq/11 sub-family (Parsons and
Ganellin, 2006). Generally, activation of H1R leads to stimulation of phospholipase C,
resulting in the hydrolysis of phosphatidylinositol 4,5-bisphosphate (PIP2) to form
inositol-1,4,5-trisphosphate (IP3) and diacylglycerol (DAG), which causes calcium
mobilization from intracellular stores and activation of protein kinase C (PKC),
respectively (Hill et al., 1997). In addition, H1R signaling also mediates other signaling
pathways such as the production of phospholipase A2 and arachidonic acid (Leurs et al.,
1994), cGMP and nitric oxide (Hill, 1992; Leurs et al., 1995; Satoh and Inui, 1984; Toda,
1987), and the activation of NF-κB (Bakker
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et al., 2001), STAT1 (Sakhalkar et al.,

2005), and STAT4 (Engelhardt, 2006). H1R-mediated PKCα stimulation activates MAP
kinase pathways, particularly MEK1 (Lipnik-Stangelj and Carman-Krzan, 2004; Megson
et al., 2001), ERK MAP kinase and p38 MAP kinase (Robinson and Dickenson, 2001;
Steffel et al., 2005) (Chapter 2). Even though H1R is the first histamine receptor to be
identified and a large number of studies on histamine and H1R have been published in the
last decade (Simons, 2004), little is known about the cell-type specific H1R signaling
pathways.
H2R signaling is mediated via the Gαs subfamily of G proteins and primarily leads
to increased cAMP production and calcium mobilization (Alewijnse et al., 1998; Del
Valle and Gantz, 1997; Leurs et al., 1994; Smit et al., 1996). H3R is coupled to Gαi/o
subfamily of G proteins and leads to inhibition of cAMP and accumulation of calcium
(Krueger et al., 2005). H4R signaling is also mediated by coupling to Gαi/o subfamily of G
proteins and induces calcium mobilization, inhibits cAMP production and activates MAP
kinases (Buckland et al., 2003; Hofstra et al., 2003; Morse et al., 2001).
In endothelial cells, H1R-mediated calcium mobilization and PKC activation
promotes cytoskeletal changes to induce cell shape change (Lum and Malik, 1994).
Additionally, H1R-mediated signals lead to disassembly of VE-cadherin complexes that
regulate endothelial barrier function (Gao et al., 2000; Winter et al., 1999). These effects
result in increased vascular permeability. H1R signaling also increases expression of
adhesion molecules such as ICAM-1, VCAM-1 and P-selectin on endothelial cells
(Gonzalez-Scarano et al., 1987; Kubes and Kanwar, 1994; Yamaki et al., 1998).
In dendritic cells, H1R provides positive signals for enhanced antigen presentation
capacity

by

upregulating

several

co- stimulatory molecules such as CD80 and
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CD86 by increasing the production of proinflammatory cytokines such as IL-1, IL-6, IL8, MCP-1 and MIP-1α and Th1 priming activity of these cells (Caron et al., 2001;
Mazzoni et al., 2001; Meretey et al., 1991). In contrast, H2R acts as a negative signal for
many of these functions. H1R induces intracellular calcium flux, actin polymerization and
chemotaxis by immature dendritic cells (Mazzoni et al., 2001). H1R is upregulated in
monocyte-derived macrophages and leads to calcium mobilization and enhanced IL-8
production (Triggiani et al., 2007). Treatment of macrophages, isolated from lung
parenchyma, with H1R blockers led to lower IL-6 production (Triggiani et al., 2001).
In B cells, H1R signals enhance anti-IgM mediated proliferation and antibody
production against a T cell-independent antigen, TNP-ficoll, indicating that H1R signals
are important in B cell receptor-triggered responses (Banu and Watanabe, 1999). H1RKO
mice produce higher ova-specific IgG1 and IgE compared to the WT mice, indicating that
H1R suppresses humoral responses (Banu and Watanabe, 1999; Jutel et al., 2001).
Studies using total splenocytes have shown that H1R regulates antigen-specific Tcell effector functions and modulates production of the cytokines IFN-γ and IL-4 (Bakker
et al., 2002; Banu and Watanabe, 1999; Bryce et al., 2006; Jutel et al., 2001) Chapter two
of this thesis will demonstrate that H1R in purified CD4 T cells regulates IFN-γ and IL-4
production.

Histamine and histamine receptor H1 in MS and EAE
The first observation of the role of histamine and histamine receptors in EAE
came from the use of pharmacological anti-histaminic agents to block the development of
the disease (Linthicum, 1982). Subsequently, several studies used these drugs,
particularly H1R blockers, to reduce the pathology of EAE (Chabas et al., 2001;
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Dietsch and Hinrichs, 1989; Dimitriadou et al., 2000; El Behi et al., 2007; Pedotti et al.,
2003; Waxman et al., 1984). The genetic susceptibility to EAE development was
originally thought to be a function of MHC genes and genes controlling hypersensitivity
to histamine (Linthicum, 1982). An analysis of CSF from several MS patients showed a
60% higher histamine content than the control group, while histamine-Nmethyltransferase, a histamine metabolizing enzyme, was lower than the control group
(Tuomisto et al., 1983). Microarray analysis of chronic plaques in MS patients revealed
relative overexpression of H1R transcripts (Dormond et al., 2002). Administration of antiH1R agents either reduced the risk of MS (Alonso et al., 2006) or improved the
neurological symptoms (Logothetis et al., 2005). H1RKO mice exhibit milder disease
than WT mice (Bakker et al., 2002)(chapter 2 and 3). Mice deficient in H2R also develop
an attenuated disease (Teuscher et al., 2004). EAE is significantly enhanced in H3Rdeficient (Teuscher et al., 2007) and H4R-deficient mice (Teuscher, unpublished data).
Mice deficient in histidine decarboxylase, and therefore in histamine, develop more
severe disease than WT mice (Musio et al., 2006). All these findings indicate a regulatory
role for histamine in the pathogenesis of EAE.
Mast cells and basophils are the major source of histamine in the body (Mekori
and Metcalfe, 2000). It has long been known that mast cells accumulate at the site of
inflammatory demyelination in the brain and spinal cord both in animal models and in
MS patients (Bebo et al., 1996; Brenner et al., 1994; Dietsch and Hinrichs, 1989; Ibrahim
et al., 1996; Kermode et al., 1990; Olsson, 1974; Orr, 1988). Mast cell numbers and/or
distribution correlated with MS lesion and EAE susceptibility (Brenner et al., 1994).
Mast cell-stabilizing drugs have been shown to improve disease symptoms in EAE
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(Brosnan and Tansey, 1984; Dietsch and Hinrichs, 1989; Seeldrayers et al., 1989). Mast
cell-deficient mice exhibited delayed onset and reduced disease severity compared to the
WT mice. The disease was restored upon reconstitution of these mice with bone marrow
derived-mast cells (Secor et al., 2000), indicating a pathologic role for mast cells in EAE.
Interestingly, reconstituted mast cells were present only in peripheral tissues but not in
the brain and spinal cord, an observation confirmed by another independent study
(Tanzola et al., 2003). The number of reconstituted mast cells in the spleen decreased
with increased disease severity. While no mast cells were detected in the lymph node of
naïve reconstituted animals, a large number of them were present in the draining inguinal
lymph node in diseased animals (Tanzola et al., 2003). These findings suggest that mast
cells act in the periphery, rather than the CNS, and therefore influence EAE during the
induction phase rather than the effector phase. In addition, immunized mast cell-deficient
mice had lower frequency of IFN-γ positive cells in the draining lymph node than WT
mice. Ex-vivo stimulated T cells from these mice produced significantly lower IFN-γ and
IL-4 than WT mice (Secor et al., 2000) (Tanzola et al., 2003). These results suggest that
mast cells, and therefore histamine, provide a permissible microenvironment for the
optimal induction of autoreactive T cells in the secondary lymphoid organs.
Due to its activity in multiple cell types including endothelial cells, antigen
presenting cells and T cells, histamine acting through H1R can function at several critical
checkpoints during both induction and effector phases of EAE. In Chapter 2, it is
demonstrated that H1R exerts its effects during the induction of encephalitogenic T cells
and that expression of H1R in T cells is sufficient to restore clinical disease severity and
cytokine production in H1RKO mice to the

WT levels, independent of its actions in
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other cell types important in the disease process. Further, in Chapter 3, it is established
that even though the resistant allele of H1R differs only by three amino acids from the
susceptible allele, it confers resistance to disease due to lack of cell surface expression.
In endothelial cells, as described before, H1R signaling leads to vasodilation,
increased vascular permeability and thus affects BBB integrity. H1R signaling also acts as
a secretagogue for the regulated release of the stored factors from endothelial-specific
storage vesicles called Weibel-Palade bodies (WPBs) (Hattori et al., 1989). The WPBs
contain several vasoactive factors such as von Willebrand factor, P-selectin, and IL-8, the
syntheses of which are induced by inflammatory signals including PTX (Rondaij et al.,
2006). When these factors are released, they act on the endothelial cells in an autocrine
fashion. The direct vasodilatory effects of histamine combined with the autocrine effects
of the WPB contents are likely to result in shock and the death observed during the
effector phase of Bphs. However, in Appendix A, it is shown that the release of WPB
contents do not mediate the shock observed during the Bphs.
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Abstract
Histamine H1 receptor (H1R) is a shared susceptibility gene in experimental
allergic encephalomyelitis (EAE) and orchitis (EAO), two classical T-cell mediated
models of organ-specific autoimmune diseases. Here we show that expression of H1R in
CD4 T cells is required for IFNγ production but is dispensable for proliferation. H1R
ligation is necessary for TCR-mediated activation of p38 MAP kinase, a known regulator
of IFNγ expression. Importantly, selective expression of H1R in CD4 T cells fully
complements both IFNγ production and EAE susceptibility of H1R deficient mice. Thus,
the presence of H1R in CD4 T cells and its interaction with histamine regulates early
TCR signals that lead to Th1 differentiation and autoimmune disease.
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Introduction
Histamine [2-(4-imidazole) ethylamine] is a ubiquitous mediator of diverse
physiological processes including neurotransmission and brain functions, secretion of
pituitary hormones, and regulation of gastrointestinal and circulatory functions (Parsons
and Ganellin, 2006). Additionally, histamine is a potent mediator of inflammation and a
regulator of innate and adaptive immune responses (Akdis and Simons, 2006). Histamine
exerts its effect through four receptors that belong to the seven-transmembrane G proteincoupled receptor family and are designated histamine H1, H2, H3, and H4 receptor,
according to the chronological order of their discovery (1, 3).
H1R couples to second messenger signaling pathways via the activation of
heterotrimeric Gαq/11 family of G proteins (Parsons and Ganellin, 2006). Generally,
activation of H1R leads to stimulation of phospholipase C, resulting in the hydrolysis of
phosphatidylinositol 4,5-bisphosphate (PIP2) to form inositol-1,4,5-trisphosphate (IP3)
and diacylglycerol (DAG), which causes calcium mobilization from intracellular stores
and activation of protein kinase C (PKC), respectively (Hill et al., 1997). In addition, H1R
signaling also mediates other signaling pathways such as the production of cGMP,
arachidonic acid and nitric oxide (Leurs et al., 1995), and the activation of NF-κB
(Bakker et al., 2001), STAT1 (Sakhalkar et al., 2005), STAT4 (Engelhardt, 2006) and
MAP kinase pathway (Lipnik-Stangelj and Carman-Krzan, 2004; Megson et al., 2001;
Robinson and Dickenson, 2001). However, even though H1R is the first histamine
receptor to be identified and a large number of studies on histamine and H1R have been
published in the last decade (Simons, 2004), little is known about the cell-type specific
H1R signaling pathways.
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In the immune system, histamine has been reported to be a potent modulator of
innate and adaptive immune responses. Histamine, acting through H1R, affects the
maturation of dendritic cells and alters their T cell-polarizing activity (Caron et al., 2001).
It regulates antigen-specific T-cell effector functions and the related antibody isotype
response (Banu and Watanabe, 1999). H1R signaling in splenocytes has been reported to
modulate cytokine secretion by these cells (Bakker et al., 2002; Banu and Watanabe,
1999; Bryce et al., 2006; Jutel et al., 2001) but no study has addressed the role of H1R in
purified CD4 T cells.
We have previously demonstrated that Hrh1 (encoding the mouse H1R protein) is
a

shared

susceptibility

gene

in

experimental

allergic

orchitis

(EAO)

and

encephalomyelitis (EAE), the autoimmune model of multiple sclerosis (MS) (Bakker et
al., 2002). In both MS and EAE, CD4 T cells secreting IFNγ (Th1) (Baron et al., 1993)
and/or IL-17 (Th17) (Krueger et al., 2005) are necessary and sufficient for eliciting EAE
pathology and clinical signs. The relative contributions of each of these cytokines to the
development of EAE in vivo are debated, because conflicting evidence exists on the
importance of IFNγ vs. IL-17. On the one hand, the importance of IL-17 is established in
studies showing that EAE is diminished in IL-23-deficient but not IL-12-deficient
animals (with no expression of the Th17-promoting or Th1-promoting cytokines,
respectively) (Cua et al., 2003), and severe EAE is observed in IFNγ knockout mice and
IFNγR knockout mice (Ferber et al., 1996; Willenborg et al., 1996). These findings
contrast with studies showing that either CD4 Th1 cells (Baron et al., 1993) or CD4 Th17
cells (Langrish et al., 2005) can transfer EAE to naïve recipients. Recent studies reporting
the predominant presence of a pre-Th1, IFNγ+/IL-17+ CD4 T cell subtype, early
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after induction of EAE with encephalitogenic myelin oligodendrocyte glycoprotein 35-55
(MOG35-55) peptide (Suryani and Sutton, 2007) may help resolve these apparent
inconsistencies. Nevertheless, IFNγ alone or in conjunction with IL-17, is wellestablished as a cytokine of relevance in EAE immunopathology.
We have previously shown that H1R deficient (H1RKO) mice exhibit a significant
delay in the onset of EAE and a reduction in the severity of the clinical signs compared to
wild-type (WT) mice (Bakker et al., 2002). This phenotype is associated with an immune
deviation of the elicited CD4 T cell population from a Th1 response to a Th2 response
with no detectable difference in IL-17 secretion, suggesting that the CD4 Th1 cells and
the IFNγ produced by them play an important role in the pathology of the disease. In this
report, we have studied the mechanism underlying the immune deviation, and show that
it is directly due to H1R regulation of cytokine responses in CD4 T cells, and not to H1R
expression in antigen presenting cells (APCs). In this study, we also show that H1R is
expressed in unstimulated CD4 T cells but is rapidly downregulated upon activation. H1R
is required for the activation of the p38 MAP kinase signaling pathway and for IFNγ
production in response to TCR stimulation in CD4 T cells. Finally, H1R mediated
signaling in CD4 T cells, independent of APCs, regulates the encephalitogenic Th1
effector cell response in EAE.
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Results
H1R expression is required for IFNγ production by CD4 T cells
MOG35-55 peptide-immunized H1RKO splenocytes produce less IFNγ and more
IL-4 than the splenocytes from immunized WT mice (Bakker et al., 2002). However, it is
not clear whether this immune deviation is due to the lack of H1R signaling in CD4 T
cells or in APCs. To investigate the role of H1R in regulating IFNγ production and Th1
differentiation, CD4 T cells were purified from WT and H1RKO mice and activated with
anti-CD3 and anti-CD28 monoclonal antibodies (mAbs) in the presence of recombinant
IL-12 and neutralizing anti-IL-4 mAb. After 4 days, Th1 effector cells were extensively
washed, counted and equal number of cells were re-stimulated with anti-CD3 mAb for 24
hours. Th1 effector cells from H1RKO mice produced considerably less IFNγ than WT
Th1 cells (Fig. 1A). We also examined the production of IL-4 upon re-stimulation of Th2
effector cells generated in presence of IL-4 and anti-IFNγ mAb. A marginal increase in
IL-4 production was observed in cells from H1RKO mice compared to cells from WT
mice (Fig. 1B). Recent studies have established IL-17 as an important cytokine in EAE
(20). Consequently, we examined IL-17 production by Th17 cells generated in the
presence of IL-6 and TGF-β and anti-IFNγ and anti-IL-4 mAbs. There was no difference
in IL-17 production by Th17 differentiated cells from H1RKO and WT mice (Fig. 1C).
Moreover, we examined the role of H1R in non-polarized effector cells, generated by
stimulating cells in the absence of exogenous cytokines for 4 days. Effector cells were
then re-stimulated with anti-CD3 mAb for 24 hours. CD4 T effector cells from H1RKO
mice produced significantly less IFNγ than those from WT mice (Fig. 1D). Thus, under
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these conditions, IFNγ production in H1RKO effector CD4 T cells is impaired.
IFNγ production by CD4 T cells contributes to their differentiation into Th1
effector cells (Robinson and O'Garra, 2002). To examine the role that H1R signaling
plays in this process, purified CD4 T cells from H1RKO and WT mice were stimulated
with anti-CD3 and anti-CD28 mAbs for different periods of time and IFNγ production
was quantified. CD4 T cells from H1RKO mice produced significantly lower IFNγ than
those from WT mice at all time points examined (Fig. 1E). In contrast, no difference in
IL-2 production between WT and H1RKO CD4 T cells was observed (Fig. 1F).
Furthermore, proliferation was comparable between WT and H1RKO CD4 T cells (Fig.
1G). Taken together, these results demonstrate that H1R expression in CD4 T cells plays
a critical role in regulating IFNγ production during the activation and differentiation of
these cells.
H1R gene expression is downregulated early upon TCR activation
In order to demonstrate that the reduced secretion of IFNγ by CD4 T cells is due
to the absence of a functional H1R in these cells, we carried out H1R complementation in
to H1RKO CD4 T cells by retroviral transduction. We generated a retroviral construct
using the pEGZ-HA vector where H1R was subcloned downstream of a hemagglutinin
(HA) tag and upstream of IRES-EGFP. To confirm that the HA-H1R could be properly
expressed we transiently transfected HEK293T cells with the pEGZ-HA-H1R construct
and examined its expression by Western blot analysis using anti-HA mAb. A band
corresponding to the HA-H1R size (~55 kDa) was present only in HA-H1R transfected
cells (Fig. 2A). To demonstrate that the HA-H1R was expressed on the cytoplasmic
membrane,

the

HA-H1R

transfected HEK293T cells were stained using anti40

HA mAb and examined by confocal microscopy. HA-H1R was expressed on the
cytoplasmic membrane only in HA-H1R transfected cells (Fig. 2B).
H1R coupling to second messenger pathways is primarily via Gαq/11 (Parsons and
Ganellin, 2006). The ability of the transfected HA-H1R to activate Gα11 was tested in a
[35S] GTPγS binding assay. When membrane fractions from transfected HEK293 cells
were used in the [35S] GTPγS binding assay, HA-H1R was capable of activating Gα11 in
response to histamine (Fig. 2C). Taken together, these results show that HA-H1R is
properly expressed and is functional.
To perform retroviral transduction, CD4 T cells were isolated from H1RKO and
WT mice, activated with anti-CD3 and anti-CD28 mAbs for 16 hours and transduced
with either pEGZ or pEGZ-HA-H1R retroviruses. Expression of HA-H1R in transduced
CD4 T cells was confirmed by confocal microscopy and flow cytometry (data not
shown). After 2 days, transduced CD4 T cells were isolated by cell sorting based on
EGFP expression and equal numbers of cells were activated with anti-CD3 mAb for an
additional 24 hours. Both pEGZ and pEGZ-HA-H1R transduced CD4 T cells from
H1RKO mice produced significantly lower levels of IFNγ than those from WT mice (Fig.
3A). These results indicate that the expression of H1R in activated CD4 T cells does not
restore the IFNγ production in H1R deficient cells.
Retroviral transduction requires prior activation of CD4 T cells for at least 16
hours to induce cell cycling. Thus, if H1R is normally required during the early phase of
activation concomitant with TCR engagement, the retroviral transduction would not
rescue the H1R deficiency. Our results above (Fig.1C) indicated that the IFNγ production
was already reduced at 36 hours in H1RKO

CD4 T cells compared to the WT cells.
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We therefore examined IFNγ production by H1RKO CD4 T cells earlier during the
activation with anti-CD3 and anti-CD28 mAbs. Although lower levels of IFNγ were
present in WT CD4 T cells at 24 hours of activation, H1RKO CD4 T cells still produced
significantly less IFNγ (Fig. 3B) indicating that H1R plays a role early during the
activation of CD4 T cells.
H1R expression during mouse T cell activation has not been investigated. We
therefore analyzed the H1R gene expression in WT CD4 T cells stimulated for different
periods of time with anti-CD3 and anti-CD28 mAbs. Relative levels of H1R mRNA were
examined by conventional and quantitative real time RT-PCR analysis. CD4 T cells
markedly downregulated H1R mRNA expression by 24 hours after activation (Fig. 3C
and 3D), further indicating that H1R plays a role early (< 24 hours) after TCR
engagement and that it is not required for IFNγ production by CD4 T cells once they are
activated.
Selective H1R expression in T cells in transgenic mice restores IFNγ production
To examine the role of H1R during the initial activation of CD4 T cells, we
generated transgenic mice expressing H1R under the control of distal lck promoter, which
drives expression in T cells (Wildin et al., 1991). Transgenic mice were generated
directly on the C57BL/6J background. Two transgenic founders were identified and
crossed to H1RKO mice to obtain H1RKO mice expressing H1R selectively in T cells
(H1RKO-Tg mice). The expression of the transgene in CD4 T cells from two lines
(H1RKO-Tg-1 and H1RKO-Tg-3) was confirmed by RT-PCR using transgene-specific
primers (Fig. 4A). We examined the surface expression of the transgene in CD4 T cells
by immuno-staining using anti-HA mAb and
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confocal microscopy (Fig. 4B). The

transgene was expressed in CD4 T cells from both transgenic lines. No differences in the
total numbers or distribution of T cell subpopulations in the thymus and peripheral
lymphoid tissues were observed among WT, H1RKO and either of the H1RKO-Tg lines
(data not shown).
We then examined whether the expression of H1R in H1RKO CD4 T cells
restored IFNγ production. CD4 T cells from WT, H1RKO and H1RKO-Tg mice were
stimulated with anti-CD3 and anti-CD28 mAbs and IFNγ levels quantified. The levels of
IFNγ secreted by CD4 T cells from H1RKO-Tg-3 were comparable to WT CD4 T cells
and those from H1RKO-Tg-1 remained slightly lower than the WT CD4 T cells but
significantly higher than the levels in H1RKO CD4 T cells (Fig. 4C). Analyses at
different periods of time after activation confirmed that the transgenic expression of H1R
in H1RKO CD4 T cells fully restores IFNγ production (Fig. 4D).
We also studied the IFNγ production from Th1 polarized and non-polarized
effector cells from H1RKO-Tg mice. CD4 T cells from WT, H1RKO and H1RKO-Tg
mice were differentiated in the absence of exogenous cytokines (non-polarized) or in the
presence of recombinant IL-12 and anti IL-4 mAb (Th1). After 4 days, effector cells were
re-stimulated with anti-CD3 mAb for 24 hours and IFNγ production was measured. Both
Th1 polarized (Fig. 4E) and non-polarized CD4 effector T cells (Fig. 4F) from H1RKOTg mice produced significantly more IFNγ than the H1RKO effectors. Furthermore, the
levels of IFNγ in H1RKO-Tg cells were comparable to those in WT CD4 T cells.
Together, these data demonstrate that the presence of H1R at the time of activation of
CD4 T cells under both polarizing and non-polarizing conditions regulates IFNγ
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production and Th1 differentiation.
Impaired activation of p38 MAP kinase by TCR ligation in H1RKO CD4 T cells
In order to dissect the molecular mechanism of H1R signaling in regulating IFNγ
production by CD4 T cells, we examined the signaling pathways that have been
previously associated with H1R in other cell types. NF-κB has been shown to be activated
through H1R in green monkey kidney cells (Bakker et al., 2001) and has been associated
with regulation of IFNγ expression in CD4 T cells (Aronica et al., 1999). Therefore, we
performed an electrophoretic mobility shift assay (EMSA) to examine NF-κB DNA
binding. CD4 T cells from WT and H1RKO mice were stimulated with anti-CD3 and
anti-CD28 mAbs for different periods of time. There was no difference in NF-κB
activation between WT and H1RKO CD4 T cells (Fig. 5A). STAT1 is also known to
regulate IFNγ expression in CD4 T cells (Ramana et al., 2002) and it has recently been
shown that H1R signaling regulates STAT1 phosphorylation in splenocytes (Sakhalkar et
al., 2005). Therefore we examined activation of STAT1 by Western blot analysis in
stimulated CD4 T cells. STAT1 phosphorylation was undetected at early time points up
to 3 hours of activation in both WT and H1RKO cells (data not shown). Phospho-STAT1
was detected after 3 hours of activation but there was no difference in STAT-1
phosphorylation between WT and H1RKO CD4 T cells (Fig. 5B). Although H1R
signaling has also been reported to regulate STAT4 phosphorylation in splenocytes
(Engelhardt, 2006), phospho-STAT4 was not detected in WT and H1RKO CD4 T cells
after activation with anti-CD3 and anti-CD28 mAbs (data not shown).
H1R ligation has recently been shown to lead to the phosphorylation of p38 MAP
kinase in DDT1MF-2 cells (Robinson and

Dickenson, 2001) and in human aortic
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endothelial cells (Steffel et al., 2005). Activation of p38 MAP kinase pathway is required
for IFNγ production and Th1 differentiation (Rincon et al., 1998). We therefore examined
the activation of p38 MAP kinase by Western blot analysis. CD4 T cells from WT and
H1RKO mice were stimulated with anti-CD3 and anti-CD28 mAbs for different periods
of time. p38 MAP kinase was activated in WT CD4 T cells but was markedly impaired in
H1RKO CD4 T cells (Fig. 5C). In contrast, no difference in ERK MAP kinase activation
was observed between WT and H1RKO CD4 T cells (Fig. 5D). As has been reported by
us previously (Weiss et al., 2000), activation of JNK MAP kinase could not be detected at
the earlier time points in both WT and H1RKO CD4 T cells stimulated with anti-CD3
and anti-CD28 mAbs (data not shown). We further examined the activation of p38 MAP
kinase by TCR ligation in H1RKO-Tg CD4 T cells. Unlike H1RKO CD4 T cells, the
levels of phospho p38 MAP kinase in H1RKO-Tg CD4 T cells were equivalent to those
in the WT CD4 T cells (Fig. 5E). Thus, TCR mediated activation of p38 MAP kinase
required the presence of H1R in CD4 T cells.
Activation of p38 MAP kinase by TCR is mediated by histamine/H1R binding
To understand the mechanism by which H1R could regulate TCR mediated p38
MAP kinase activation, we examined if histamine itself could activate the p38 MAP
kinase in CD4 T cells. Histamine is already present at low concentrations (about 10-7M)
in the serum used for the culture medium. Therefore, we assessed p38 MAP kinase
phosphorylation in response to histamine using a medium prepared with previously
dialyzed serum to deplete histamine (Banu and Watanabe, 1999). CD4 T cells from WT
and H1RKO mice were resuspended in the histamine-free medium and treated with
histamine. p38 MAP kinase was activated by histamine in WT CD4 T cells but not
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in H1RKO CD4 T cells (Fig. 6A), indicating that histamine activates this pathway in
CD4 T cells through H1R.
Since histamine was present in the normal medium used to activate CD4 T cells
with anti-CD3 and anti-CD28 mAbs (Fig. 5C and 5E), it was possible that the activation
of p38 MAP kinase by TCR ligation was co-dependent upon histamine signaling through
the H1R. To test this possibility, we examined p38 MAP kinase activation upon anti-CD3
and anti-CD28 mAb stimulation in histamine-free medium. TCR ligation failed to
activate p38 MAP kinase in both WT and H1RKO CD4 T cells in histamine-free medium
(Fig. 6B). In contrast, the absence of histamine did not affect TCR-mediated ERK
activation (Fig.8) or the intracellular calcium mobilization (data not shown) in WT CD4
T cells. To further demonstrate the selective requirement for histamine in TCR-mediated
p38 MAP kinase activation, WT and H1RKO CD4 T cells were stimulated in histaminefree medium with anti-CD3 and anti-CD28 mAbs in the presence of histamine. TCRmediated p38 MAP kinase activation was restored by histamine in WT CD4 T cells but
not in H1RKO CD4 T cells (Fig. 6C), indicating that binding of histamine to H1R was
required for activation of p38 MAP kinase upon TCR ligation. Interestingly, the levels of
phospho-p38 MAP kinase in WT CD4 T cells treated anti-CD3 and anti-CD28 mAbs and
histamine were similar to the levels obtained when the cells were treated with histamine
alone (Fig. 6C). The inability of TCR to activate p38 MAP kinase in H1R deficient cells
in normal medium (Fig. 5C), the inability of TCR ligation to activate p38 MAP kinase in
the histamine-free medium (Fig. 6B) and the inability of TCR to further increase p38
MAP kinase activation when histamine was added to the histamine free medium strongly
suggest that the activation of p38 MAP kinase observed upon TCR ligation is dependent
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upon concomitant H1R signaling.
Although the precise mechanism by which p38 MAP kinase regulates IFNγ
production in CD4 T cells remains unclear, recent studies have suggested that the
activation of the this MAP kinase pathway is required for T-bet expression (Engelhardt,
2006; Jones et al., 2003) and T-bet regulates IFNγ production (Szabo et al., 2000). We
therefore examined T-bet expression by Western blot analysis during activation of WT
and H1RKO CD4 T cells. T-bet levels were lower in activated H1RKO CD4 T cells
compared to the WT CD4 T cells (Fig. 6D). Thus, the impairment in p38 MAP kinase
activation in the absence of H1R reduces the T-bet expression and thereby IFNγ
production by CD4 T cells during TCR activation.
In order to demonstrate that the reduced p38 MAP kinase activation in H1RKO
CD4 T cells in responsible for the lower IFNγ production by these cells, we crossed
H1RKO mice with the previously described distal MKK6Glu-Tg mice (Rincon et al.,
1998). These mice express a constitutively active form of MKK6, a specific upstream
activator of p38 MAP kinase, under the control of dlck promoter to drive the expression
in T cell lineage. Thus p38 MAP kinase is constitutively and selectively active in T cells
in these mice. Anti-CD3 and anti-CD28 mAb stimulated CD4 T cells from H1RKOMKK6Glu-Tg mice produced significantly more IFNγ than CD4 T cells from littermate
H1RKO mice (Fig. 6E), indicating that the diminished activation of p38 MAP kinase in
H1RKO CD4 T cells is responsible for the reduced IFNγ production by these cells.
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H1R signaling directly in CD4 T cells regulates encephalitogenic Th1 effector
responses
As a shared autoimmune disease susceptibility gene, Hrh1 has been shown to
control numerous disease associated subphenotypes, including blood brain barrier
permeability, antigen presentation and delayed type hypersensitivity responses (Caron et
al., 2001; Gao et al., 2003). To assess whether or not H1R signaling in CD4 T cells
influences EAE by regulating encephalitogenic Th1 responses, we examined the
susceptibility of H1RKO and H1RKO-Tg mice to EAE using the classical MOG3555+CFA+PTX

model and the 2× MOG35-55+CFA model (Teuscher et al., 2006a), which

does not use PTX as an ancillary adjuvant. Regression analysis (Teuscher et al., 2006a)
revealed that the clinical disease courses elicited by both induction protocols fit a
Sigmoidal curve and that compared to H1RKO mice the clinical course of EAE is
significantly more severe in the transgenic mice [MOG35-55+CFA+PTX model: (overall F
= 66.1; p < 0.0001) with WT (F = 132.1; p < 0.0001), H1RKO-Tg-1 (F = 127.5; p <
0.0001), and H1RKO-Tg-3 (F = 83.3; p < 0.0001) mice significantly greater than
H1RKO mice; 2× MOG35-55+CFA model: (overall F = 8.9; p < 0.0001) with WT (F =
226.9; p < 0.0001), H1RKO-Tg-1 (F = 134.0; p < 0.0001) and H1RKO-Tg-3 (F = 215.8;
p < 0.0001) mice significantly greater than H1RKO mice].
An analysis of EAE associated clinical quantitative trait variables (Butterfield et
al., 1998) revealed that the mean day of onset (DO), cumulative disease score (CDS),
number of days affected (DA), overall severity index (SI) and the peak score (PS) were
significantly different among the strains immunized with either MOG35-55+CFA+PTX
(Table 1) or 2× MOG35-55+CFA (Table 2). Post hoc multiple comparisons of each
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trait variable revealed that WT = H1RKO-Tg-1 = H1RKO-Tg-3 > H1RKO. Additionally,
compared to H1RKO mice both MOG35-55+CFA+PTX (Fig. 7C) and 2× MOG35-55+CFA
(Fig. 7D) immunized H1RKO-Tg-1 and H1RKO-Tg-3 mice exhibited significantly more
severe overall CNS pathology (Blankenhorn et al., 2000) which was equivalent in
severity to that seen in WT mice. Therefore, H1R expression in CD4 T cells alone is
capable of complementing EAE susceptibility in H1R deficient animals.
We also examined cytokine production following ex-vivo stimulation of
splenocytes from mice immunized with MOG35-55+CFA+PTX and 2× MOG35-55+CFA.
The H1R transgene fully complemented IFNγ production by H1RKO CD4 T cells and
restored IL-4 production to WT levels (Fig. 7E and 7F). In contrast, no significant
differences in TNFα or IL-17 production were detected among WT, H1RKO and
H1RKO-Tg mice. Together, these data indicate that H1R signaling in CD4 T cells
complements EAE severity independently of TNFα and IL-17 production.
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Discussion
Although H1R has been previously shown to play a role in regulating
encephalitogenic Th1 immune response in EAE (Bakker et al., 2002), it was unclear
whether this was caused by the deficiency of H1R in CD4 T cells or APCs. In this study,
we show that the presence of H1R in CD4 T cells is essential for the activation of p38
MAP kinase and IFNγ production by these cells and the lack of H1R in CD4 T cells is
responsible for the increased EAE resistance of H1RKO mice. These findings also
explain the likely cause of the Th2 deviation and aberrant IL-4 production seen in the
H1RKO (Bakker et al., 2002), a result we confirmed in the present study. This deviation
could logically be due to the impairment in p38 MAP kinase activation that reduces the
T-bet expression and thereby IFNγ production by CD4 T cells during TCR activation.
Without H1R, naïve T cells cannot be driven into the full Th1 developmental pathway,
and the result is an unbalanced immune repertoire that is generally thought to be
protected from signs of EAE (Shaw et al., 1997).
Even though the expression of H1R in CD4 T cells has been reported (Sachs et al.,
2000) it was unknown how H1R is regulated during the activation phase of CD4 T cells.
Here we show, for the first time, that the H1R gene expression is silenced early after the
activation of CD4 T cells. Modulation of H1R signaling, like other GPCRs, is complex
and includes receptor desensitization, internalization and the subsequent down-regulation
(McCreath et al., 1994; Smit et al., 1996). Desensitization of H1R is induced by both
agonist specific (homologous) and agonist non-specific (heterologous) pathways, mainly
involving PKC-mediated phosphorylation of H1R (Fujimoto et al., 1999; Miyoshi et al.,
2004). PKC activation has been shown to inhibit H1R both at the protein level as
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well as at the gene expression level (Miyoshi et al., 2006; Pype et al., 1998; Yoshimura et
al., 2005). Because TCR ligation leads to potent activation of PKC (Acuto and Cantrell,
2000), silencing of H1R expression in activated CD4 T cells may be a consequence of
PKC activation. Although the transcriptional regulation of H1R promoter is not well
understood, H1R-mediated signaling has been shown to be necessary for continued H1R
expression (Miyoshi et al., 2006; Yoshimura et al., 2005). Thus, the loss of H1R gene
expression in activated CD4 T cells in mice may be a mechanism to turn off possible
subsequent histamine signals in these cells. In humans, H1R expression is reported to
increase in Th1 differentiated cells (Jutel et al., 2001). However, H1R mRNA was rapidly
downregulated even during the Th1 differentiation of mouse CD4 T cells (data not
shown). These apparently contradictory results may be explained by the different origin
of the T cells (mouse vs. human) or by other differences in the culture conditions used.
H1R has been previously implicated in the regulation of IFNγ production. H1Rdeficient splenocytes have been shown to produce lower IFNγ when activated by antiCD3 and-CD28 mAbs or by specific antigen (Bakker et al., 2002; Banu and Watanabe,
1999; Bryce et al., 2006; Jutel et al., 2001) but no studies have addressed the role of H1R
in isolated CD4 T cells. Here we show that H1R expression in CD4 cells is essential
specifically for IFNγ production by these cells but not for IL-2 production or
proliferation. A previous report showed hypoproliferation of total splenocytes from H1R
deficient mice in response to anti-CD3 mAb (Banu and Watanabe, 1999). However, the
low proliferative response could be due to the H1R deficiency in cells other than CD4 T
cells, such as antigen presenting cells (e.g. macrophages or dendritic cells) that also
express H1R. Although CD4 T cells also

express H2R and H4R, in addition to H1R,
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the selective restoration of the IFNγ response in CD4 T cells from H1RKO-Tg mice
clearly demonstrates that signaling through H1R is necessary for regulation of IFNγ
production in these cells.
Several studies have shown that p38 MAP kinase is activated in CD4 T cells or
total T cells upon TCR activation. Co-stimulatory molecules (such as CD28, 4-1BB,
ICOS, CD30) also contribute to the activation of p38 MAP kinase during activation
(Dodeller and Schulze-Koops, 2006). While most studies agree on the role of p38 MAP
kinase on IFNγ production and Th1 differentiation, recent studies have questioned the
requirement of TCR-mediated p38 MAP kinase activation. Instead, they propose that
activation of this pathway by cytokines such as IL-12 or IL-18 is probably more relevant
(Berenson et al., 2006). To date, the effect of other components also present in the milieu
during TCR activation has not been addressed. Here we show, for the first time, that
activation of p38 MAP kinase by TCR/CD28 ligation is dependent on the presence of
histamine and its binding to H1R. A previous study has shown the requirement of H1R for
ZAP-70 activation in H1RKO total splenocytes in conjunction with the hypoproliferative
defect in these cells (Banu and Watanabe, 1999). However, here we show that in CD4 T
cells, H1R is not required for other key signaling pathways such as ERK activation
(Fig.8), NF-κB activation (Fig. 5A) or calcium mobilization (data not shown), as well as
for IL-2 production and proliferation. Thus, deficiency of H1R in CD4 T cells appears to
selectively impair the activation of the p38 MAP kinase pathway, but the mechanism
remains to be investigated further. p38 MAP kinase is normally activated through the
upstream MAPKK, MKK3 and MKK6 (and MKK4 in response to some stimuli)
(Kyriakis and Avruch, 2001). It has been shown that GADD45 proteins interact
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with MEKK4, an upstream kinase of MKK3 and MKK6 and thus activate p38 MAP
kinase (Takekawa and Saito, 1998). An alternative pathway for activation of p38 MAP
kinase through its autophosphorylation has also been recently proposed (Salvador et al.,
2005). H1R signaling is mediated by Gαq/11 protein, which is also associated with TCR
signaling through CD3ε (Stanners et al., 1995). Thus, it is possible the H1R through
Gαq/11 could regulate GADD45 members (α, β and γ) and lead to p38 MAP kinase
activation through either the classical or alternative pathway in CD4 T cells.
Epidemiological data indicate that the use of sedating H1R antagonists is
associated with decreased MS risk (Alonso et al., 2006); and in a small pilot study,
patients with relapsing-remitting or relapsing-progressive MS given the H1R antagonist
hydroxyzine remained stable or improved neurologically (Logothetis et al., 2005).
Additionally, microarray analysis revealed that the H1R is overexpressed in the chronic
plaques of MS patients (Dormond et al., 2002). Historically, the role of histamine in
autoimmune inflammatory disease of the CNS has been viewed as a mediator of the
effector or inflammatory phase of the disease (Bebo et al., 1996). However, recent data
showing that EAE and neuroantigen specific T effector cell responses are significantly
different in histamine- and histamine receptor-deficient mice compared to WT mice
revealed that histamine plays a role during the induction phase and priming of
autoreactive effector T cells (Bakker et al., 2002; Fillmore et al., 2004; Musio et al.,
2006). In this regard, our results show that H1R signaling in T cells regulates Th1 effector
functions, but not Th17 effector functions, and EAE severity, independent of APCs and
other hematopoietically-derived cells. Moreover, our results demonstrate that H1R
signaling in CD4 T cells regulates the encephalitogenic Th1 effector responses
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during the priming of naïve antigen-specific CD4 T cells. Taken together, this suggests
that pharmacological targeting of the H1R may be useful early in the treatment of MS and
other autoimmune inflammatory diseases in which molecular mimicry, bystander
activation (with or without epitope spreading), and viral persistence play a role in
perpetuating immunopathology as a consequence of continual priming of pathogenic
adaptive immune responses (Fujinami et al., 2006).
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Materials and methods
Mice
C57BL/6J mice were purchased from the Jackson Laboratory (Bar Harbor, ME).
B6.129P-Hrh1tm1Wat (H1RKO) (Banu and Watanabe, 1999) mice were maintained in the
animal facility at the University of Vermont (Burlington, VT). The experimental
procedures used in this study were approved by the Animal Care and Use Committee of
the University of Vermont.
For transgenic mouse generation, an HA-H1R construct was made by deleting the
methionine of the Bphs-susceptible H1R allele (Bakker et al., 2002) and adding an HA
tag at the N-terminus using TOPO cloning vector (Invitrogen, Carlsbad, CA). The HAH1R was then subcloned downstream of the distal lck promoter (Wildin et al., 1991). The
linear DNA fragment containing the distal lck promoter, the HA-H1R gene and the human
growth hormone (hGH) intron and polyadenylation signal was injected directly into
fertilized C57BL/6J eggs at the University of Vermont transgenic/knockout facility. Mice
were screened by DNA slot blot using a BamHI–SacI 0.5 kb fragment from the hGH gene
as a probe. Two founders were generated and were crossed to H1RKO mice to establish
transgenic mouse lines in H1RKO background (H1RKO-Tg mice). Distal lck MKK6Glu
transgenic mice (Rincon et al., 1998) were crossed to H1RKO mice to generate H1RKOMKK6Glu transgenic mice.
Cell preparation and culture conditions
CD4 T cells were isolated from spleen and lymph nodes by negative selection for
CD8-, MHC class II-, NK1.1- and CD11b-positive cells using magnetic beads from
Qiagen,

Valencia,

CA,

as

previously
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described (Rincon et al., 1998). Purified

CD4 T cells were stimulated with plate bound anti-CD3 (5 μg/ml) and soluble anti-CD28
(1 μg/ml) monoclonal antibodies (mAbs) from BD Pharmingen (Franklin Lakes, NJ).
Th1 polarized CD4 effector T cells were generated by culturing the CD4 T cells (1×106
cells/ml) with anti-CD3 and anti-CD28 mAbs in presence of 4 ng/ml of recombinant IL12 (R&D systems, Minneapolis, MN) and 10 μg/ml of anti IL-4 mAb (BD Pharmingen,
San Diego, CA). Th2 polarized CD4 effector T cells were generated by activating cells
(1×106/ml) with anti-CD3 and anti-CD28 mAbs in presence of 30 ng/ml of recombinant
IL-4 (R&D systems, Minneapolis, MN) and 10 μg/ml of anti IFNγ-4 mAb. Effector Th17
CD4 T cells were generated by activating CD4 T cells (1×106 cells/ml) with anti-CD3
and anti-CD28 mAbs in presence of 1 ng/ml of TGFβ (Peprotech Inc, Rocky Hill, NJ)
and 30 ng/ml of IL-6 (R&D systems, Minneapolis, MN) and 10 μg/ml of anti-IFNγ and
10 μg/ml of anti IL-4 mAbs. After 4 days, the cells were extensively washed, counted
and equal number of cells were restimulated with anti-CD3 mAb. After 24 hours, the
supernatants were collected and IFNγ, IL-4 and IL-17 were analyzed by ELISA. Nonpolarized effector cells were generated by culturing CD4 T cells with anti-CD3 and antiCD28 mAbs in the absence of exogenous cytokines for four days. The cells were then
extensively washed, counted and equal numbers of cells were restimulated with anti-CD3
mAb. After 24 hours, the supernatants were collected and IFNγ was analyzed by ELISA.
Histamine dihydrochloride was obtained from Sigma-Aldrich (St. Louis, MO).
RPMI prepared with 10% Fetalclone © bovine serum (Hyclone, Logan,UT ), serum
dialyzed twice with 10,000 kDa molecular cutoff, was used as histamine free medium.
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Cytokine production
ELISAs were performed on the cell culture supernatants as described previously
(Fillmore et al., 2004), using the primary antibodies: anti-IFNγ, anti-IL-2, anti-IL-4 and
anti-IL17 mAbs and their corresponding biotinylated mAbs (BD Pharmingen, San Diego,
CA). Other ELISA reagents included: Horseradish peroxidase-conjugated avidin D
(Vector Laboratories, Burlingame, CA), TMB microwell peroxidase substrate and stop
solution (Kirkegaard and Perry Laboratories, Gaithersburg, MD) and recombinant IFNγ,
IL-4 and IL-2 (R&D Systems, Minneapolis, MN) used as standards.
For cytokine analysis in ex-vivo stimulated splenocytes from mice immunized
with the classical MOG35-55+CFA+PTX model and the 2x MOG35-55+CFA model, single
cell suspensions were prepared @ 1x106 cells/ml in RPMI medium and stimulated with
50 μg/ml of MOG35-55. Cell culture supernatants were recovered at 72 hours and cytokine
levels were measured by ELISA using anti-IFNγ, anti-IL-4 and anti-IL17 mAbs and their
corresponding biotinylated mAbs (BD Pharmingen, San Diego, CA). TNFα ELISA kit
was from (BD Pharmingen, San Diego, CA).
Proliferation Assays
CD4 T cells (2.5×105 cells/well) were activated with anti-CD3 and anti-CD28
mAbs for 72 h and proliferation was determined by 3[H]-thymidine incorporation during
the last 18 h of culture.
Quantitative Real-Time Polymerase Chain Reaction (RT-PCR)
Total RNA was extracted from CD4 T cells using RNeasy RNA isolation reagent
(Qiagen, Valencia, CA) as recommended by the manufacturer. cDNA generated from 1
μg total RNA was used in quantitative real
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time RT-PCR using the SYBR green

method.

The

sequences

of

Hrh1

primers

used

were

F:

5’-

CCAGAGCTTCGGGAAGATAA-3’ and R: 5’ACCACAGCATGAGCAAAGTG-5’. β2-microglobulin was used as reference gene and relative mRNA levels were calculated
using comparative CT method. For conventional RT-PCR, the cDNA was amplified by
PCR and visualized on 1% gel. The primers mentioned above were used for Hrh1 and
the primers used for Hprt1 were F: 5’-GTTGGATACAGGCCAGACTTTGTTG-3’and
R:5’-GAGGGTAGGCTGCCTATAGGCT-3”. To study the transgene expression in
H1RKO-Tg mice, the cDNA prepared as explained above was amplified using a forward
primer in Hrh1 (5”-CTCCCGGACCACAGACTCAGA-3’) and a reverse primer in the
3rd exon of hGH (5’-GACGGAGGTCTGGGGGTTCTG) and the PCR product was
visualized on 1% agarose gel.
Retroviral transduction experiments
The retroviral vector plasmid pEGZ-HA was a generous gift from Dr. Ingolf
Berberich (University of Wurzburg, Wurzburg, Germany) and packaging vectors
pHIT123 and pHIT 60 were generous gifts from Dr. Alan Klingsman (Oxford University,
Oxford. UK). Two restriction sites, BamHI and EcoRI were inserted into the mouse H1R
cDNA by PCR and cloned such that the second codon is in frame with the HA tag of
pEGZ generating an HA-H1R fusion protein. pEGZ is a bicistronic system with IRESEGFP. EGFP served as a marker for transfected cells.
The retroviral vector plasmids, pEGZ-HA-H1R or the empty pEGZ and the
packaging vectors pHIT60 and pHIT123 were transiently transfected into human
embryonic kidney fibroblasts expressing the SV40 large T antigen (HEK293T) cells
using the calcium phosphate method. After two
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days,

the

retrovirus

containing

supernatants were used to transduce (by centrifugation at 800g for 3 hours at 320C) CD4
T cells previously activated with anti-CD3 and anti-CD28 mAbs for 16 hours. The
transduced CD4 T cells were cultured in presence of 50 U/ml of IL-2 for two days and
were sorted using a FACSAria instrument (BD Pharmingen, San Diego, CA), based on
their EGFP expression. Equal numbers of EGFP positive cells were restimulated with
anti-CD3 mAb and 24 hours later IFNγ was measured in the supernatant by ELISA.
Confocal microscopy
HEK293T cells were transfected with pEGA-HA-H1R or empty pEGZ control
vector (5 μg total DNA) using the calcium phosphate method. Cells were fixed,
permeabilized and stained using an anti-HA mAb (Cell Signaling Technologies, Danvers,
MA) followed by an incubation with Alexa-568 anti-mouse antibody (Molecular Probes,
Eugene, Oregon). TOPRO-3 nuclear stain (Molecular Probes, Eugene, Oregon) was used
as a nuclear marker. Cells were examined by confocal microscopy using Zeiss LSM 510
META Confocal Laser Scanning Imaging System (Carl Ziess Microimaging Inc,
Thronwood, NY)
Cell lysates and Western blotting
Whole-cell lysates were prepared from 1x106-5x106 cells in Triton lysis buffer
and were then separated via sodium dodecyl sulfate-polyacrylamide gel electrophoresis
(SDS-PAGE) and transferred to nitrocellulose membranes as described previously (Farley
et al., 2006). Primary antibodies used for Western blot analysis include anti-HA (Abcam
Inc. Cambridge, MA), anti-p38, anti-phospho-p38, anti-phospho-STAT1, anti-phosphoSTAT4, anti-phospho-ERK, anti-ERK, anti-phospho-JNK, anti-JNK (Cell Signaling
Technologies. Danvers, MA), anti-T-bet (a gift from Dr. L. Glimcher, Harvard
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University School of Public Health, Boston, MA) and anti-actin (Santa Cruz
Biotechnology, Santa Cruz, CA).
[35S]GTPγS binding assay
The HA-H1R cDNA was subcloned into pcDNA3 using restriction sites
EcoRI/BamHI. The [35S]GTPγS binding experiments were initiated by the addition of 50
fmols of receptor to an assay buffer (20mM HEPES (pH 7.4), 3mM MgCl2, 100mM
NaCl, 1µM GDP, 0.2mM ascorbic acid, and 100nCi [35S]GTPγS) containing 100μM
histamine. Non-specific binding was determined in the above condition with the
addition of 100µM GTPγS. Reactions were incubated for 15 min at 300C and were
terminated by the addition of 500µl of ice-cold buffer containing 20mM HEPES (pH
7.4), 3mM MgCl2, 100mM NaCl and 0.2mM ascorbic acid. The samples were
centrifuged at 16,000 x g for 10 minutes at 40C. The resulting pellets were re-suspended
in solubilization buffer (100mM Tris, 200mM NaCl, 1mM EDTA, and 1.25% Nonidet
P-40) plus 0.2% SDS. Samples were precleared with Pansorbin for 1 hour, followed by
immunoprecipitation with C-terminal Gα11 antiserum. Finally, the immunocomplexes
were washed with solubilization buffer and bound [35S]GTPγS was estimated by liquid
scintillation-spectrometry.
Electrophoretic mobility shift assay (EMSA)
Nuclear extracts were prepared from anti-CD3 and anti-CD28 mAbs treated CD4
T cells as previously described (Berenson et al., 2006). Binding reactions for
electrophoretic gel mobility shift assay were carried out at room temperature using 2 μg
nuclear proteins and [32P]dCTP-end labeled double-stranded oligonucleotide probes
containing NF-κB binding site from the

mouse κ intron enhancer (Sense 5’60

GATCAGAGGGGACTTTCCGAGGGAT-3’
GATCCCTCGGAAAGTCCCCTCTGAT-3’).

and
Samples

anti-sense
were

separated

5’by

electrophoresis under non-denaturing conditions and exposed to film for autoradiography.
Induction and Evaluation of EAE
Mice were immunized for the induction of EAE using either the MOG35-55complete Freund’s adjuvant (CFA) double-inoculation (Butterfield et al., 1998) or the
MOG35-55-CFA+PTX single-inoculation protocols (Teuscher et al., 2006a). For the
double-injection protocol mice were injected subcutaneously with an emulsion of 100 μg
of MOG35-55 and an equal volume of CFA containing 200 μg of Mycobacterium
tuberculosis H37RA (Difco Laboratories, Detroit, MI) in the posterior right and left
flank; one week later all mice were similarly injected at two sites on the right and left
flank anterior of the initial injection sites. Animals immunized using the MOG35-55CFA+PTX single-inoculation protocol received an emulsion of 200 μg MOG35-55 and
equal volume of CFA containing 200 μg of Mycobacterium tuberculosis H37RA by
subcutaneous injections distributed equally in the posterior right and left flank and scruff
of the neck. Immediately thereafter, each animal received 200 ng PTX (List Biological
Laboratories, Campbell, CA) by intravenous injection. Mice were scored daily starting at
day 5 post-injection as previously described (Teuscher et al., 2006a). Clinical quantitative
trait variables including disease incidence and mean day of onset (DO), cumulative
disease score (CDS), number of days affected (DA), overall severity index (SI) and the
peak score (PS) were generated as previously described (Butterfield et al., 1998).
Brains and SC were dissected from calvaria and vertebral columns, respectively,
and fixed by immersion in 10% phosphate- buffered formalin (pH 7.2). Following
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adequate fixation, brain and SC were trimmed and representative transverse section
embedded in paraffin, sectioned at 5 µm, and mounted on glass slides. Sections were
stained with hematoxylin and eosin for routine evaluation and Luxol fast blue-periodic
acid Schiff for demyelination. Sections from representative areas of the brain and SC
were scored in a semi-quantitative fashion for the various histopathologic parameters as
previously described (Blankenhorn et al., 2000). An overall CNS pathology index (PI) for
each lesions was obtained by calculating the average scores for the lesions observed in
the brain and spinal cord.
Statistical analysis
The statistical analyses, as indicated in the figure legends, were performed using
GraphPad Prism 4 software (GraphPad software Inc, San Diego, CA).
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Figure 1. H1R is required for IFNγ production by CD4 T cells.
Purified CD4 T cells from WT and H1RKO mice were activated with anti-CD3 (5μg/ml) and
anti-CD28 (1μg/ml) mAbs either in presence of IL-12 (4ng/ml) and anti-IL-4 mAb (10μg/ml)
(A), or IL-4 (30ng/ml) and anti-IFNγ mAb (10μg/ml) (B) or TGF-β (1ng/ml), IL-6 (30ng/ml) and
anti-IFNγ (10μg/ml) and anti-IL4 mAbs (10μg/ml) (C). After 4 days, cells were restimulated with
anti-CD3 mAb (5μg/ml) for 24h. IFNγ (Α), IL-4 (B) or IL-17 (C) production was determined by
ELISA in triplicate. *, p < 0.05, compared with H1RKO cells (Student’s t-test). (D) CD4 T cells
were activated with anti-CD3 (5μg/ml) and anti-CD28 (1μg/ml) mAbs. After 4 days, cells were
restimulated with anti-CD3 mAb (5μg/ml) for 24h and IFNγ production was determined by
ELISA.**, p = 0.002 compared with H1RKO cells (Student’s t-test). (E and F) CD4 T cells were
stimulated as in (D) for the indicated periods of time. Supernatants were analyzed for IFNγ (E)
and IL-2 (F) by ELISA. Significance of differences in cytokine production were assessed by
two-way ANOVA (F = 168.8; p < 0.0001) followed by post-hoc comparisons using one-way
ANOVA (** p < 0.01; *** p < 0.001). (G) CD4 T cells from WT and H1RKO mice were
stimulated as in (E) and 18h 3[H]-thymidine incorporation measured in total 72h culture. All the
data are representative of at least two independent experiments.
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Figure 2. Expression and function of HA-H1R in HEK293T cells.
(A) HEK293T cells were transfected with empty pEGZ (control) and pEGZ-HA-H1R
plasmids and the expression of HA-H1R was determined by Western blot using an antiHA mAb. The data is representative of at least three independent experiments. (B)
HEK293T cells were transfected as in (A), fixed, permeabilized and stained with an antiHA mAb (red) and Topro-nuclear dye (blue). EGFP expression (green) represents
transfected cells. Cells were visualized by confocal microscopy. The data are
representative of at least three independent experiments. (C) HEK293 cells were
transfected with pHA-H1R-Gα11 fusion construct, membrane fractions generated and
were used in absence (basal) or presence of 10-4M histamine in [35S] GTPγS binding
assay. Samples were then used in immuno-precipitation using Gα11 antiserum and the
bound [35S] GTPγS was measured by liquid-scintillation spectrometry.
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Figure 3. H1R expression is downregulated upon activation in CD4 T cells.
(A) CD4 T cells from WT and H1RKO mice were stimulated in the presence of anti-CD3
and anti-CD28 mAbs for 16h and then retrovirally transduced with pEGZ-HA-H1R or
with empty pEGZ control plasmids. Transduced, sorted EGFP+ cells were then restimulated with anti-CD3 mAb and 24h later the supernatants were harvested for
determination of IFNγ by ELISA in triplicate. The data presented is representative of two
independent experiments. ***, p < 0.0001 compared with H1RKO cells (Student’s t-test).
(B) Freshly isolated CD4 T cells from WT and H1RKO were activated with anti-CD3
and anti-CD28 mAbs. After 24h, IFNγ production was determined by ELISA. The results
shown are representative of at least three independent experiments. ***, p < 0.001
compared with H1RKO cells (Student’s t-test). (C and D) CD4 T cells were isolated from
WT mice and stimulated with anti-CD3 and anti-CD28 mAbs. Cells were harvested at the
indicated time point, total RNA was isolated and used to examine H1R expression by
conventional RT-PCR with HPRT as the endogenous control (C) and by quantitative real
time RT-PCR relative to β2-microglobulin as the endogenous control (D). Data presented
as expression relative to the unstimulated CD4 T cells. The data are representative of at
least three independent experiments.
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Figure 4. Transgenic expression of H1R in H1RKO CD4 T cells complements IFN-γ
production.
(A) H1R transgene expression was analyzed by RT-PCR in CD4 T cells from WT,
H1RKO mice and the two independent lines of H1R transgenic mice crossed with
H1RKO mice (H1RKO-Tg-1 and H1RKO-Tg-3). (B) CD4 T cells were stained with antiHA mAb (red) and visualized by confocal microscopy. Nuclear stain Topro (blue) is
shown. (C) CD4 T cells were activated with anti-CD3 and anti-CD28 mAbs for 72 h and
IFNγ was determined by ELISA. Data are expressed as IFNγ production relative to that
by WT cells (set as 100%). (D) CD4 T cells from WT, H1RKO and H1RKO-Tg-3 were
stimulated as in (C) for the indicated periods of time and IFNγ was determined by
ELISA. Statistical analysis using two-way ANOVA (F=55.1; p<0.0001) followed by
post-hoc comparisons using one-way ANOVA was performed (**, p<0.01; ***,
p<0.001). (E) CD4 T cells were activated with anti-CD3 and anti-CD28 mAbs in
presence of IL-12 (4ng/ml) and anti-IL-4 mAb (10μg/ml). After 4 days, cells were
restimulated and IFNγ production was determined. Statistical analysis using one-way
ANOVA (F=25.4; p<0.001) followed by Bonferroni’s post-hoc comparisons with
H1RKO cells was performed (**, p<0.01). (F) CD4 T cells were activated with anti-CD3
and anti-CD28 mAbs. After 4 days, cells were restimulated with anti-CD3 mAb for 24h
and IFNγ production was determined by ELISA. Significance of differences was
determined as in (E) (***, p < 0.001). The data presented are representative of at least
three independent experiments.
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Figure 5. Activation of p38 MAP kinase by TCR ligation requires H1R signals.
(A) Purified CD4 T cells from WT and H1RKO mice were stimulated with anti-CD3 and
anti-CD28 mAbs for the indicated periods of time, nuclear extracts were prepared and
analyzed for NF-κB DNA binding by EMSA. (B) CD4 T cells from WT and H1RKO
mice were stimulated with anti-CD3 and anti-CD28 mAbs for the indicated periods of
time, whole cell lysates were prepared and analyzed for phospho-STAT1 (P-STAT1) and
total STAT1 by Western blot analysis. Actin was used as loading control. (C) CD4 T
cells from WT and H1RKO were treated with anti-CD3 and anti-CD28 mAbs for the
indicated periods of time, whole cell lysates were prepared and analyzed for phospho-p38
MAP kinase and total p38 by Western blot analysis. (D) CD4 T cells from WT and
H1RKO were activated with anti-CD3 and anti-CD28 mAbs for the indicated periods of
time, whole cell lysates were prepared and analyzed for phospho-ERK and total ERK by
Western blot analysis. (E) CD4 T cells from WT, H1RKO and H1RKO-Tg-3 mice were
stimulated with anti-CD3 and anti-CD28 mAbs for the indicated periods of time and
whole cell lysates were analyzed for phospho-p38, total p38 and actin by Western
blotting. All the results presented are representative of at least two independent
experiments.
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Figure 6. Activation of p38 MAP kinase by TCR ligation is mediated by
histamine/H1R binding.
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(A) CD4 T cells from WT and H1RKO mice were treated with histamine (10-7 M) for the
indicated periods of time in the histamine-free medium. Whole cell extracts were used to
analyze phospho-p38, total p38 and actin by Western blotting. (B) CD4 T cells were
isolated from WT and H1RKO mice and stimulated with anti-CD3 and anti-CD28 mAbs
in the histamine free-medium for the indicated periods of time. CD4 T cells stimulated in
10-7M histamine (Hist) containing medium are shown as positive control for p38 MAP
kinase activation. Phospho-p38, total p38 and actin are shown. (C) CD4 T cells from WT
and H1RKO were incubated with anti-CD3 and anti-CD28 mAbs, 10-7M histamine or
both in the histamine-free medium for 30 minutes and whole cell lysates were analyzed
for phospho-p38, total p-38 and actin by Western blotting. (D) CD4 T cells from WT and
H1RKO mice were stimulated with anti-CD3 and anti-CD28 mAbs for the indicated
periods of time and whole cell lysates were analyzed for T-bet expression by Western
blot. Actin is shown as loading control. (E) Purified CD4 T cells from WT, H1RKO and
H1RKO-MKK6Glu transgenic mice were stimulated with anti-CD3 and anti-CD28 mAbs
for the indicated periods of time and supernatants were analyzed for IFNγ production by
ELISA in triplicate. Significance of differences were determined by Student’s t-test (***
p < 0.001). All the data are representative of at least two independent experiments.
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Figure 7. H1R signaling directly in CD4 T cells regulates encephalitogenic Th1
effector responses.
Clinical EAE course, severity of CNS pathology and ex-vivo cytokine responses of WT,
H1RKO and H1RKO-Tg mice were compared following immunization with MOG3555+CFA+PTX (A, C and E) and 2× MOG35-55+CFA (B, D and F). Cytokine production
was assessed by stimulating splenocytes with MOG35-55 on D10 post-injection,
supernatants collected and quantified by ELISA in triplicate. The significance of
differences in the course of clinical disease, clinical disease traits, CNS pathology indices
(PI) and cytokine responses were assessed by regression analysis (63), Chi-square test,
or ANOVA followed by post hoc multiple comparisons. With the exception of disease
incidence, and TNF-α and IL-17 production, significant differences among the strains
were detected for all parameters at p < 0.0001 with C57BL/6J = H1RKO Tg-1 = H1RKO
Tg-3 > H1RKO.
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Figure 8. Absence of histamine does not affect TCR-mediated ERK activation.
WT CD4 T cells were activated with anti-CD3 and anti-CD28 mAbs for 30 min in
presence or absence of 10-7M histamine and whole cell lysates were analyzed for
phospho-ERK, total ERK and actin by Western blotting.
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Cumulative
disease
score

Days
affected

Severity
index

Peak
score

Strain

Incidence

Day of
onset

C57BL/6J

19/19

13.1±0.3

56.2±4.6

18.0±0.3

3.1±0.2

3.9±0.3

H1RKO

55/56

15.7±0.4

32.1±1.4

15.0±0.4

2.1±0.1

3.0±0.1

Tg-1

24/24

12.9±0.4

50.0±3.7

17.8±0.5

2.8±0.2

3.6±0.2

Tg-3

23/25

12.1±0.1

50.0±3.2

18.7±0.2

2.7±0.2

3.6±0.2

χ2 = 4.5
p = 0.2

F = 20.6
p < 0.0001

18.1
< 0.0001

32.5
< 0.0001

11.7
< 0.0001

8.1
< 0.0001

C57BL/6J = H1RKO-Tg-1 = H1RKO-Tg-3 > H1RKO

Table 1: Clinical disease parameters in MOG35-55+CFA+PTX immunized mice
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Cumulative
disease
score

Days
affected

Severity
index

Peak
score

Strain

Incidence

Day of
onset

C57BL/6J

18/18

16.6±0.7

37.6±2.9

14.2±0.7

2.6±0.1

3.2±0.2

H1RKO

26/33

17.1±0.5

20.0±1.8

9.8±0.9

1.6±0.1

2.2±0.1

Tg-1

22/23

16.2±0.6

36.4±3.8

13.3±0.8

2.5±0.2

3.2±0.2

Tg-3

23/25

15.7±0.4

46.1±4.0

14.0±0.9

2.7±0.2

3.6±0.2

χ2 = 7.5
p = 0.06

F = 1.5
p = 0.051

5.1
0.0025

11.2
< 0.0001

12.2
< 0.0001

9.5
< 0.0001

C57BL/6J = H1RKO-Tg-1 = H1RKO-Tg-3 > H1RKO

Table 2: Clinical disease parameters in 2x (MOG35-55+CFA) immunized mice
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ABSTRACT
Structural polymorphisms (L263P, M313V and S331P) in the third intracellular
loop of the murine histamine receptor H1 (H1R) are candidates for Bphs, a shared
autoimmune disease locus in experimental allergic encephalomyelitis (EAE) and
experimental allergic orchitis. The P-V-P haplotype is associated with increased disease
susceptibility (H1RS) whereas the L-M-S haplotype is associated with less severe disease
(H1RR). Here we show that selective reexpression of the H1RS allele in T cells fully
complements EAE susceptibility and the production of disease associated cytokines while
selective reexpression of the H1RR allele does not. Mechanistically, we show that the two
H1R alleles exhibit differential cell surface expression and altered intracellular
trafficking, with the H1RR allele being retained within the endoplasmic reticulum (ER).
Moreover, we show that all three residues (L-M-S) comprising the H1RR haplotype are
required for altered expression. These data are the first to demonstrate that structural
polymorphisms influencing cell surface expression of a G-protein coupled receptor in T
cells regulates immune functions and autoimmune disease susceptibility.
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INTRODUCTION
Multiple sclerosis (MS) is the major demyelinating disease of the central nervous
system (CNS) in humans, affecting more than 2.5 million people worldwide (Greenstein,
2007). Both environmental and genetic factors contribute to the immunopathologic
etiology of the disease. A genetic component in disease susceptibility is supported by the
20-30% concordance rate among monozygotic twins and 3-5% for dizygotic twins.
Compared to the general population, MS is 20-40 times more common in first degree
relatives and there is no excess risk in adopted relatives of patients with MS (Hafler et al.,
2005). Evidence of an environmental etiology in MS comes primarily from migration
studies and geographic distribution data. Migration studies indicate that individuals
moving from high-risk areas before puberty tend to adopt the lower risk of the native
population and vice versa (Kantarci and Wingerchuk, 2006). Thus, susceptibility to MS is
likely the result of environmental triggers acting on a susceptible genetic background at
the population level.
Experimental allergic encephalomyelitis (EAE), the primary animal model of MS,
is also a genetically determined inflammatory disease of the CNS (Gold et al., 2000).
EAE can be actively induced in genetically susceptible animals by immunization with
either whole spinal cord homogenate or encephalitogenic proteins/peptides and adjuvants
(Kuchroo et al., 2002). EAE, like MS, is a complex polygenic disease (Andersson and
Karlsson, 2004), with multiple genes exerting a modest effect, thus making it difficult to
study the contribution of individual loci to overall disease

pathogenesis. However,

reduction of complex disease states into intermediate or subphenotypes that are
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under the control of a single locus has the potential to facilitate mechanistic studies and
gene identification (Andersson and Karlsson, 2004). One such phenotype associated with
EAE is Bordetella pertussis toxin-induced histamine sensitization, which is controlled by
the single autosomal dominant locus known as Bphs (Ma et al., 2002). Previously, we
identified Hrh1/H1R as the gene underlying Bphs (Ma et al., 2002) and as a shared
autoimmune disease susceptibility gene in EAE (Linthicum and Frelinger, 1982) and
experimental allergic orchitis (EAO) (Teuscher, 1985). H1R is a seven-transmembrane
spanning, G protein coupled receptor (GPCR). Generally, ligation of H1R with histamine
is believed to couple to second messenger signaling pathways via the activation of the
heterotrimeric Gαq/11 family of G proteins and leads to a variety of signaling cascades
depending on the cell type involved (Parsons and Ganellin, 2006).
Compared to wild-type (WT) mice, H1R deficient (H1RKO) mice exhibit
significantly reduced EAE susceptibility (Ma et al., 2002). As a disease susceptibility
gene, Hrh1/H1R can exert its effect in multiple cell types involved in the disease process
including endothelial cells, antigen presenting cells and T cells. Moreover, H1R may
function at critical check points during both the induction and effector phases of the
disease. In this regard, we recently demonstrated that selective reexpression of the H1RS
allele in T cells is sufficient to complement EAE in H1RKO mice and that H1R signals
are important during priming of naïve T cells rather than during the effector phase of the
disease (Noubade et al., 2007).
Hrh1/H1R-susceptible (Hrh1S/H1RS) and –resistant (Hrh1R/H1RR) alleles differ by
three amino acids in their coding sequences (Ma et al., 2002). The H1RR haplotype
possesses a L263, M313 and S331 whereas the H1RS haplotype is characterized by P263,
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V313 and P331 (Ma et al., 2002). The mechanism whereby these polymorphic residues
influence EAE susceptibility is unknown but it was hypothesized to be the result of
differential coupling to second messenger signaling pathways, because the three residues
reside within the third intracytoplasmic domain associated with Gαq/11 activation (Tan et
al., 2004). Here we show that, unlike the H1RS allele (Noubade et al., 2007), expression
of the H1RR allele in T cells does not complement EAE in H1RKO mice and that the
polymorphic residues of the H1RR allele affect intracellular trafficking and retention in
the ER rather than the inherent capacity to signal. Moreover, we show that all three
residues (L-M-S) comprising the H1RR haplotype are required for altered cell surface
expression. These data are the first to demonstrate that structural polymorphisms
influencing differential cell surface expression of a GPCR in T cells can regulate immune
functions and susceptibility to autoimmune disease.
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RESULTS
Expression of H1RR does not complement EAE in H1R deficient mice
Using transgenic complementation, we recently showed that expression of the
H1RS allele only in T cells of H1RKO mice was sufficient to restore EAE severity to WT
levels in these mice (Noubade et al., 2007). To understand if the H1RR allele would also
complement EAE in H1RKO mice, we generated transgenic mice expressing the Nterminus hemagglutinin (HA)-tagged H1RR allele under the control of the distal lck
promoter, which drives expression in peripheral T cells (Wildin et al., 1991). The
transgenic founders were generated directly on the C57BL/6J background and were
crossed to H1RKO mice to obtain H1RKO mice expressing the H1RR allele selectively in
T cells. The expression of the transgene in CD4 T cells was assessed by RT-PCR using
transgene-specific primers (Fig. 1A) and by real time RT-PCR using primers that
recognize H1R (Fig. 1B). The two established lines of H1RR (H1RKO-TgR1 and H1RKOTgR2) expressed the transgene mRNA at levels comparable to one of the H1RS allele
transgenic mice (H1RKO-TgS) that we reported previously (Noubade et al., 2007).
We then examined the susceptibility of these transgenic mice to myelin
oligodendrocyte glycoprotein peptide 35-55 (MOG35-55) induced EAE. We used two
protocols to induce disease, one using MOG35-55 plus complete Freund’s adjuvant (CFA)
and pertussis toxin (PTX) (MOG35-55-CFA plus PTX) (Fig. 1C) and the other using two
injections of MOG35-55 plus CFA (2× MOG35-55-CFA) (Fig. 1D), which does not use PTX
as an ancillary adjuvant. Regression analysis revealed that the clinical disease courses
elicited by both induction protocols fit a
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Sigmoidal curve and that the clinical

course of disease in two independent lines of H1RKO–TgR mice was not different from
that in H1RKO mice. However, as reported previously (Noubade et al., 2007), the clinical
course of EAE in H1RKO-TgS mice was significantly more severe than that of H1RKO
mice and was equivalent to the disease course observed in WT mice. These results
indicate that, unlike the H1RS allele, expression of the H1RR allele by H1RKO T cells
does not complement EAE susceptibility.
An analysis of EAE-associated clinical quantitative trait variables from the two
transgenic cohorts revealed that the mean day of onset (DO), cumulative disease score
(CDS), overall severity index (SI) and the peak score (PS) were significantly different
among the strains immunized with either MOG35-55-CFA plus PTX or 2× MOG35-55-CFA
(Table 1). Post hoc multiple comparisons of each trait variable revealed that H1RKO-TgS
mice were equivalent to WT mice while H1RKO-TgR mice were equivalent to H1RKO
mice. Furthermore, for each trait, H1RKO-TgS and WT mice were significantly greater
than H1RKO-TgR and H1RKO mice.
We next analyzed the ex vivo MOG35-55 specific proliferative response of spleen
and draining lymph node (DLN) cells from mice immunized with 2× MOG35-55-CFA.
Significant differences in proliferative responses were not detected among WT, H1RKO,
H1RKO-TgS and H1RKO-TgR mice (data not shown). Since MOG35-55-stimulated
splenocytes from immunized-H1RKO mice exhibit an immune deviation from Th1 to
Th2 response in ex vivo recall assays (Ma et al., 2002), we analyzed cytokine production
by MOG35-55-stimulated spleen and DLN cells from mice immunized with both EAEinduction protocols. With the classical MOG35-55-CFA plus PTX protocol, as we
observed previously (Noubade et al., 2007),

antigen-stimulated spleen and DLN cells
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from H1RKO-TgS mice produced significantly greater amounts of IFN-γ compared to
H1RKO mice and at levels comparable to WT mice (Fig. 2A). In contrast, the levels of
IFN-γ produced by antigen-stimulated spleen and DLN cells from the two lines of
H1RKO-TgR mice were equivalent to those produced by H1RKO mice. Similarly,
antigen-stimulated spleen and DLN cells from H1RKO-TgS mice produced IL-4 at levels
comparable to WT mice while those from H1RKO-TgR mice were similar to H1RKO
mice (Fig. 2B). Similar results for IFN-γ (Fig. 2D) and IL-4 (Fig. 2E) were observed for
2× MOG35-55-CFA immunized mice.
Because IL-17 is considered to be an important effector cytokine in EAE
(Furuzawa-Carballeda et al., 2007), we examined IL-17 production by spleen and DLN
cells following ex vivo stimulation with MOG35-55. IL-17 production by WT, H1RKO,
H1RKO-TgS and H1RKO-TgR mice immunized with MOG35-55-CFA and PTX was not
significantly different (Fig. 2C) among strains. In contrast, IL-17 production by MOG35-55
stimulated spleen and DLN cells from animals immunized with 2× MOG35-55-CFA
differed significantly among the strains (Fig. 2F). Compared to WT mice, H1RKO mice
produced significantly less IL-17, indicating that H1R signaling regulates IL-17
production by T cells. Moreover, production of IL-17 by H1RKO-TgS mice was not
significantly different from WT mice and IL-17 production by H1RKO-TgR mice was not
significantly different from H1RKO mice (Fig. 2F). Taken together, like EAE, H1RR
expression in H1RKO T cells does not complement cytokine production by these cells.
H1R alleles activate Gαq and Gα11 equally well in vitro
The above results suggest that the H1RR allele is not functional relative to the
H1RS allele. To understand the mechanism by which the polymorphic residues of the
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H1RS and H1RR alleles influence H1R function, we examined the predicted structural
location for the three residues within H1R. The three polymorphic residues reside within
the third intracytoplasmic loop of H1R (Fig 3A), which is the region frequently associated
with recruitment and activation of downstream G proteins (Tan et al., 2004). We,
therefore, examined whether the polymorphic residues distinguishing the H1RS and H1RR
alleles might result in significant alterations in G protein activation. Since H1R is
normally coupled to Gαq and/or Gα11 proteins, we generated fusion proteins of the two
H1R alleles with both Gαq and Gα11 by linking in-frame the N-terminus of Gαq/11 with the
C-terminal tail of H1RR or H1RS.
HEK293 cells were transfected with the H1RS-Gαq/11 or H1RR-Gαq/11 fusion
proteins, lysed and membrane fractions prepared from these cells. These were used
initially to measure the levels of expression of each construct via the specific binding of
the H1R antagonist [3H]mepyramine. There were no differences in the levels of specific
binding of [3H]mepyramine between the various constructs, indicating that the
polymorphisms did not alter total protein expression. Also, the binding affinity of
[3H]mepyramine was not different between the two alleles (Fig 3B). To study their
differential capacity to activate Gαq and Gα11, membrane amounts containing exactly the
same number of copies of each construct were employed in [35S]GTPγS binding assays.
A maximally effective concentration of histamine stimulated binding of [35S]GTPγS
equally to Gαq or Gα11 when each G protein was linked to either the H1RS or H1RR
variants (Fig. 3C, Fig. 3D). The dose-response curves to histamine indicated that the
potency of histamine is equivalent for each receptor variant (data not shown). These data
indicate that the H1RS and H1RR alleles can
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activate these G proteins equally well and

that the phenotypic difference associated with the H1R alleles is not inherently a function
of differential capability to activate Gαq or Gα11.
H1R alleles are differentially expressed on the cell surface
Specific mutations in the signaling domain of several GPCRs (e.g. vasopressin V2
receptor, rhodopsin) can interfere with their cell surface expression and are associated
with disease (Tao, 2006). To determine if the polymorphisms in H1R influence cell
surface expression of the receptor, HA-H1RS or HA-H1RR expression vectors were used
to transfect HEK293T cells. The expression of these receptors at the cell surface was then
examined by Flow cytometric analysis using an anti-HA mAb. HA-H1RS was expressed
at higher levels than HA-H1RR (Fig. 4A). The number of H1RS-positive cells (Fig. 4B)
and the mean florescence intensity of H1RS were considerably higher than those of H1RR,
(Fig. 4C) indicating that the two H1R alleles are differentially expressed on the cell
surface. We observed similar results when the H1RS and H1RR constructs were transfected
into 721.221 B cells (data not shown).
In parallel, we examined the cell surface expression of H1RS and H1RR by
confocal microscopy using anti-HA mAb in cells stained prior to permeabilization. The
results confirmed higher expression of H1RS on the surface than H1RR (Fig. 4D).
However, Western blot analysis of H1RS and H1RR expression in lysates of transfected
HEK293T cells showed no difference in the amount of total protein present (Fig. 4E).
Taken together, these data indicate that the polymorphic residues associated with the
H1RS and H1RR haplotypes result in differential translocation of the receptor to the cell
surface.
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H1RR is retained in the endoplasmic reticulum
The Western blot results described above (Fig. 4E) suggest that the H1RS and
H1RR alleles are expressed at similar levels but that the H1RR allele is largely retained in
intracellular compartments instead of being trafficked to the cell surface. To investigate
this possibility, HEK293T cells were transfected with HA-H1RS or HA-H1RR constructs.
After 24 h cells were fixed, permeabilized, stained with anti-HA mAb and observed by
confocal microscopy. A predominantly plasma membrane staining pattern was observed
for the H1RS allele (Fig. 5A). In contrast, a large fraction of the H1RR allele appeared to
localize intracellularly (Fig. 5B) indicating that H1RR is retained in the intracellular
compartments and fails to traffic efficiently to the cell surface. The network-like
intracellular distribution of H1RR throughout the cell (Fig. 5B, right panel) resembled that
of endoplasmic reticulum (ER). Therefore, to determine if the H1RR allele is retained in
this compartment, we transiently co-transfected HEK293T cells with H1RS or H1RR
constructs and a plasmid expressing the dsRed fluorescent protein that targets the ER.
Co-localization of the two proteins was examined by confocal microscopy following
staining the cells for HA-H1R. The majority of H1RR was again expressed intracellularly
and co-localized with the dsRed protein, while minimal colocalization of H1RS with the
ER-targeted dsRed protein was observed (Fig. 5B). Using LSM5 image browser
software, we quantified the number of pixels that express both dsRed protein and HAH1R in multiple cells that were imaged under exactly the same settings. The results
showed a significant difference in the co-localization of the H1RS and H1RR alleles in ER
(Fig. 5C), suggesting that the H1RR L-M-S haplotype leads to its sequestration and
retention in ER.
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Retention of H1RR in the ER requires the L-M-S haplotype
To understand which of the three amino acids comprising the H1RR L-M-S
haplotype is responsible for the observed differential cell surface expression of the allele
we generated single H1RS mutants, replacing each of the H1RS haplotype associated
residues with the corresponding H1RR allele (P263L, V312M, and P330S), by site
directed mutagenesis. HEK293T cells were transfected with H1RS, H1RR and each of the
three H1RS mutant constructs. Cells were stained with anti-HA mAb, without
permeabilization, and cell surface expression of H1R analyzed by Flow- cytometry. Each
of the single H1RS mutants was expressed at higher levels on the cell surface than the
H1RR allele (Fig. 6A) with the levels comparable to those observed with the H1RS allele.
This indicates that the presence of a single H1RR polymorphism is not sufficient to induce
its intracellular retention. We also generated double mutants of the H1RS allele wherein
we replaced two residues of the H1RS haplotype with the corresponding residues of the
H1RR allele (P263L and V312M, P263L and P330S, V312M and P330S). Similar to the
single H1RS mutants, the double H1RS mutants were expressed on the cell surface at
levels comparable to the H1RS and at significantly higher levels than the H1RR allele (Fig.
6B). We observed similar results in 721.221 B cells following transient transfection with
H1RS, H1RS mutants and H1RR constructs (data not shown). Furthermore, when
HEK293T cells were co-transfected with double H1RS mutants and the dsRed plasmid,
each of the mutants showed a typical plasma membrane expression pattern with very
little co-localization with the ER-targeted dsRed protein (Fig. 6C). Quantification of the
number of pixels expressing dsRed- protein and HA-H1R confirmed that each of the
double H1RS mutants behaved like H1RS and only H1RR was retained in ER (Fig. 6D),
90

confirming the flow cytometry data that all the polymorphic residues are required for
differential cell surface expression of the H1R alleles. Taken together, these data indicate
that all three residues of the H1RR L-M-S haplotype are required for its intracellular
sequestration. Interestingly, we sequenced the H1R alleles from more than 100 different
inbred laboratory and wild-derived mouse strains and did not identify any recombinant
haplotypes (Table 2), suggesting that the two alleles are evolutionarily conserved and
have been selected for functionally.
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DISCUSSION
To date, Hrh1/H1R is the only murine EAE and EAO susceptibility gene that has
been positionally cloned (Ma et al., 2002). In this study, using transgenic mouse models,
we show that polymorphic variants in H1R regulate cytokine production by T cells
thereby influencing susceptibility to EAE. Furthermore, using HEK293T cells, we show
that the polymorphisms in H1R affect its functions by modulating cell surface expression
rather than inherently altering the capacity of the receptor to generate intracellular
signals.
Hrh1/H1R has long been implicated in EAE susceptibility (Linthicum and
Frelinger, 1982; Ma et al., 2002). As H1R is widely expressed (Parsons and Ganellin,
2006), this suggested that it might act in different cell types and at multiple checkpoints.
We recently showed, however, that H1R expression in T cells is sufficient to complement
EAE severity in H1RKO mice. In this study, we show that the polymorphic residues of
the H1RR allele interfere with its ability to complement EAE in H1RKO mice. This is in
accordance with genetic complementation studies in F1 hybrids between H1RKO and
strains of mice expressing the H1RS or H1RR alleles. Susceptibility to histamine
sensitivity could be restored in F1 hybrids of H1RKO and SJL/J, 129X1/SvJ or
C57BL/6J that express H1RS allele but not in F1 hybrids between H1RKO and C3H/HeJ
or CBA/J mice that express H1RR (Ma et al., 2002).
Hrh1/H1R also controls delayed type hypersensitivity (DTH) responses when
PTX is used as an adjuvant. The DTH response is mediated by CD4 T cells that produce
large amounts of IFN-γ (Sewell et al., 1987; Sewell et al., 1984; Sewell et al., 1983).
Using C3H.BphsS congenic mice expressing the H1RS allele from SJL/J mice on the
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resistant C3H/HeJ background, Gao et al., (Gao et al., 2003) showed that polymorphisms
in H1R regulate ovalbumin-specific DTH response elicited in mice immunized with
ovalbumin in CFA and PTX, indicating that the polymorphisms in H1R regulate IFNγ
production by CD4 T cells. This study confirms the role of H1R polymorphisms in
regulating IFN-γ production by these cells. Further, the complementation of IFN-γ
production by splenocytes immunized using the 2× MOG35-55 model suggests that H1R
regulation of IFNγ production by T cells does not require PTX.
Recently, IL-17-producing Th17 CD4 T cells have been considered more
pathogenic in EAE (Furuzawa-Carballeda et al., 2007). We show here, for the first time,
that H1R signaling regulates IL-17 production and that H1R polymorphisms influence IL17 production by T cells. However, it is noteworthy that we did not observe differences
in IL-17 production between WT and H1RKO mice immunized with MOG35-55-CFA plus
PTX, nor in Th17 cells differentiated in vitro in the presence of excessive amounts of IL6. PTX promotes the generation of Th17 cells, by inducing IL-6 production (Chen et al.,
2007). Thus, it is possible that immunization with PTX (in vivo) or addition of exogenous
IL-6 (in vitro) enables CD4 T cells to overcome the absence of H1R signals required for
the optimal IL-6 production and generation of Th17 cells. Even though we observed
significant differences in IL-17 production by spleen and DLN cells from transgenic mice
selectively expressing either H1RS or H1RR in T cells, we believe, based on in vitro
differentiation data, that the H1R regulation of IL-6 and IL-17 is independent of H1R
signals in T cells. In this regard, compared to WT macrophages H1RKO macrophages
produce significantly less IL-6 (unpublished data) and treatment of lung parenchymal
macrophages with H1R blockers results in decreased IL-6 production (Triggiani et
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al., 2001). Further studies are being carried out to elucidate the role of H1R in the
generation of Th17 CD4 T cells.
GPCRs, in spite of the diversity of their polypeptide sequences, as a family retain
enough structural information to allow them to be properly folded in the ER and adopt
their highly conserved seven transmembrane confirmation (Spiegel and Weinstein, 2004).
Several studies have identified critical residues and motifs important in many of the
functions of GPCRs including ligand binding, G protein coupling, internalization,
downregulation and intracellular trafficking (Duvernay et al., 2005). However, the three
polymorphic residues distinguishing the H1RS and H1RR alleles are located in the third
intracytoplasmic loop and do not constitute any known motif. Even though the exact
PXXP motif is not present, it is worth noting that two of the three polymorphic residues
associated with the H1RS haplotype are prolines, and that proline rich-motifs are known
to mediate protein-protein interactions with Src homology SH3 domains (Sparks et al.,
1996). In this regard, polymorphic residues containing polyproline motifs in the third
intracytoplasmic loop of the dopamine D4 receptor and β1-adrenergic receptor have been
shown to interact with multiple SH3 domain-containing proteins (Oldenhof et al., 1998)
and affect the trafficking of these receptors. However, at this point, we do not have any
evidence to suggest that H1R interacts with any of the known SH3 domain-containing
proteins or that such interactions differ between H1RS and H1RR alleles. Future studies
will address this issue.
GPCRs interact with numerous proteins that play a role in their cellular trafficking
(Tan et al., 2004). H1R has an unusually long third intracytoplasmic loop, suggesting that
the polymorphic residues may result in
94

improper folding of the receptor to a non-

native conformation in ER, which is then recognized by the quality control machinery of
molecular chaperones and excluded from ER export. Several chaperone proteins [such as
Nina (Schneuwly et al., 1989; Shieh et al., 1989), ODR-4 (Dwyer et al., 1998;
Gimelbrant et al., 2001) and a variety of receptor activity modifying proteins (RAMPs)
(Christopoulos et al., 2003; McLatchie et al., 1998)] that support the trafficking of a
range of GPCRs to their target site have been identified. Therefore, it is possible that
polymorphic residue-induced misfolding of H1RR could hinder its interaction with an
essential chaperone thereby affecting its trafficking.
Proper cell surface expression of GPCRs is required to access the requisite ligands
and signal transduction machinery (Tan et al., 2004). The functional importance of proper
GPCR localization is emphasized by several human diseases that result from receptor
mutation and mislocalization, including X-linked nephogenic diabetes, retinitis
pigmentosa and hypogonadotrophic hypogonadism, which result from intracellular
accumulation of mutant V2 vasopressin receptor, rhodopsin and gonadotropin releasing
hormone receptor, respectively (Tao, 2006). In fact, mutations that lead to intracellular
accumulation comprise the largest class of mutations in GPCRs that result in human
diseases (Tan et al., 2004). Accordingly, our results are the first to demonstrate that
structural polymorphisms influencing differential trafficking and cell surface expression
of a GPCR in T cells can regulate immune functions and susceptibility to autoimmune
disease.
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MATERIALS AND METHODS
Mice
C57BL/6J mice were purchased from the Jackson Laboratory (Bar Harbor, ME).
B6.129P-Hrh1tm1Wat (H1RKO) (Banu and Watanabe, 1999) mice were maintained in the
animal facility at the University of Vermont (Burlington, VT). The experimental
procedures used in this study were approved by the Animal Care and Use Committee of
the University of Vermont.
For transgenic mouse generation, the HA-H1RS or HA-H1RR constructs were
made by deleting the methionine of the Bphs-susceptible H1R allele from SJL/J and
Bphs-resistant C3H/HeJ mice, respectively (Ma et al., 2002), and adding an HA tag at the
N-terminus using TOPO cloning vector (Invitrogen, Carlsbad, CA). The HA-H1R was
then subcloned downstream of the distal lck promoter (Wildin et al., 1991). The linear
DNA fragment containing the distal lck promoter, the HA-H1R gene and the human
growth hormone (hGH) intron and polyadenylation signal was injected directly into
fertilized C57BL/6J eggs at the University of Vermont transgenic/knockout facility. Mice
were screened by DNA slot blot testing using a BamHI–SacI 0.5 kb fragment from the
hGH gene as a probe. Two founders were generated for both the H1RS and H1RR alleles
and each was crossed to H1RKO mice to establish transgenic mouse lines on the H1RKO
background (H1RKO-TgS1 and H1RKO-TgS2 and H1RKO-TgR1 and H1RKO-TgR2
mice). Mice from the H1RKO-TgS1 line expressed the transgene at comparable levels to
the two lines expressing the H1RR allele, so it was used in all the experiments in this
study.

96

Cytokine production
For cytokine analysis spleen and lymph nodes were obtained from mice
immunized ten days earlier with either MOG35-55-CFA plus PTX or 2× MOG35-55-CFA
model, single cell suspensions prepared at a concentration of 1 × 106 cells/ml in RPMI
medium and stimulated with 50 μg/ml of MOG35-55. Cell culture supernatants were
recovered at 72 h and cytokine levels measured by ELISA using anti-IFN-γ, anti-IL-4 and
anti-IL17 mAbs and their corresponding biotinylated mAbs (BD Pharmingen, San Diego,
CA). TNF-α ELISA kit was from (BD Pharmingen, San Diego, CA).
Proliferation Assays
Mice were immunized with the 2× MOG35-55-CFA protocol: single cell
suspensions were prepared at 2.5 × 105 cells/well in RPMI medium and stimulated in a 96
well plate with different concentrations (0, 2, 10 and 50 μg/ml) of MOG35-55 for 72 h and
proliferation was determined by [3H]-thymidine incorporation during the last 18 h of
culture.
Cell surface expression studies
The pEGZ-HA vector plasmid was a generous gift from Dr. Ingolf Berberich
(University of Wurzburg, Wurzburg, Germany). Two restriction sites, BamHI and EcoRI
were inserted into H1RS or H1RR cDNA by PCR and cloned such that the second codon is
in-frame with the HA tag of pEGZ generating an HA-H1R fusion protein. pEGZ is a
bicistronic system with IRES-EGFP. EGFP served as a marker for transfected cells.
HEK293T cells were plated at 1.25 × 106 cells/plate and cultured in DMEM-F12
containing 10% FBS. When the cells were about 50-80% confluent, they were transfected
with 5 μg of pEGZ-HA-H1RS, pEGZ-HA-

H1RR or the empty pEGZ vector using
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calcium phosphate method. After 16-24 h, cells were scraped off the plate by rigorous
pipetting with 1% Calf serum in PBS and stained with anti-HA mAb conjugated to PE
(Miltenyi Biotech, Auburn, CA) according to the manufacturer’s guidelines. Cells were
analyzed by Flow cytometry using FACSAria instrument (BD Pharmingen, San Diego,
CA) and the data were further analyzed using FlowJo flow cytometry analysis software
(Tree star Inc, Ashland, OR).
Confocal microscopy
HEK293T cells were transfected with pEGA-HA-H1RS, pEGZ-HA-H1RR or
empty pEGZ control vector (5 μg total DNA) using the calcium phosphate method. Cells
were fixed, permeabilized and stained using an anti-HA mAb (Cell Signaling
Technologies, Danvers, MA) followed by an incubation with Alexa-568 anti-mouse
antibody (Molecular Probes, Eugene, Oregon). TOPRO-3 nuclear stain (Molecular
Probes, Eugene, Oregon) was used as a nuclear marker. For non-permeabilized cells, the
transfected HEK293T cells were stained with the anti-HA mAb and were then fixed.
Cells were examined by confocal microscopy using Zeiss LSM 510 META Confocal
Laser Scanning Imaging System (Carl Ziess Microimaging Inc, Thronwood, NY).
Cell lysates and Western blotting
Whole-cell lysates were prepared from HEK293T cells transfected with various
pEGZ constructs in Triton lysis buffer and were then separated via sodium dodecyl
sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) and transferred to nitrocellulose
membranes as described previously (Noubade et al., 2007). Anti-HA mAb (Abcam Inc.
Cambridge, MA) was used as primary antibody. Anti-actin (Santa Cruz Biotechnology,
Santa Cruz, CA) was used as a loading control.
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[3H]mepyramine binding studies
[3H]mepyramine binding studies were conducted as described (Bakker et al.,
2004) and were used to measure expression levels of H1R variants and the H1RS-Gαq/11
and H1RR-Gαq/11 fusion proteins.
[35S]GTPγS binding Assay
[35S]GTPγS binding experiments to assess the capacity of H1R variants to cause
activation of Gαq/11 were initiated by the addition of cell membranes containing 50 fmols
of H1R variant constructs to assay buffer (20mM HEPES (pH 7.4), 3mM MgCl2, 100mM
NaCl, 1µM GDP, 0.2mM ascorbic acid, and 100nCi [35S]GTPγS) containing 100μM
histamine. Non-specific binding was determined in the above condition with the
addition of 100µM GTPγS. Reactions were incubated for 15 min at 300 C and were
terminated by the addition of 500µl of ice-cold buffer containing 20mM HEPES (pH
7.4), 3mM MgCl2, 100mM NaCl and 0.2mM ascorbic acid. The samples were
centrifuged at 16,000 × g for 10 min at 40 C. The resulting pellets were re-suspended in
solubilization buffer (100mM Tris, 200mM NaCl, 1mM EDTA, and 1.25% Nonidet
P-40) plus 0.2% SDS. Samples were precleared with Pansorbin for 1 h, followed by
immunoprecipitation with a C-terminal anti- Gαq/Gα11 antiserum (Mitchell et al., 1991).
Finally, the immunocomplexes were washed with solubilization buffer and bound
[35S]GTPγS was estimated by liquid scintillation-spectrometry.
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Site directed mutagenesis
pEGZ-HA-H1RS was used as template to generate single H1RS mutants with each
of the polymorphic residues replaced with the corresponding residue of the H1RR allele
using the Quickchange (Strategene) site directed mutagenesis kit, according to the
manufacturer’s guidelines. The forward primers used for the mutagenesis were: for
P263L 5’- GGGGGTCCAGAAGAGGCCGTCAAGAGACCCTACTGG-3’, for V312M
5’- CATGCAGACACAGCCTGTGCCTGAGGGAGATGCCAGG-3’, for P330S 5’CCAGACCTTGAGCCAGCCCAAAATGGATGAGCAGAGC-3’. The reverse primers
were the complementary sequences of these primers. The altered nucleotides are shown
in bold and underlined. The mutants were sequence confirmed and were used as template
for the generation of different combinations of double H1RS mutants.
Conventional and Quantitative Real-Time Polymerase Chain Reaction (RT-PCR)
Total RNA was extracted from CD4 T cells using RNeasy RNA isolation reagent
(Qiagen, Valencia, CA) as recommended by the manufacturer. cDNA generated from 1
μg total RNA was used in conventional and quantitative real-time RT-PCR as described
earlier (11).
Induction and Evaluation of EAE
Mice were immunized for the induction of EAE using either the MOG35-55complete Freund’s adjuvant (CFA) double-inoculation (2× MOG35-55-CFA) (Butterfield
et al., 1998) or the MOG35-55-CFA plus PTX single-inoculation (MOG35-55-CFA plus
PTX) protocols (Teuscher et al., 2006b). For the 2× MOG35-55-CFA induction protocol
mice are injected subcutaneously with an emulsion of 100 μg of MOG35-55 and an equal
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volume of CFA containing 200 μg of Mycobacterium tuberculosis H37RA (Difco
Laboratories, Detroit, MI) in the posterior right and left flank; one week later all mice
were similarly injected at two sites on the right and left flank anterior of the initial
injection sites. Animals immunized using the MOG35-55-CFA plus PTX single-inoculation
protocol received an emulsion of 200 μg MOG35-55 and equal volume of CFA containing
200 μg of Mycobacterium tuberculosis H37RA by subcutaneous injections distributed
equally in the posterior right and left flank and scruff of the neck. Immediately thereafter,
each animal received 200 ng PTX (List Biological Laboratories, Campbell, CA) by
intravenous injection. Mice were scored daily starting at day 5 post-injection as
previously described (Teuscher et al., 2006b). Clinical quantitative trait variables
including disease incidence and mean day of onset (DO), cumulative disease score
(CDS), number of days affected (DA), overall severity index (SI) and the peak score (PS)
were generated as previously described (Butterfield et al., 1998).
Statistical analysis
Statistical analyses, as detailed in the figure legends, were performed using GraphPad
Prism 4 software (GraphPad software Inc, San Diego, CA). A P value of 0.05 or less was
considered significant.
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Figure 1. Transgenic expression of H1RR in H1RKO T cells fails to complement
EAE in H1RKO mice.
H1R transgene expression was analyzed by (A) RT-PCR and (B) quantitative RT-PCR of
H1R mRNA expression from CD4 T cells from H1RKO mice and the transgenic mice
expressing H1RS or H1RR that were crossed with H1RKO mice (H1RKO-TgS, H1RKOTgR1 and H1RKO-TgR2). H1RKO-TgR1 and H1RKO-TgR2 represent two independent
lines. (C) Clinical EAE in WT (n = 19), H1RKO (n = 56), H1RKO-TgS (n = 24), and
H1RKO-TgR (n = 25) mice that were immunized with MOG35-55+CFA+PTX. Mice were
scored daily starting at D5. Regression analysis revealed that the disease course elicited
fits a Sigmoidal curve and that the clinical disease course of the animals was significantly
different among the strains (F = 66.1; p < 0.0001) and that WT (F = 132.1; p < 0.0001)
and H1RKO-TgS (F = 127.5; p < 0.0001) mice were significantly different from H1RKOTgR and H1RKO mice. (D) WT (n = 18), H1RKO (n = 33), H1RKO-TgS (n = 23), and
H1RKO-TgR (n = 25) mice were immunized 2× with MOG35-55+CFA. EAE severity was
significantly different among the strains (F = 8.9; p < 0.0001) with WT (F = 226.9; p <
0.0001), and H1RKO-TgS (F = 134.0; p < 0.0001) mice being significantly different from
H1RKO-TgR (F = 215.8; p < 0.0001) H1RKO mice.
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Figure 2. Transgenic expression of H1RR in H1RKO T cells fails to complement
cytokine production by H1RKO mice.
(A-C) Spleen and draining lymph node (DLN) cells isolated from MOG35-55 plus CFA
plus PTX-immunized WT, H1RKO, H1RKO-TgS and H1RKO-TgR mice 10 days post
immunization and stimulated with the indicated 50mg/ml of MOG35-55 for 72h.
Supernatants were collected and analyzed for the production of IFN-g (A), IL-4 (B) and
IL-17 (C). Significance of differences in cytokine production were assessed by one-way
ANOVA (F = 14.89; p < 0.001 for IFNγ, F = 28.93; p < 0.001 for IL-4, p > 0.5 for IL-17)
followed by Benfeorroni’s post-hoc comparisons. Except for IL-17, WT = H1RKO-TgS >
H1RKO-TgR1 = H1RKO-TgR2 = H1RKO mice. (D-F) Spleen and DLN cells from 2x
MOG35-55 plus CFA immunized mice were collected on day 10 post immunization and
were activated with 50μg/ml of MOG35-55 for 72h, supernatants were collected and
analyzed for IFNγ (D), IL-4 (E) and IL-17 (F) by ELISA in triplicate. Significance of
differences in cytokine production were assessed by one-way ANOVA (F = 28.92; p <
0.0001 for IFNγ, F = 3.766; p < 0.0001 for IL-4, F = 10.29; p < 0.0001 for IL-17)
followed by Benfeorroni’s post-hoc comparisons. For all the cytokines tested WT =
H1RKO-TgS > H1RKO-TgR1 = H1RKO-TgR2 = H1RKO mice.
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Figure 3. H1RS and H1RR activate Gαq/11 G proteins equally well.
(A) The amino acid sequence of the mouse histamine H1 receptor is displayed with
differences between the H1RR allele (red) and the H1RS allele (yellow) highlighted. Each
of the sites of variation is within the long, third intracellular loop. (B) Saturation
[3H]mepyramine binding studies were performed on membranes of HEK293T cells
transfected to express a H1R-Gαq fusion protein (H1RR-left panel, H1RS-right panel. Nonspecific binding (shown in red) was determined in the same manner but with the
additional presence of 1μM mianserin. These studies provided quantitation of construct
expression levels. (C & D) Membranes containing 50 fmol of H1RS or H1RR linked to
either Gαq (C) or Gα11 (D) were used in [35S]GTPγS binding studies conducted in the
absence (basal, open bars) or presence (histamine, filled bars) of 100μM histamine to
assess the capability of the two variants to activate the G proteins. H1RS and H1RR were
equi-effective in causing activation of each G protein. Representative data are shown.

107

Figure 4. H1RS and H1RR are differentially expressed on the cell surface.
(A) HEK293T cells were transfected with empty pEGZ, pEGZ-HA-H1RS or pEGZ-HAH1RR plasmids in triplicate cultures. Cells were collected 16-24h later without
trypisinization, stained with anti-HA mAb and analyzed by Flow cytometry. Thin line
represents cells transfected with empty pEGZ, thick line represents cells transfected with
HA-H1RS and the filled area represents cells transfected with HA-H1RR. (B & C)
HEK293T cells were analyzed as in (A) and the percentage (B) and the mean florescence
intensity of anti-HA on H1RS positive cells (C) were determined (n=3). (D) HEK293T
cells transfected with HA-H1RS or HA-H1RR plasmids and 24 h later cells were stained
with anti-HA mAb (red) without permeabilization. Cells were visualized by confocal
microscopy. GFP (green) is shown as a marker of transfected cells. (E). HEK293T cells
were transfected as in (A), whole cell lysates prepared and analyzed by Western blotting
using anti-HA mAb. Actin is shown as loading control.

108

Figure 5. H1RR is retained in endoplasmic reticulum.
(A) HEK293T cells were transfected with HA-H1RS or HA-H1RR plasmids. 24h later,
cells were fixed, permeabilized, stained with anti-HA mAb (red) and TOPRO-3 nuclear
stain (green) and visualized by confocal microscopy. (C) HEK293T cells were cotransfected with pdsRed plasmid that express ER targeted florescent dsRed protein (red)
and HA-H1RS or HA-H1RR. 24h later cells were fixed, permeabilized, stained with antiHA mAb (green) and the co-localization of HA-H1R with dsRed was visualized by
confocal microscopy. Yellow color represents the co-localization of red and green colors.
(D) Quantification of HA-H1R colocalization with dsRed protein. Using Zeiss LSM 510
META Confocal imaging software the number of pixels expressing both colors were
determined in a number of cells (n=36) and the data are presented as the average number
of pixels that co-express dsRed and HA-H1R. Error bars indicate SEM.
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Figure 6. ER retention of H1RR requires all of its three polymorphic residues.
(A)HEK293T cells were transfected with empty control, HA-H1RS, single HA-H1RS mutants or
HA-H1RR plasmids. Cells were collected 16-24 h later without trypisinization, stained with antiHA mAb and analyzed by flow cytometry. Thin line represents cells transfected with empty
pEGZ, thick line represents cells transfected with HA-H1RS and the filled area represents cells
transfected with HA-H1RR. (B) HEK293T cells were analyzed as in (A) and the mean florescence
intensity of anti-HA on H1RS positive cells was determined. The data presented is the average of
triplicate transfections. (C) HEK293T cells were co-transfected with pdsRed plasmid that express
ER targeted dsRed protein (red) and HA-H1RS, mutants of HA-H1RS or HA-H1RR. 24h later, cells
were fixed, permeabilized, stained with anti-HA mAb (green) and the co-localization of HA-H1R
with dsRed (red) was visualized by confocal microscopy. Yellow color represents the colocalization of red and green colors. (D) Quantification of HA-H1R colocalization with dsRed
protein. Using Zeiss LSM 510 META Confocal imaging software the number of pixels
expressing both the colors was determined in a number of cells (n≥16) and the data is presented
as the average of number of pixels that co-express dsRed and HA-H1R. Error bars indicate SEM.
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(A)
Incidence

Day of
onset

Cumulative
disease
score

Severity
index

Peak
score

C57BL/6J

19/19

13.1±0.3

56.2±4.6

3.1±0.2

3.9±0.3

H1RKO

55/56

15.7±0.4

32.1±1.4

2.1±0.1

3.0±0.1

H1RKO-TgS

24/24

12.9±0.4

50.0±3.7

2.8±0.2

3.6±0.2

H1RKO-TgR

16/17

13.3±0.3

50.0±3.2

2.7±0.2

3.6±0.2

χ2 = 2.5
p = 0.5

F = 13.5
p < 0.0001

19.2
< 0.0001

14.4
< 0.0001

Strain

21.2
< 0.0001

C57BL/6J = H1RKO-TgS ≠ H1RKO-TgR = H1RKO

(B)
Incidence

Day of
onset

Cumulative
disease
score

Severity
index

Peak
score

C57BL/6J

18/18

16.6±0.7

37.6±2.9

2.6±0.1

3.2±0.2

H1RKO

26/33

17.1±0.5

20.0±1.8

1.6±0.1

2.2±0.1

H1RKO-TgS

22/23

16.2±0.6

36.4±3.8

2.5±0.2

3.2±0.2

H1RKO-TgR

13/14

18.7±0.6

18.6±3.1

1.6±0.2

1.9±0.2

Strain

χ2 = 7.4
p = 0.06

F = 2.8
p = 0.05

11.6
< 0.0001

15.2
< 0.0001

C57BL/6J = H1RKO-TgS ≠ H1RKO-TgR = H1RKO

Table 1. Clinical disease traits following imuunization of mice with
(A) MOG35-55+CFA + PTX and (B) 2x (MOG35-55+CFA)
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14.0
< 0.0001

H1RS
129 / SvJ
129S1/SvImJ
129T2/SvEmsJ
A/J
A/WySnJ
ALR/LtJ
ALS/LtJ
B10.S/DvTe
BALB / cByJ
BALB/ cJ
BDP/J
BPH/2J
BPL/1J
BPN/3J
BTBR T+ tf/J
BXSB/MpJ
C57BL/10J
C57BL/10SnJ
C57BL/6ByJ
C57BL/6J
C57BLKS/J
C57BR/cdJ
C57L/J
C58/J
CALB/RkJ
CE/J
DBA/1J
DBA/2J
DDY/JclSidSeyFrkJ
EL/SuzSeyFrkJ
FVB/NCr
IS/CamRkJ
KK/HIJ

H1RR
LEWES/EiJ
LG/J
LP/J
Ma/MyJ
MOR/RkJ
NOD/LtJ
NON/LtJ
NOR/LtJ
NZO/HlLtJ
P/J
PANCEVO/EiJ
PERA/EiJ
PERC/EiJ
PL/J
RBF/DnJ
RIIIS/J
SB/LeJ
SEA/GnJ
SEC/1ReJ
SENCARA/PtJ
SENCARB/PtJ
SENCARC/PtJ
SJL/J
SJL/Bm
SM/J
SPRET/EiJ
ST/bj
SWR/ J
SWXL-4/TyJ
TIRANO/EiJ
WSB/EiJ
YBR/EiJ
ZALENDE/EiJ

AKR/J
BPL/1J
C3H/HeJ
CASA/RkJ
CAST/EiJ
CBA/J
CZECHI/EiJ
CZECHI/EiJ
I/LnJ
JF1/Ms
MOLC/RkJ
MOLD/RkJ
MOLF/Eij
MRL/MpJ
MSM/Ms
PWK/PhJ
RF/J
SF/CamEiJ
SKIVE/EiJ

Table 2. The P-V-P and L-M-S haplotypes of H1R are evolutionarily
conserved in mice.
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CHAPTER 4: CONCLUSIONS AND FUTURE DIRECTIONS
Complex diseases such as MS and EAE are governed by multiple susceptibility
genes and the risk conferred by polymorphisms in their alleles. Identifying such “risk
alleles” and gaining mechanistic understanding of their contribution in the disease
development will yield newer targets for therapeutic intervention in ameliorating these
diseases. Even though more than 40 QTLs (Becanovic et al., 2006) in EAE and
polymorphisms in many of their candidate genes, such as IL-2 (Encinas et al., 1999),
MCP-1 and MCP-5 (Butterfield et al., 1999), and Ncf-1 (Becanovic et al., 2006) have
been identified, no study has systematically elaborated the pathways of their mechanisms.
To date, only one QTL, originally identified as Idd5.1 and encompassing the gene coding
for costimulatory molecule ICOS-1, has been shown to modulate EAE. This is through
the differential expression of ICOS-1 in activated CD4 T cells, with higher expression in
the resistant NOD/J mice than the congenic mice expressing ICOS-1 from the susceptible
C57BL/6J mice (Greve et al., 2004). Our laboratory had previously identified
polymorphisms in Hrh1/H1R and shown that it is a susceptibility gene in EAE (Ma et al.,
2002). In this study, the role of these polymorphisms was delineated and shows that they
affect H1R functions by differential cell surface expression. Further, the molecular
pathways, through which H1R contributes to the pathogenesis of EAE were identified and
demonstrate that H1R influences EAE by regulating proinflammatory cytokine
production by T cells.
H1R is one of the widely expressed GPCRs and is present on multiple cells types
involved in EAE pathogenesis (Parsons and Ganellin, 2006). This study demonstrates
that H1R expression in T cells is important
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and

sufficient

to

influence

the

susceptibility to EAE. Re-expressing the susceptible allele of H1R (H1RS) in T cells of
H1RKO mice complemented EAE severity and disease-associated cytokine production
by these mice, but the resistant allele of H1R (H1RR) failed to do so. This clearly show
that the H1R polymorphisms affect its ability to influence EAE pathogenesis and suggests
that H1RR is not a functional receptor.
A functional GPCR such as H1R, once synthesized, adopts a “native” structure
that enables the receptor to pass through the quality control machinery of the
endoplasmic reticulum (ER) and traffics to its target site, the cell surface (Spiegel and
Weinstein, 2004). In transfected 293T cells, the polymorphisms in H1R regulated the
trafficking of the receptor with H1RR failing to reach its final compartment and being
retained in ER. In contrast H1RS was efficiently trafficked and expressed on the cell
surface. Thus, polymorphisms in H1RR join the group of a number of examples in which
polymorphisms and mutations in GPCRs lead to their mislocalization and in many cases
are associated with pathologies.
This study provides evidence that the polymorphisms in H1R are evolutionarily
conserved as haplotype blocks among several inbred strains of mice. The natural
evolutionary history of the common house mouse suggests that, about a million years
ago, its ancestors evolved into at least three well-developed subspecies that dominated
different parts of the world (Wade and Daly, 2005). These include M. m. domesticus in
Western Europe, M. m. musculus in Russia, Northern China and Eastern Europe and M.
m. castaneus in West Asia, Southeast Asia and Southern China (Beck et al., 2000;
Paigen, 2003). However, it is still unclear if the three subspecies diverged simultaneously
or M. m. musculus and M. m. castaneus diverged from a common ancestor shortly after
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the divergence of M. m. domesticus (Yang et al., 2007). Several thousand years ago, the
Asian M. m. musculus and M. m. castaneus made their way to the Japanese Islands
forming a new subspecies known as M. m. molossinus (Paigen, 2003). Because of their
close cohabitation, hundreds of years ago, humans noted spontaneously arising coat
colors in mice in Europe, China and Japan and domesticated several varieties as pets.
Europeans even imported what were considered fancier coat colors from Asian regions
and bred them with local mice to create few pools of mice. Some of these fancy mice
were prized and even traded throughout Europe. With the rediscovery of Mendel’s laws
of inheritance, in the early twentieth century, geneticists such as Cuenot, Castle and Little
started studying the discrete inheritance of the coat colors in mice. They received their
animals from a large mice-breeding farm owned by Abbie Lathrop, whose colonies
originated from European and Asian fancy mice. Castle and Little recognized the value of
homozygous mice and established inbred strains of mice by brother x sister matings.
DBA (having the coat color allele, dilute, brown and non-agouti) was the first inbred
mouse strain developed in 1909. Since then, more than 450 inbred strains of mice have
been established (Beck et al., 2000; Paigen, 2003). Therefore, most of the inbred
laboratory mouse strains originated from a mixed, restricted number of founders. Based
on this, the genomes of the common inbred mice strains were proposed to represent a
mosaic of regions originating from different subspecies. M. m. domesticus is the major
contributor while M. m. musculus and M. m castaneus are the minor contributors to the
genetic background of these mice (Wade and Daly, 2005). This hypothesis was
strengthened by the observations that the mitochondrial DNA in many inbred strains of
mice was derived from M. m. domesticus while the Y-chromosome was derived from M.
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m. musuculus (Bishop et al., 1985; Ferris et al., 1982). Further, it was noted that the
musculus-type Y-chromosome originated from M. m. molossinus males (Nagamine et al.,
1992). However, strains with Y-chromosome from M. m. domesticus have also been
identified (Yang et al., 2007). Recently, the fine structure of this mosaic variation of the
mouse genome is described (Wade et al., 2002; Yang et al., 2007). Strain-to-strain
comparisons of single nucleotide polymorphisms (SNPs) revealed a long interspersed
regions of high and low sequence identities. The segments genome with extremely high
SNP variation is indicative of different subspecies origin and spanned only one-third of
the genome. The segments of the genome covered with extremely low variation represent
similar subspecies (M. m. domesticus) origin and spanned two thirds of the genome
(Yang et al., 2007). However, another study reported a predominant introgression of M.
m. domesticus segments at exceptionally high levels (86 to 96%) in the genomes of
common laboratory strains while M. m. musculus contributed about 1-8 % and M. m.
castaneus contributed only 1-2 % (Yang et al., 2007). Further, high-density sequence
based studies identified three distinct genetic variation patterns indicative of the
evolutionary origin; large monomorphic haplotypes representing a common ancestor,
large polymorphic blocks representing recombination of two ancestor genomes, and large
fragmented haplotype blocks representing greater complexity and multiple ancestor
origin (Frazer et al., 2004; Sakai et al., 2005; Zhang et al., 2005). This study herein found
that the H1R alleles are conserved among several inbred strains of mice, including the
wild-derived inbred strains, suggesting that the two haplotypes have evolutionarily coevolved over a long period of time and reflect evolutionarily conserved functional
differences. Future studies are necessary to ascertain the subspecies origin of the H1R
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haplotype block and examine if the haplotype block encompasses even a larger region of
chromosome 6.
Traditionally, histamine was considered to be a mediator of the effector phase of
EAE rather than the priming of autoreactive T cells (Bebo et al., 1996; Linthicum, 1982).
This study exhibits that Hrh1/H1R is expressed in unstimulated CD4 T cells but
downregulated upon activation. Complementation of H1R in naïve, but not in activated,
H1RKO CD4 T was able to restore the ability of these cells to produce IFN-γ to the levels
of WT CD4 T cells. These observations, along with the findings that mast cells exert their
effect outside the CNS in EAE (Tanzola et al., 2003), suggests that histamine interaction
with H1R is important during the initial induction and priming of the naïve antigenspecific CD4 T cells in EAE pathogenesis.
H1R has been previously implicated in the regulation of IFN-γ production (Banu
and Watanabe, 1999; Bryce et al., 2006; Ma et al., 2002). In this study, it is evidenced
that H1R regulates IFN-γ by modulating activation of p38MAP kinase and T-bet. Further,
it was found that histamine interaction with H1R is required for p38 MAP kinase
activation in TCR-stimulated CD4 T cells. However, how H1R activates p38 MAP kinase
is unknown. p38 MAP kinase is normally activated through the upstream MAPKK,
MKK3 and MKK6 (and MKK4 in response to some stimuli) (Kyriakis and Avruch,
2001). It has been documented that GADD45 proteins interact with MEKK4, an upstream
kinase of MKK3 and MKK6 and thus activate p38 MAP kinase (Takekawa and Saito,
1998). Whether H1R associates with GADD45 members and activates p38 MAP kinase
needs to be investigated.
Overall,

the

results

presented
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herein demonstrate the importance of

histamine and its interaction with H1R as a significant immunomodulatory factor in EAE.
Hrh1/H1R is a shared susceptibility gene in EAE and experimental allergic orchitis (Ma
et al., 2002). A shared genetic basis among different autoimmune diseases has been
proposed and non-MHC candidate loci of several autoimmune or inflammatory disease
are present as clusters in humans and in animal models (Becker et al., 1998). This
suggests common susceptibility genes or tightly linked loci in multi-gene families. Thus,
studying the role of H1R in other autoimmune diseases may shed a light on its role as a
common autoimmune modifier. Further, even though polymorphisms in human H1R have
not yet been reported, a syntenic region has been identified as a major risk factor in MS
patients. Administration of antihistaminics in MS patients stabilized the disease
progression (Dimitriadou et al., 2000). A retrospective epidemiological study found that
the use of H1R blockers reduced the risk of MS (Alonso et al., 2006). Together, all these
observations suggest that pharmacological targeting of the H1R may be useful early in the
treatment of MS and other autoimmune inflammatory diseases.

APPNEDIX A: WEIBEL PALADE BODIES NEGATIVELY
REGULATE BLOOD BRAIN BARRIER PERMEABILITY
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Abstract
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Weibel-Palade bodies (WPB) within endothelial cells (EC) are secretory granules
that release von Willebrand Factor (VWF), P-selectin, chemokines and other stored
molecules following exposure to histamine (HA). Mice with a disrupted VWF gene
(VWFKO) have EC that are deficient in WPB. These mice were used to evaluate the role
of this organelle in Bordetella pertussis toxin induced hypersensitivity to HA (Bphs), an
intermediate phenotype associated with susceptibility to experimental allergic
encephalomyelitis (EAE), the principal autoimmune model of multiple sclerosis. No
significant differences in susceptibility to Bphs between wild-type and VWFKO mice
were detected at three days; however, in VWFKO mice HA sensitivity persists
significantly longer. Correspondingly, the onset of EAE was earlier, disease was more
severe and blood brain barrier (BBB) permeability significantly increased in VWFKO
mice compared to wild-type mice. Moreover, inflammation was selectively increased in
the brains and not in the spinal cords of VWFKO mice compared to wild-type mice.
Early increases in BBB permeability in VWFKO mice were not due to increased
encephalitogenic T-cell activity because BBB permeability was significantly greater in
adjuvant treated VWFKO mice compared to littermate mice immunized with
encephalitogenic peptide plus adjuvants. Taken together, these data indicate that VWF
and/or WPBs negatively regulate BBB permeability changes and autoimmune
inflammatory lesion formation within the brain elicited by peripheral inflammatory
stimuli.
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Introduction
Pertussis toxin (PTX) is a major virulence factor of Bordetella pertussis, the
causative agent of whooping cough (Bordet and Gengou, 1906). The holotoxin is a
hexameric protein that conforms to the A/B model of bacterial exotoxins (Rappouli and
Pizza, 1991). The A-subunit is an ADP-ribosyl transferase which affects signal
transduction by ribosylation of the α-subunit of trimeric Gi/o proteins, and the βoligomer of PTX binds cell surface receptors on a variety of mammalian cells (Kaslow
and Burns, 1992). Intoxication with PTX elicits an array of physiological responses in
vivo including increased blood brain barrier (BBB) permeability and sensitization of the
vascular endothelium to vasoactive agents such as histamine (HA) (Locht, 1999; Munoz,
1985). Inbred strains of mice differ in susceptibility to challenge with vasoactive agents
following sensitization with PTX in that genetically susceptible strains succumb to
hypotensive and hypovolemic shock while resistant strains do not (Wardlaw, 1970).
Additionally, the genetic control of susceptibility to lethal shock is agent specific (Gao et
al., 2003). For example, PTX-induced vascular endothelial sensitization, controlled by
Bphs (Bordetella pertussis induced HA sensitization), is detected by HA challenge, but
not by serotonin challenge. Bphs is an autosomal dominant locus that we recently
identified as the histamine H1 receptor (Hrh1/H1R) (Kantarci et al., 2002). Importantly,
susceptibility to experimental allergic encephalomyelitis (EAE), the principal
autoimmune model of multiple sclerosis (MS) (Musio et al., 2006), is also controlled by
Bphs/Hrh1 (Kantarci et al., 2002; Linthicum, 1982), underscoring the role of genetic
factors in regulating BBB permeability and susceptibility to inflammatory demyelinating
diseases of the CNS.
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The mechanism whereby PTX sensitizes the vascular endothelium to HA is
unknown, but it is consistent with a two-step process: an induction phase, characterized
by a 2- to 3-day latent period following intoxication, and an effector phase, manifest by
rapid onset of lethal shock that usually occurs within ten minutes of HA challenge
(Bergman and Munoz, 1968),(Munoz et al., 1981). Bphs is also characterized by a
protracted period of sensitivity that persists upwards of 30 days (Munoz et al., 1981). The
fact that sensitization of the vascular endothelium continues well beyond the likely halflife of the toxin in vivo suggests that the induction phase may be associated with the
synthesis and storage of additional vasoactive factors within endothelial cells (ECs) that
are released by exposure to HA during the effector phase. In this regard, it is known that
following inflammation preformed KC (IL-8 homologue), eotaxin-3, von Willebrand
Factor (VWF), P-selectin, CD63/lamp3, angiopoietin 2, endothelin-1, endothelin
converting enzyme, tissue-type plasminogen activator (t-PA), factor XIIa and/or α1,3fucosyltransferase VI can be stored in EC Weibel Palade bodies (WPBs) (Rondaij et al.,
2006), and that HA is a secretagogue for the release of these agents (Hattori et al., 1989).
Under a hypothetical two-step model, lethal shock would be due to the direct vasodilatory
activity of HA combined with the effects of the stored products released from WPBs. In
the absence of exposure to PTX, the ECs must be able to compensate for the effects of
subsequently administered HA because most mice do not succumb following HA
challenge alone. In contrast, EC would not be able to compensate for the increase in
synergistic second messenger signaling arising from exposure to both HA and PTXinduced stored vasoactive factors. In this study, mice with a disrupted VWF gene
(VWFKO) and a consequent deficiency in WPBs (Denis et al., 1998) were used to
122

directly test this hypothesis and to evaluate the role of WPBs in regulating BBB
permeability and susceptibility to EAE. We report that, contrary to this model, WPBs
suppress Bphs and adjuvant-induced alterations in BBB function associated with actively
induced EAE.
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Results
Bphs in VWFKO mice
The role of WPBs in Bphs was evaluated by i.v. sensitization of B6 and VWFKO
mice with 200 ng PTX on day 0. Three days later HA sensitivity was assessed in a dose
response fashion by i.v. challenge with HA and deaths were recorded at 30 min. A
significant difference in the LD50 values between the two strains was not detected (B6 =
1.65 ± 0.05 mg/kg vs. VWFKO = 1.41 ± 0.08 mg/kg; F = 0.55, p = 0.46), indicating that
neither VWF nor WPBs are required for Bphs susceptibility. Given the role of WPBs in
vascular function, we nevertheless assessed their effect on the persistence of HA
sensitivity. Compared to B6 mice, HA sensitivity persistent longer in VWFKO mice at all
challenge doses studied (F = 38.25; p < 0.0001) (Fig. 1). The half-life of sensitization was
64.8 days in VWFKO mice compared 34.4 days in B6 mice at 100 mg/kg HA challenge.
Similarly, the sensitization half-lives were 66.0 and 63.3 days in VWFKO mice at 50
mg/kg and 25mg/kg of HA respectively while the corresponding sensitization half-lives
in WT mice were 34.2 and 30.7 days. Taken together, these data demonstrate that WPBs
and/or VWF ordinarily act to shorten the longevity of HA sensitivity elicited by in vivo
intoxication with PTX.
EAE in VWFKO mice
Because VWFKO mice exhibited significantly prolonged sensitivity to HA, and
because Bphs is an EAE susceptibility gene (Kantarci et al., 2002), we studied the role of
WPBs in regulating EAE induced by immunization with MOG35-55+CFA+PTX.
Compared to B6 mice, VWFKO mice developed significantly more severe clinical signs
of EAE (Fig. 2). Clinical signs of EAE in

VWFKO mice were notably enhanced
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during the acute-early phase (D7 through D18 postimmunization) compared to the
chronic late-phase of the disease (day 20-30) (Polanczyk et al., 2004). The mean day of
disease onset in VWFKO mice was 14.1 ± 2.0 vs. 16.4 ± 3.2 (p = 0.01) in B6 mice. The
acute-early phase cumulative disease score in VWFKO mice was 22.6 ± 11.1 vs. 13.3 ±
11.9 (p = 0.008) in B6 mice.
Histological analysis of CNS samples obtained during the acute-early phase of the
disease revealed that VWFKO mice exhibited significantly greater pathology in the brain
than did B6 mice (Fig. 3A-3E). VWFKO mice had a higher overall pathology index with
significantly greater lesion scores, more severe demyelination, more severe suppuration,
and more extensive mononuclear cell infiltrates compared to B6 mice. In contrast,
however, no difference in the overall severity of the lesions between VWFKO and B6
mice was observed in the spinal cord (Fig. 3F). These results demonstrate that the
absence of WPB and/or VWF selectively promotes lesion formation in the brain,
compared to the spinal cord-dominant disease seen in mice with intact VWF and WPBs.
We examined a number of T cell parameters in B6 and VWFKO mice following
sensitization with MOG35-55+CFA+PTX in order to evaluate the encephalitogenic T cell
response elicited in each strain. No difference in the proliferative response of spleen cells
to MOG35-55 at day 10 p.i. was observed between B6 and VWFKO mice (Fig. 4A).
Similarly, no significant differences in cytokine and chemokine expression following ex
vivo restimulation with MOG35-55, were detected between B6 and VWFKO animals (Fig.
4B, C). Taken together, these results indicate that the more severe acute-early phase
disease seen in VWFKO mice is unlikely to be due to a direct effect of the absence of
VWF or WPBs on T cell effector responses.
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Increased BBB permeability in VWFKO mice during EAE
To delineate the mechanisms underlying the more severe acute-early phase of
EAE in VWFKO mice, we analyzed EC function by measuring BBB permeability. A
BBB permeability index (BBB-PI) was determined by measuring the traverse of
systemically injected FITC-labelled bovine serum albumin (BSA) into the cerebrospinal
fluid of EAE-induced mice at 8, 10 and 12 days p.i. (Fig. 5). BBB-PIs were not
significantly different between unmanipulated B6 and VWFKO mice; however, BBB-PIs
were significantly elevated in both mouse strains (p = 0.01 for B6 and p < 0.001 for
VWFKO) following immunization with MOG35-55+CFA+PTX. Moreover, the test of the
main effect of group (mouse strain) showed a significant difference (p = 0.02) between
the two strains over time, with the BBB-PI being greater in VWFKO mice compared to
B6 mice.
The significant difference in clinical signs and brain pathology between B6 and
VWFKO mice during the acute-early phase of the disease, despite the absence of
detectable differences in encephalitogenic T cell effector responses, point to a potential
role for WPBs in regulating the interface between the circulation and the brain. We
therefore compared the integrity of the BBB in B6 and VWFKO mice at various time
points after injection with MOG35-55+CFA+PTX or CFA+PTX. Immunization with
CFA+PTX alone lead to increased BBB permeability in B6 mice (Fig. 6A) to an extent
that was not different from that seen following immunization with MOG35-55+CFA+PTX
(p = 0.45). The change in BBB permeability over time was also not significant in B6
mice (Fig. 6B) (p = 0.08). Similarly, immunization with CFA+PTX alone significantly
increased the BBB permeability in VWFKO mice but again, there was no difference in
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the BBB-PIs between the animals immunized with or without the encephalitogen (p =
0.47). This indicates that in both B6 and VWFKO mice, antigen-specific
encephalitogenic T cells are not responsible for eliciting increased BBB permeability
across the time points studied. Because the BBB-PIs between the animals immunized
with or without MOG35-55 were not different, they were pooled and reanalyzed. The
results revealed that the BBB-PI in VWFKO mice was significantly greater than the
BBB-PI in B6 mice (p = 0.001) (Fig. 6C) when CFA and PTX are used as adjuvants, and
that this difference is encephalitogen-independent.
To understand which component of the adjuvants (CFA or PTX) is responsible for
increased BBB permeability, we determined the BBB-PIs in B6 and VWFKO mice
injected with either CFA or PTX alone. Immunization with CFA alone increased BBB
permeability in both B6 and VWFKO mice compared to unimmunized mice (p < 0.001
for both B6 and VWFKO) (Fig. 7A). The BBB-PI for CFA-immunized mice was
significantly greater in VWFKO than in B6 mice (p = 0.03). Interestingly, the effect of
CFA on BBB permeability was greater on day 8 and decreased over time, reaching
almost basal levels both in B6 and VWFKO mice, indicating that ECs can overcome the
CFA-induced inflammatory signals that compromise BBB integrity. Importantly, the
decrease in CFA-induced BBB permeability over time was significant (p < 0.0001), but
the rate of change was not different between strains.
PTX alone also independently increased BBB permeability in both B6 and
VWFKO mice compared to untreated mice (p = 0.0001 for both B6 and VWFKO) (Fig.
7B). However, the effect of PTX on BBB permeability was different than that of CFA.
BBB permeability changes induced by PTX did not vary over time (p = 0.67) and
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remained elevated at each of the time points examined. However, as with CFA, the BBBPI elicited by in vivo intoxication with PTX alone was significantly greater in VWFKO
than in B6 mice (p = 0.02). These data suggest that BBB compromise and repair by ECs
differs depending on the peripheral inflammatory stimulus. Therefore in order to assess if
the ECs responses elicited independently by CFA and PTX are capable of cross
regulating each other when administered simultaneously (CFA+PTX), we compared the
BBB-PIs from animals receiving CFA and PTX alone with those from animals that
received CFA+PTX. When CFA+PTX were injected at the same time, the BBB-PIs in
both B6 (Fig. 8A) and VWFKO (Fig. 8B) were significantly lower compared to the BBBPIs elicited by these agents separately. Although the CFA-induced increase in BBB
permeability was greater at day 8 and decreased to basal levels by day 12 (conditions
under which PTX-induced changes remain relatively constant), when the two agents were
used together, the vascular permeability was, in contrast, lowest on day 8 with the BBBPIs increasing to the PTX levels by day 12. These data support the concept that changes
in BBB permeability elicited by CFA and PTX alone occur via different pathways and
that the two pathways cross regulate each other with the overall differences in BBB
permeability reflecting their integration over time. Moreover, these data indicate that
WPBs and/or VWF protect against the vascular permeability changes induced by these
inflammatory agents.
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Discussion
In this study we show that the absence of WPBs and/or VWF leads to increased
BBB permeability and, in appropriately immunized mice, concomitantly more severe
EAE. The disruption of BBB integrity is due to adjuvants alone; and although the
mechanism(s) by which CFA and PTX act to increase BBB permeability is unknown,
these processes are independent of encephalitogenic T cell responses. Moreover, our
study indicates that ECs respond differently to CFA and PTX with the outcome of
simultaneous exposure being the integration of the different pathways over time. This is
in agreement with previous studies examining the effects of inflammatory pain elicited by
formalin, CFA and λ-carrageenan on BBB permeability (Brooks et al., 2005; Brooks et
al., 2006). BBB permeability changes elicited by these stimuli were associated with
unique alterations in the temporal expression of tight junctional proteins as well as
disruption of the interaction between tight junctional complexes and the cytoskeleton. It
is unclear what the mechanism(s) for tight junctional alterations following peripheral
inflammation might be, but both CFA and PTX are known to lead to increased levels of
IL-1β, TNF-α, and/or IL-6 within the periphery and CNS rapidly after exposure
(Armstrong et al., 2003; Donnelly et al., 2001; Loscher et al., 2000; Raghavendra et al.,
2004; Samad et al., 2001). Within the CNS the increase in IL-1β expression is associated
with widespread changes in neuronal activity, including Cox-2 expression in CNS
neurons leading to elevated prostaglandin E2 levels in the CSF (Ek et al., 2001).
Consequently, alterations in BBB permeability might be subject to modulation via both
peripheral and centrally mediated responses to inflammatory stimuli. In fact, we recently
demonstrated that neurogenic control of
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BBB

permeability

is

negatively

regulated by central histamine H3 receptor signaling (Teuscher et al., 2007).
Alterations in BBB permeability can occur in a variety of different situations
(Brooks et al., 2005), some of which relate directly to MS. There is an increasing body of
evidence in both EAE (Tonra, 2002; Tonra et al., 2001) and MS (Mathews et al., 1993;
Minagar et al., 2006) that subtle, progressive alterations in BBB integrity precede the
formation of inflammatory lesions. These changes are detected in all MS disease
subtypes, suggesting that a common abnormality in BBB function exists in the normalappearing white matter of MS patients and may be a predisposing factor in initiating and
propagating new inflammatory foci. Importantly, in our studies the WPB-related changes
in BBB permeability also do not derive from T cell activity, indicating that WPBs play an
important role in regulating BBB permeability in response to peripheral inflammatory
stimuli. In this setting, understanding the mechanism of Bphs as a genetic model of BBB
dysregulation is important.
The effector phase of Bphs is characterized by death due to hypotensive and
hypovolemic shock within minutes of HA challenge (Bergman and Munoz, 1968). This
time frame suggests that the effector phase may be associated with a sudden and rapid
release of preformed factors generated during the sensitization phase rather than the
induction of new gene expression by HA receptor signaling. Since inflammatory signals
such as PTX induce the synthesis and storage of the vasoactive factors in the WPBs
(Wolff et al., 1998) (Utgaard et al., 1998); (Utgaard et al., 1998) and because HA is a
secretagogue for the release of these agents (Hattori et al., 1989), the shock following
PTX sensitization and HA challenge could be due to the combined direct vasodilatory
effects of HA and autocrine activity of the released stored products from WPBs.
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However, our results in VWFKO mice demonstrate that the stored vasoactive factors in
WPBs are not responsible for the sensitization and that VWF and/or other WPB
components are instead protective in this model.
This observation was surprising given the fact that WPBs store several factors that
are good candidates for the observed trait, the sudden release of which could change
endothelial function in an autocrine fashion. WPBs are dynamic granules with very
random movements in resting cells (Romani de Wit et al., 2003). WPBs are released from
ECs in response to a large number of secretagogues, which can be divided into 2 distinct
groups: those that act by elevating intracellular calcium levels such as thrombin and HA
and those that act by raising cAMP levels such as epinephrine and vasopressin (Rondaij
et al., 2006). Calcium raising agonists induce a periphery–directed movement of WPBs
while cAMP-mediated agonists induce a transport-directed redistribution towards the
center of the cell leading to a star-like cluster at the perinuclear region (Vischer et al.,
2000). WPB clustering is believed to prevent excessive release of WPB constituents, and
may also lead to a selective exclusion of subsets of WPBs from exocytosis. Clustering is
induced by thrombin stimulation in human aortic EC (Vinogradova et al., 2000) but not
in HUVECs (Rondaij et al., 2006). In HUVECs, PTX can inhibit both VWF and tissue
plasminogen activator (tPA) release from WPBs in response to thrombin, most likely due
to inhibition of calcium influx as well as inhibit HA-induced calcium release (van den
Eijnden-Schrauwen et al., 1997). PTX causes ADP ribosylation of Gi/o family of G
proteins that are negative regulators of Gαs protein and its subsequent activation of
adenylate cyclase. Through this mechanism, PTX treatment leads to increased
intracellular

cAMP

concentration

(Wettschureck
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and

Offermanns,

2005),(Mittra and Bourreau, 2006), (Sugden et al., 2004; Zawilska et al., 2004). Hence, it
is possible that the suppression of Bphs observed in mice that have VWF and WPBs
could be due to PTX-induced, cAMP-mediated clustering of WPBs and sequestration of
their contents in B6 mice and not in VWFKO mice.
Several studies have provided evidence in support of the existence of different
subsets of WPBs that apart from VWF do not contain the same set of additional
constituents (Fiedler et al., 2004; Oynebraten et al., 2004; Utgaard et al., 1998; Wolff et
al., 1998). It has also been reported that different stimuli induce different WPB responses,
depending on the physiological need. In the case of vascular damage, thrombin induces a
rapid, local response leading to exocytosis of the WPBs while epinephrine induces a
gradual release of WPBs (Vischer et al., 2000). Moreover, epinephrine induces the
exocytosis of only the peripheral WPBs whereas thrombin stimulates the exocytosis of
peripheral, as well as central WPBs (Vischer et al., 2000). This difference in release
pattern and the fact that different stimuli, such as thrombin and epinephrine, induce WPB
exocytosis via distinct mechanisms enables the cell to regulate the exocytosis of WPBs,
and possibly the release of specific WPB constituents, in such a way that it meets the
patho-physiological requirements induced by distinct triggers (Burgoyne and Morgan,
2003). Therefore in an inflammatory disease as complex as EAE, stored factors in WPBs
may regulate a fine balance between pro-inflammatory and anti-inflammatory responses
while in animals that lack WPBs this regulation is lost, which may explain increased
susceptibility of VWFKO mice to EAE. In addition, VWF is an adhesion molecule for
leukocytes (Pendu et al., 2006) that may be involved in their recruitment (Wagner DD,
unpublished data). VWF has also been reported to mediate clearance of metastatic tumor
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cells in lungs through a mechanism still not known (Pendu et al., 2006). Therefore, it is
possible that VWF may be promoting the clearance of pathogenic autoimmune cells or
proinflammatory debris in the CNS of B6 mice leading to lesser CNS inflammation than
in VWF deficient mice.
The mechanism of BBB disruption in MS and EAE is unknown. Currently it is
believed that neuroantigen-specific T cells within the systemic circulation interacting
with ECs bring about the changes that lead to the formation of inflammatory foci and
promote BBB permeability (Wingerchuk et al., 2001). Our results, however, indicate that
disruption of the BBB in active EAE is independent of the encephalitogenic T cell
responses and that this is caused by the interaction of EC with peripheral inflammatory
stimuli such as CFA and PTX, and may also include neuropathic and inflammatory pain
(Brooks et al., 2005; Inoue, 2006), which can be a major component of most forms of MS
including benign disease (Glad et al., 2006). Overall, our study demonstrates that the
interaction of EC with environmental agents other than those that lead to pathogenic T
cell responses also influence the development of autoimmune disease by modifying BBB
permeability. Taken together our findings underscore the potential importance of coinfection and/or non-autoimmune related gene-by-environment interactions in the
etiology of MS.
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Materials and Methods
Animals. B6.129S2-Vwftm1Wgr (VWFKO) mice (Denis et al., 1998) were
maintained in the vivarium of the Given Medical Building at the University of Vermont
(Burlington, VT). C57BL/6J (B6) mice were purchased from the Jackson Laboratory
(Bar Harbor, ME). Animals were fed RMH 3000 Lab Diet Rodent Chow (Ralston-Purina,
St. Louis, MO) and tap water ad libitum and maintained in accordance with the Animal
Welfare Act and the Public Health Service Policy on the Humane Care and Use of
Laboratory Animals. The experimental procedures used in this study were approved by
the Animal Care and Use Committee of the University of Vermont.
Pertussis toxin in vivo intoxication. Mice were injected intravenously (i.v.) with
purified PTX (List Biological Laboratories, Inc.) in 0.025 M Tris buffer containing 0.5 M
NaCl and 0.017% Triton X-100, pH 7.6. Control animals received carrier.
Histamine sensitivity testing. HA sensitivity was determined by the i.v. injection
of amounts of HA (mg/kg dry weight free base) suspended in PBS. Deaths were recorded
at 30 min post challenge. The results are expressed as the number of deaths over the
number of animals studied.
Induction and evaluation of EAE. EAE was induced as previously described
(Teuscher et al., 2006a). Briefly, mice were injected subcutaneously in the flanks and
neck with 0.1 ml of an emulsion containing 200 μg of myelin oligodendrocyte
glycoprotein 35-55 (MOG35-55) (Beckman Institute, Palo Alto, CA) in saline and an equal
volume of complete Freund’s adjuvant (CFA) containing 200 μg of Mycobacterium
tuberculosis H37RA (Difco Laboratories, Detroit, MI). On the day of immunization, each
mouse received 200 ng of PTX (List

Biological Laboratories Inc., Campbell,
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CA) by i.v. injection. The mice were assessed daily for clinical signs of EAE using the
following scale: 0, normal; 1, limp tail or mild hind limb weakness; 2, moderate hind
limb weakness or mild ataxia; 3, moderately severe hind limb weakness; 4, severe hind
limb weakness or mild forelimb weakness or moderate ataxia; 5, paraplegia with no more
than moderate forelimb weakness; 6, paraplegia with severe forelimb weakness or severe
ataxia or moribund condition
Brains and spinal cords (SC) were dissected from calvaria and vertebral columns,
respectively, and fixed by immersion in 10% phosphate-buffered formalin (pH 7.2).
Following adequate fixation, brain and SC were trimmed and representative transverse
section embedded in paraffin, sectioned at 5 µm, and mounted on glass slides. Sections
were stained with hematoxylin and eosin for routine evaluation and Luxol fast blueperiodic acid Schiff for demyelination. Sections from representative areas of the brain
and SC were scored in a semi-quantitative fashion for the various histopathologic
parameters, as previously described (Teuscher et al., 2006a).
Blood brain barrier permeability determinations. Blood brain barrier (BBB)
permeability was assessed as previously described (Tang et al., 1996). Briefly, a 50 μg/g
dose of FITC-labeled BSA (Sigma, St. Louis, MO) was injected i.v. into B6 and
VWFKO mice on day 8, 10 or 12 post immunization with CFA+PTX+MOG35-55,
CFA+PTX, CFA or PTX. Cerebrospinal fluid and blood were collected after 4 h. Both
CSF and plasma samples, prepared by centrifugation at 3000 rpm for 15 min, were
diluted in PBS, and the fluorescence intensity was measured with a microplate
fluorescence reader (Flx-800-I, Bio-Tek Instruments Inc, Winooski, VT) using the
software KC-4, with an excitation wavelength of 485 nm and an emission wavelength of
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528 nm. The BBB permeability index is expressed as the ratio of the fluorescence
intensity of the CSF divided by the fluorescence intensity of the plasma.
Statistical analysis. Statistical analyses, as indicated in the figure legends, were
performed using GraphPad Prism 4 software (GraphPad software Inc, San Diego, CA).
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Figure 1. Assessment of Bphs in B6 and VWFKO.
Mice were sensitized with 200 ng purified PTX by i.v. injection on day 0. Mice were
challenged with HA (mg dry weight free base) by i.v. injection on the indicated day and
deaths were recorded at 30 min post challenge. The results are expressed as the number
of animals dead over the number of animals studied (% mortality).
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Figure 2. Early onset and severe clinical course of EAE in VWFKO mice.
EAE was induced in B6 (n = 18) and VWFKO (n = 27) mice by immunization with
MOG35-55+CFA+PTX. Regression analysis (Teuscher et al., 2006a) indicates that the
disease course in both strains fits a variable slope sigmoidal curve and is significantly
different between the two strains (F = 32.5; p < 0.0001).
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Figure 3. Severe histopathological EAE in VWFKO brain.
Comparison of the histopathologic lesions caused by EAE in the brains of B6 (A, C) and
VWFKO (B, D) strains of mice. Note the minimal inflammatory response around
capillaries and post capillary venules in the interface area between the brainstem and
hippocampal formation (H) in the B6 brain than the marked inflammatory response in
VWFKO brain. The inflammatory cells consisted of an admixture of lymphocytes and
monocytes with occasional neutrophils and rare eosinophils. There was no primary
demyelination in these areas of inflammation in B6 while minimal to mild primary
demyelination was observed in VWFKO brain. H&E stain, scale bar = 200 µm. (B and
D) higher magnification of B6 and VWFKO mouse brain, respectively. H&E stain, scale
bar = 200 µm. Quantification of lesion severity in B6 and VWFKO mice revealed that the
lesions in the brains (E) but not in SC (F) of MOG35-55+CFA+PTX immunized VWFKO
mice are more severe compared to WT controls. Significance of differences was
determined using the Student’s t-test.
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Figure 4. Normal T cell responses in EAE induced B6 and VWFKO mice.
(A) B6 and VWFKO CD4 T cells have equivalent ex vivo proliferative responses to
MOG35-55 ten days following immunization with MOG35-55+CFA+PTX. Mean CPM ± SD
were calculated from triplicate wells. (B) Production and/or (C) expression of
cytokines/chemokines by MOG35-55 stimulated splenocytes does not differ between B6
and VWFKO mice immunized with MOG35-55+CFA+PTX ten days earlier. Cytokine
production was determined by ELISA or cytometric bead assay and the expression were
determined by real time RT-PCR. Significance of differences between B6 and VWFKO
CD4 T-cells responses was determined using the Student’s t-test with a p-value of 0.05 as
the significance threshold.
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Figure 5. VWFKO mice exhibit increased BBB permeability compared to B6 mice
following injection with MOG35-55+CFA+PTX.
The permeability indices were calculated by determining the fluorescence in the CSF and
the plasma collected 4h after i.v. injection of FITC-BSA and is the ratio of the
fluorescence intensity of the CSF divided by the fluorescence intensity of the plasma.
Changes in BBB permeability differ significantly over time (F = 5.61; p = 0.02).
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Figure 6. Increased BBB permeability in VWFKO mice is independent of
encephalitogenic T cells.
BBB permeability in MOG35-55+CFA+PTX and CFA+PTX immunized B6 (A), VWFKO
mice (B). There was no difference in BBB permeability by treatment (p = 0.45) or over
time (p = 0.08) in B6 animals while there was a significant difference in vWFKO animals
over time (p = 0.003) but not by treatment (p = 0.47). Since there was no difference
between MOG35-55+CFA+PTX and CFA+PTX immunized animals, the data was pooled
and re-analyzed (C). Changes in BBB permeability differ significantly over time between
B6 and VWFKO mice (p = 0.001).
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Figure 7. BBB compromise and repair by endothelial cells differs depending on the
peripheral inflammatory stimulus.
BBB permeability in WT and VWFKO animals immunized with CFA alone (A), and
PTX alone (B). Changes in BBB permeability differ significantly between WT and
VWFKO mice (p<0.05).
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Figure 8. Comparison of BBB permeability in animals immunized with components
of adjuvants either alone or in combination.
BBB indices in B6 (A) and VWFKO mice (B) immunized with CFA or PTX or both
CFA+PTX. The p-values for the different interactions are shown.
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